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Approximately half a million individuals suffer from fractures every year and the demand for 
bone graft procedures is on a continuous increase. Scaffold based bone tissue engineering (BTE) 
has made great progress in regenerating lost bone tissue. Several materials are used for 
fabrication of scaffolds for BTE. Biopolymers apart from being a cost effective alternative to 
conventional synthetic polymers used for fabrication of scaffolds, offer advantages such as 
greater bioactivity and biocompatibility with mammalian tissue. A clinically relevant cell type 
proven to improve bone healing is bone marrow derived mesenchymal stem cells (MSCs). The 
biomaterial used to deliver these stem cells can induce their differentiation into the osteoblastic 
lineage and hasten bone healing. 
In this project we used polysaccharide and protein chemistry in a hierarchical scaffold design to 
accomplish structural stability and bioactivity. In these scaffolds, a cellulose derivative formed 
the micro scale structures, while collagen the most abundant osteogenic extracellular matrix 
(ECM) protein of bone, formed the self assembled nanostructures.  This dissertation aims at 
characterizing these three- dimensional (3D) porous biopolymeric scaffolds of cellulose acetate 
(CA) and cellulose acetate coated with Nano-fibrous collagen (CAc), in terms of their ability to 
induce bone healing in combination with MSCs.  
The CA and CAc scaffolds were compared to similar polyester (Poly-lactic acid co-glycolic 
acid) (PLGA) 3D porous scaffolds for their material properties and biological performance. It 
was seen that the CA scaffolds had greater hydrophilicity and when functionalized with collagen 
led to a more biomimetic self-assembly of collagen nanofibers. During the induced 
differentiation of seeded human bone marrow derived mesenchymal stem cells (hMSCs) in vitro, 
the cells on polysaccharide scaffolds showed higher levels of osteoblastic progression than the 
cells on the polyester scaffolds.  
The polysaccharide scaffolds also showed greater biocompatibility at twelve weeks of 
subcutaneous implantation in rats. On the other hand, polyester scaffolds started exhibiting 
increased foreign body response (FBR) by later time points. Finally, when implanted into critical 
sized calvarial defects of mice, the polysaccharide scaffolds seeded with bone marrow stromal 
cells showed greater bone formation and greater levels of collagen content, along with a more 
even distribution of osteoblastic markers throughout the scaffold structure than the control 
polyester scaffolds. Hence these findings demonstrated the potential of cellulose acetate and 
collagen, micro- nano structured biopolymeric scaffolds to be used in combination with MSCs as 
a biomaterial for bone regeneration.  
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1 Chapter 1 
1.1 Bone Loss and demand for implants 
 
High impact trauma, pathological conditions such as tumors and infections and conditions 
such as osteoporosis can lead to massive defects of the bone(1). About 5- 10% of the total 
number of bone fractures result in delayed or non-union and surgical intervention is 
needed(2-4). The ease of handling combined with the huge demand renders bone as one of 
the most transplanted organs(5). About 0.5 million bone grafts are carried out in the U.S. 
alone, while more than two million procedures are performed around the globe (6-8) per 
annum(5). Though using bone from the patient itself (autografting) is considered the golden 
standard for achieving bone healing, it is restricted by availability and discomfort to the 
patient. Allografts on the other hand help overcome these limitations, but carry the threat of 
low remodeling due to excessive processing and possibility of disease transmission(9). Hence 
bone tissue engineering, where biomaterial scaffolds, biological factors and cells are used 
alone or in a combination promises better bone regeneration(9). The demand for bone graft 
subsititutes is constantly increasing at a rate of 3.8% every year(10). 
 
1.2 Clinical treatment of critical sized bone defects 
1.2.1 Autograft  
Autograft is bone harvested from a non- essential site in the host. Hence the donor and the 
host are the same in the case of autografts. This grafted bone could be obtained most 
commonly from the iliac crest or fibula, chin, ribs, mandibles and parts of the skull from the 
patient(11, 12).  The outcomes of autografting of bone are seen to be superior to any other 
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bone grafting technique. There is regeneration with new bone formation at the defect site, 
with complete remodeling of the implanted autograft, with no immune issues(13).  Hence 
autografts are termed the ‘golden standard’. On the flipside, there are two surgeries needed 
on the patient, one for explantation of the autograft and another for implantation of the graft 
into the defect site(14). Therefore the procedures are complicated by morbidity at the donor 
site. Additionally the availability of non-essential bone is limited in very young and very old 
patients, posing another limitation(12, 15).  
1.2.2 Allograft  
Allograft is bone obtained from another human donor, different from the patient undergoing 
the transplantation. This source could be alive as seen with patients who have a total hip 
replacement, where the extracted bone could be processed and implanted as a bone graft in a 
patient requiring an allograft implantation. The source could be cadaveric and such bone 
could be banked, processed and used in patients as an allograft(16). While allografts 
overcome limitations of autografts such as no excessive pain to the patient associated with 
explantation of the bone to be grafted, and is not limited by availability, they have their set 
off limitations. The allografts have been documented to have issues of disease transmission 
and immune rejection by host tissue(17, 18). Hence they tend to be treated by extreme 
measures to ensure the elimination of biologics that may ensue in disease transmission or 
rejection of the allograft. This processing leaves the allograft with poor biological properties 
for bone regeneration. Hence unlike autografts, allografts tend to be mildly osteogenic, but 
pose a challenge to remodeling and regeneration of lost bone(19).  
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1.2.3 Xenograft  
Xenograft is a graft obtained from species other than human. Most of these xenografts are 
highly processed materials, with high calcium content to favor bone formation. Some popular 
products are a coral based xenograft called coral derived granules (CDG)(20), bovine(21) 
and porcein processed bone materials. Interpore and Pro-osteon (Interpore International, Inc., 
Irvine, CA) are coral based products available in the market. Bio-Oss (Geistlich 
Biomaterials, Geistlich, Switzerland), Osteograf-N (CeraMed Co., Denver, CO), and 
Endobon (Merck Co., Darmstadt, Germany) are bovine-based products in the market(22). 
While encouraging results have been seen in dentistry with the use of xenografts(23), 
orthopaedic outcomes have been limited. There are also concerns of disease transmission and 
hence xenografts are not a popular clinical option as bone grafts(24, 25). 
1.2.4 Other materials  
Other materials used as bone grafts are ceramics, and composites of calcium phosphate such 
as HA and tri calcium phosphate (TCP)(25), calcium phosphate cements(26), and calcium 
sulphate(27). Since bone contains calcim and phosphate as its mineral component, these 
materials are biocompatible and osteoconductive(28). They are however brittle with 
mechanical strength far below that of cortical bone. Hence though these ceramic and calcium 
phosphate based fillers are used in smaller defects, they are not used in the case of load 
bearing long bone defects. 
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1.3 Bone Tissue Engineering (BTE) 
 
Though the concept of application of materials to replace lost tissue started, as early in the 
17th century when artificial legs were made out of wood and metal(29), the concept of tissue 
engineering is relatively young as it has been around for only the past twenty-five years(30). 
The term ‘tissue engineering’ was coined in 1987(30, 31). Tissue engineering involves the 
integration of engineering, chemistry and biology to achieve tissue regeneration(29). Rather 
than the earlier concept of using an inert material that acts as a mechanical replacement for 
the lost tissue, the tissue-engineering concept takes advantage of the knowledge gained from 
multiple fields and applies it to formulate a platform made of biomaterials, cells, factors and 
design considerations to achieve complete healing of lost bone(32).  
1.4 Scaffolds in BTE 
 
The scaffold for BTE act as a template for regeneration to occur and the properties of the 
biomaterial can dictate the nature of bone regeneration achieved(33). It is well known that 
the scaffold’s material properties such as moderate hydrophilicity(34), morphology(35), 
porosity(36), chemical functionalities(37, 38) and biomechanical properties(39) can be used 
to direct effective bone healing, by influencing the resident osteoblasts and by inducing the 
homing, growth and differentiation of progenitor cells. BTE scaffolds act as the delivery 
vehicle for stem cells and growth factors, and their design considerations can lead to 
controlled delivery of these agents in order to elicit maximum regeneration of lost bone(40). 
Therefore the selection of an appropriate material to formulate the scaffold and have a smart 
design are important for a biomaterial scaffold for BTE to perform well. 
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1.5 Attributes of a successful BTE scaffold 
 
There are three essential attributes for a scaffold for BTE: Osteoconductivity, 
osteoinductivity and osteointegrativity. 
1.5.1 Osteoconduction  
Osteoconduction is the ability of the scaffold to allow the resident cells in bone to grow into 
the scaffold(41). Hence osteoconductive materials provide a conducive environment that 
allows the bone to grow on the biomaterial’s surface(42). An important consideration in 
achieving osteoconduction is vascularization of the biomaterial to maintain live osteoblasts 
on the scaffold surface(43). A number of pro-proliferative growth factors like Insulin-like 
growth factor (IGF-I, II), fibroblast growth factors (FGFs), transforming growth factor β 
(TGF-β), and platelet-derived growth factor (PDGF) are known to be osteoconductive(44). 
Collagen and calcium phosphate based materials are known to be osteoconductive(30).  
1.5.2 Osteoinduction  
Osteoinduction is the ability of the scaffold to facilitate the differentiation of progenitor cell 
population into the osteoblastic lineage. This property is important to the scaffold system as 
these progenitor cells can further recruit other cell types and secrete factors that hasten the 
process of bone healing(45). The first instance of osteoinduction was seen with bone 
formation by the implantation of demineralized bone matrix in the muscle, termed extopic 
bone formation. Bone morphogenetic proteins (BMPs) were the factors isolated and found to 
be responsible for osteoinduction(46). Progenitor cells are found to secrete this growth factor 
in response to bone injuries as well(29). Hence most systems utilize BMPs or progenitor cells 
to make the systems osteoinductive. 
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1.5.3 Osteointegration  
Osteointegration is the ability of the scaffold to establish and maintain intimal contact with 
the living bone tissue(47, 48). Osteointegration can be seen as an extension of the scaffold’s 
ability to be osteoconductive and osteoinductive. A material that allows for progenitor cell 
recruitment, differentiation and allows for the proliferation of cells in the bone forms a good 
contact with the neighboring bone tissue(49). Rough surfaces and mineral (HA deposited) 
scaffold surfaces are known to show greater osteointegration(49). The layer of integration is 
about 40- 150 nm thick and hence it is tough to examine by microscopic examination(50). 
1.6 Materials used as scaffolds for BTE 
 
Materials of many different properties and origin are used to formulate scaffolds for tissue 
engineering. Though initially the idea was to have an inert matrix that allows the lost tissue 
to be mechanically replaced, and the expectation from the material was to be immune 
acceptable, nowadays smart materials capable of inducing bone regeneration are sought. 
Polymers of both natural and synthetic origin have been used for a variety of bone BTE 
applications. A way of categorizing these polymers used for BTE is based on their origin- 1. 
Synthetic polymers and 2. Natural polymers. 
1.6.1 Synthetic polymers in BTE 
Most synthetic polymers used in tissue engineering are designed to be degradable, so as to 
transfer the load onto the regenerating tissue as they dissolve away. Most of these polymers 
have chemical groups that have chemical bonds that are break on the action of water 
(hydrolytically degradation) or due to enzymes (enzymatic degradation). Most synthetic 
polymers undergo hydrolytic degradation(51). However there are a few engineered polymers 
that use amino acid monomers and are engineered to degrade enzymatically. Hydrolytically 
degradable polymers are synthesized by condensation (step) polymerization or chain 
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(addition) polymerization reaction(52). The classes of hydrolytically degradable synthetic 
polymers used in tissue engineering are: 
1. Poly(α-hydroxy acid)s 
2.  Poly(ortho esters) 
3. Polyanhydrides 
Though a number of scaffolds have been made with each of these polymers and their 
combinations there are a few polymers that have been approved by regulatory authorities for 
use in biomedical devices(53). These polymers are: 
1.6.1.1 Poly(α-hydroxy acid)s 
 
Poly (α-esters) are polymers that have a labile aliphatic ester linkage in their chemical 
backbone. Ring opening and condensation polymerization reactions lead to the synthesis of 
poly (α-esters). Poly (α-hydroxy acid)s constitute the most popular and well studied group of 
Poly(α-esters). Though polycondensation of monomers could be employes to synthesize 
these poly(α-hydroxy acid)s, ring opening polymerization (ROP) reaction offers greater 
control over the molecular weight of the product formed. Additionally the reaction conditions 
seen with ROP process render it mild in contrast to polycondensation and hence the process 
is industrially relevant for scale up of production(54). Poly -lactides, glycolides and 
caprolactones are the most widely used poly(α-hydroxy acid)s in BTE applications. 
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1.6.1.1.1 Polyglycolides  (PGA) 
Polyglycolides were some of the earliest degradable polymers employed in tissue 
engineering(55). The chemical structure of PGA is given above (Figure 1.1). The high tensile 
strength and the solubility of polyglycolides can be attributed to their highly crystalline 
nature (45- 55%). Some matrices made of polyglycolide exhibit a modulus of 12.5 GPa. Due 
to their great initial mechanical property, BiofixR has been developed as a polyglycolide 
based device for bone. Polyglycolides however undergo bulk degradation of the polymer 
matrix(56). The end product of degradation is glycine. These degradation products are highly 
acidic, but can be shuttled into the tricarboxylic acid metabolic cycle. The buildup of the 
acidic pH could be overwhelming for the tissue and hence this polymer is most commonly 
used in combination with other polymers to combat the disadvantage(57). 
 
Figure 1.1. Stucture of PGA 
 
1.6.1.1.2  Polylactides (PLA) 
Polylactide is a chiral molecule. The L- and D- optically active isoforms are seen in 
polylactide as a racemic micture of (D, L)- lactide. The L- lactide isoform is the naturally 
occurring one.  Poly (L- lactide) (PLLA) is also a crystalline (37% crystallinity) polymer. 
The general chemical structure of PLA is shown above (Figure 1.2)  PLLA is slow degrading 
and has a high modulus of 4.8 GPa. Hence a number of implants and devices for orthopaedic 
application have been developed using PLLA. Phantom Soft Thread Soft Tissue Fixation 
 9 
Screws, Phantom Suture Anchors (DePuy), Full Thread Bio Interference Screws (Arthrex), 
BioScrews, Bio-Anchors, Meniscal Stingers (Linvatec), and 
Clearfix Meniscal Darts (Innovasive Devices) are some examples of such orthopaedic 
devices(58, 59). Since PLLA is more hydrophobic than polyglycolides, it has a very long 
degradation time of more than five years in the body. Hence poly (DL-lactides) (PDLLA) has 
also been investigated for tissue engineered device formulation. PDLLA has a lower modulus 
than PLLA (1.9 GPa). Mass loss occurs at 12- 16 months in the case of PDLLA(57). All 
polylactides exhibit bulk degradation properties(60). Lactic acid is the end product from their 
degradation and this can be shuttled into the tricarboxylic acid metabolic cycle for 
elimination(57).  
 
Figure 1.2 Structure of PLA 
1.6.1.1.3 Poly(lactide-co-glycolide) 
The chemical structure of Poly(lactide-co-glycolide) (PLGA), is given above (Figure 1.3). 
PLGA is the co-polymer of L / -DL- Lactide and glycolide. Different ratios of lactide and 
glydolide have been used to formulate PLGA of various molecular weights and degradation 
rates. In the case of PLGA, polymers with an intermediate composition (50/50) were more 
susceptible to degradation (1-2 months in vivo) than compositions at the either extreme ends 
of the compositional spectrum (75/ 25 PLGA: 4-5 months in vivo, and 85/15 PLGA: 5-6 
months in vivo for degradative mass loss)(61). Many studies have used PLGA to create micro 
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and nanoscale featured scaffolds for BTE(62). PLGA due to its ease of being engineered to 
desired qualities lends itself to be fabricated using a number of scaffold fabrication 
techniques such as gas foaming(63), 3D sintered microspheres(64) and electrospun nanofiber 
scaffolds(65) . Hence PLGA is a polymer under extensive investigation for BTE and the 
United States Food and Drug Administration (U.S.F.D.A) has approved it for several drug 
delivery applications. However the degradation kinetics and the degradation products 
associated with PLGA continue to pose limitations on achieving controlled release(66) of 
factors from the polymer and sometimes pose the threat of loss of activity of factors due to 
change in pH.  
 
 
Figure 1.3 PLGA Structure.  
The chemical structure of Poly(lactide-co-glycolide) (PLGA) (Ratio of PGA: PLA is m:n and it 
can be modulated to achieve different kinds of PLGA copolymer). 
 
1.6.1.1.4 Polycaprolatone 
Polycaprolatone (PCL) is a polymer of ε-caprolactone formed by ring opening 
polymerization reaction. It takes around two to three years to degrade in the body. The 
chemical strcture of PCL is given above (Figure 1.4). PCL too has good mechanical 
properties. It has an excellent elongation coefficient of seven hundred percent its original 
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length at break. Composites of PCL with calcium phosphate may be suitable scaffolds for 
BTE(67).  
 
Figure 1.4 Structure of PCL 
1.6.1.2 Poly (ortho esters) 
 
Poly (ortho ester) (POE) was developed to be a hydrophobic polymer with surface erosion 
characteristics by ALZA corporation (Alzamer). The polymer’s hydrophobic nature 
combined with its ester linkage that is hydrolytically labile render them slow to degradation 
and better at achieving slow and sustained delivery of molecules entrapped into its matrix. 
The unique feature of POEs is their ability to be engineered into pH sensitive matrices. Thus 
this class of polymer was developed as an ideal platform for drug delivery applications by 
tuning the pH of excipients used to control the temporal release of encapsulated drug. There 
are four classes of POEs: 
POE class I: Diol and diethoxytetrahydrofuran tranesterification yielded POE I. One of their 
degradation products acted as an autocatalyst and accelerated the degradation of the polymer. 
Hence class II POEs were developed. 
POE class II: Diols reacted with diketene acetal led to the synthesis of POE II. Acidic 
excipients were needed to accelerated their degradation rate.  
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POE class III: Reaction of a triol with an orthoester led to the synthesis of viscous POE III.  
However their consistency posed problems with scale-up of production at an industrial levels 
and hence the POE class IV polymers were synthesized.  
POE class IV:  Adding short segments of lactic or glycolic acid to POE II led to the 
formulation of POE IV. This gave POE IV the advantage of accelerated degradation without 
the addition of pH modulating excipients. These POE IV polymers are being considered for 
formulation of BTE scaffolds(68).  
1.6.1.3 Polyanhydrides 
 
Polyanhydrides are surface eroding polymers that have aliphatic anhydride bonds in their 
backbone that are sensitive to attack by water. However they are highly hydrophobic, 
confining the degradation to their surface. Due to their surface eroding property, this class of 
polymer is highly suitable for controlled release of drugs. FDA had approved the use of a 
Polyanhydride for drug delivery in 1996(69). Many different kinds of polymerization 
reactions including melt condensation, ring opening polymerization, interfacial condensation, 
and dehydrochlorination can produce polyanhydrides. Polymers such as poly(sebacic 
anhydride) (PSA) due to their fast rate of degradation and highly crystalline nature have 
limited applications(70). However, poly ((carboxy phenoxy propane)-(sebacic acid))  (PCPP-
SA) is a well characterized polyanhydride approved by US FDA for drug delivery 
applications(71). A 1:1 sebacic acid and erucic acid dimeric copolymer system has been 
approved for drug delivery in osteomyeltis(72). 
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Table 1.1 Popular synthetic polymers, their properties and applications 
Polymer Degradation 
Mechanism 
Degradation time Modulus 
(GPa) 
Area of 
application 
Commercial 
products Molecular 
weight / 
mechanical 
property 
loss 
(months) 
Mass loss 
(months) 
PDLLA  
(70/30) 
Bulk erosion 5-6 12-18 1.9-2.4 
(Film or 
disk) 
Oral and 
Maxillofaci
al 
Surgery, 
Orthopedic 
Surgery 
ResorPin, 
Leadfix 
MacroSorb 
System 
(screws and 
plates, 
mesh, nails, 
pins) 
PolyPin 
PLLA Bulk erosion 9-15 36-48 1.2–3.0 
(Film or 
disk) 
Orthopedic 
Surgery, 
Oral and 
Maxillofaci
al Surgery 
FixSorb 
System 
(screws, 
nails, pins) 
Neofix 
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(screws, 
nails, pins) 
PGA Bulk erosion 0.5-1 3-4 7–14 
(Fiber) 
Orthopedic 
Surgery 
Biofix 
PLGA 
 
Bulk erosion   1.4–2.8   
10/ 90 1-2 3-4 Periodontal 
suture 
Vicryl suture 
85/ 15 1-2 4-5   
75/ 25 1-2 4-5 
50/ 50 1-2 3-4 
PCL Bulk and surface 
erosion 
9-12 24-36  Drug 
delivery and 
composite 
orthopedic 
devices 
Capranor 
Poly(orth
o-esters) 
Surface erosion 4-6 12-18 2.5–4.4   
Poly(anh
ydrides) 
Surface erosion 4-6 12-18 0.14–1.4 Animal 
experiments 
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1.6.2 Natural polymers in BTE 
 
Polysaccharides, proteins and polyesters derived from both plant and animal kingdoms 
constitute the family of natural polymers. Several of these polymers are part of our diet and 
have been used in a variety of human applications in pharmaceutical excipients, prosthetics, 
drug delivery and imaging applications. These polymers are known to be recognized by the 
biological environment and channeled into metabolic degradation. Due to the similarity that 
natural polymers share with the ECM components, these materials may also avoid the 
stimulation of chronic immunological reactions and toxicity, often detected with synthetic 
polymers(73). 
1.6.2.1 Polysaccharides in tissue engineering and drug delivery1 
 
Polysaccharides consist of monosaccharides (sugars) linked together by O-glycosidic 
linkages. Differences in the monosaccharide composition, linkage types and patterns, chain 
shapes and molecular weight dictates their physical properties, such as solubility, viscosity, 
gelling potential and/or surface and interfacial properties. Polysaccharides are derived from 
renewable resources, like plants, animals and microorganisms and are therefore widely 
distributed in nature. In addition, polysaccharides perform different physiological functions 
and hence have great potential applications in the fields of tissue engineering and 
regenerative medicine(73)(Figure 1.5). 
There are hundreds of known polysaccharides. A list of polysaccharides from varying 
sources is listed below: 
                                                
1 This section was published as a book chapter: Aravamudhan A, Ramos D, Nada AA, Kumbar 
SG, Natural Polymers: Polysaccharides and Their Derivatives for Biomedical Applications, 
Natural and Synthetic Biomedical Polymers; pg. 67-90, Elsevier Science; 2014. 
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Examples of polysaccharides from higher plants include starch, cellulose, exudate gums like 
arabinogalactan, gaur gum, and gum arabic. 
Examples of algal polysaccharides: Alginates, galactans, and carrageenan. 
Examples of polysaccharides from animals: chitin, chitosan, glycosaminoglycans, and 
hyaluronic acid 
Examples of polysaccharides from microorganisms: dextran, gellan gum, pullulan, xanthan 
gum, and bacterial cellulose. 
Their monomer composition and biological source provides these polysaccharides with 
different sets of physico-chemical properties. Often, polymers of natural origin have 
limitations in terms of their solubility and industrially acceptable processability factors such 
as high temperature of melting, which are commonly applied to synthetic polymers. For 
instance, majority of polysaccharides are water-soluble and oxidize at elevated temperatures 
beyond their melting point. These limitations have to be overcome prior to designing any 
products using polysaccharides. For instance techniques to crosslink polymer chains have 
been developed to stabilize polysaccharide structures in order to give structural stability in 
aqueous environments(74, 75). Polysaccharide chitin in its native form cannot be produced 
into desired sizes and shapes due to its inability to dissolve in most common industrial 
solvents. Thus, chitosan, the deacetylated form of chitin, was produced and applied widely 
instead of native chitin itself, as chitosan is water-soluble polymer at low pH. Due to its 
properties, chitosan is widely used for biomedical applications(76). The following sections 
will summarize these efforts in the context of biomedical applications (as shown in Figure 
1.5) of polysaccharides invoking native polysaccharides, semi-synthetic polysaccharide 
derivatives and their blends with other synthetic polymers.      
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Polymers derived from plants and animal kingdoms have been widely researched as 
biomaterials for a variety of biomedical applications including drug delivery and regenerative 
medicine. These polymers have biochemical similarity with human ECM components and 
hence readily accepted by the body. Additionally, these polymers inherit several advantages 
including natural abundance, relative ease of isolation and room for chemical modification to 
meet the technological needs. In addition, these polymers undergo enzymatic and/or 
hydrolytic degradation in the biologic environment with body friendly degradation 
byproducts. Natural polymers include the list of polysaccharides (carbohydrates) and animal-
derived proteins. Polysaccharides are an important class of biomaterials with significant 
research interest for a variety of drug delivery and tissue engineering applications due to their 
assured biocompatibility and bioactivity. Polysaccharides are often isolated and purified from 
renewable sources including plants, animals and microorganisms. Essentially these polymers 
have structural similarities, chemical versatility and their biological performance with the 
ECM components; often mitigate issues associated with biomaterial toxicity and host 
immune responses. The building blocks of carbohydrate monosaccharide are joined together 
by O-glycosidic linkages to form a polysaccharide chain. Polysaccharides offer a diverse set 
of physicochemical properties based on the monosaccharide that constitutes the chain, its 
composition and source. The popular list of polysaccharides used for a variety of biomedical 
applications cellulose, chitin/chitosan, starch, alginates, hyaluronic acids, pullulan, gaur gum, 
xanthan gum, and glycosaminoglycans. In spite of many merits as biomaterials these 
polysaccharides suffer from various drawbacks including variations in material properties 
based on the source, microbial contamination, uncontrolled water uptake, poor mechanical 
strength and unpredictable degradation pattern. These inconsistencies have limited their 
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usage and biomedical application related technology development. Numerous synthetic 
polymers with well-defined mechanical and degradation properties have been developed to 
meet the technological needs in the biomedical applications.  However, these polymers from 
the biologic stand point, lack much-desired bioactivity and biocompatibility and may cause 
toxicity and immune response. Polysaccharide structure offers freely available hydroxyl and 
amine functionalities that makes it possible to alter its physicochemical properties by 
chemically modifying polysaccharide structure. For instance, grafting synthetic monomers on 
the polysaccharide chain offers an easy way to control polymer solubility in desired solvents, 
water uptake and degradation. These semi-synthetic polymers offer best features of the both 
natural and synthetic polymers. Various crosslinking techniques to restrict the polysaccharide 
chain movement to control their water uptake, degradation and mechanical properties have 
also been developed. Polysaccharide-based porous scaffolds, fiber matrices, hydrogels, micro 
and nanoparticles have been developed for a variety of tissue regeneration and drug delivery 
applications. In the recent years glycochemistry has gained research momentum for 
understanding carbohydrate biological functions and development of carbohydrate-based 
drugs and vaccines. Engineered carbohydrate based polymeric structures may serve as an 
alternative material platform for a variety of regenerative medicine and drug delivery 
applications.  
A new non-petroleum based biomaterial platform to meet the versatile needs in biological 
science and biomedical engineering could be achieved by collaborative efforts between 
academia, government, and industry partnership.  The collaborative efforts should include 
bringing scientists working in different disciplines of chemistry, biology, polymers, materials 
sciences and engineering to work towards these activities. These collaborative efforts could 
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lead to the development of a methodology for synthesis of natural polymer based semi-
synthetic polymers and provide a greater depth of understanding of carbohydrate biological 
functions, polymer structure, material properties, degradation and mechanical properties. 
Further development of modeling tools to predict structure-property and biological activity of 
carbohydrates for biomedical applications. The goal of the new initiatives should focus on 
the development of natural polymer based orthopaedic fixation devices, biomedical implants, 
drug delivery vehicles, carbohydrate based drugs, hydrogels, surfactants, coagulants and 
absorbents for a variety of biomedical applications. The research activities in this area could 
generate commercially available technologies and products from the renewable resources and 
contribute immensely towards economic development.  
 20 
 
Figure 1.5 Polysaccharides in biomedical applications 
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1.6.2.1.1 Hyaluronic acid 
1.6.2.1.1.1 1.6.2.1.1.1 Chemical structure, properties and sources 
Chemically HA is a linear polysaccharide made up of: D-glucoronic acid and N-Acetyl-D- 
Glucosamine that are linked to one another by a β-(1->3) linkage. There could be 250-25000 
such basic disaccharide units in a polymer chain of hyaluronic acid, connected by β-(1-> 4) 
linkage (Figure 1.6). The disaccharide units of hyaluronic acid are extended, forming a rigid 
molecule whose many repelling anionic groups bind cations and water molecules. In 
solution, hyaluronate occupies a volume approximately 1000 times that in its dry state. 
Hyaluronate solutions exhibit clear viscoelastic properties that make them excellent 
biological absorbers and lubricants. These properties also attribute to its preferred form of 
fabrication into hydrogels. Because of its hydration properties, HA has the ability to bear 
compressive loads in vivo, and provide lubrication at the same time. In vitro, HA has been 
shown to facilitate cell migration and pericellular matrix formation(77).  
Biologically, HA are an important glycosaminoglycan (GAG) component of connective 
tissue, synovial fluid (the fluid that lubricates joints) and the vitreous humor of the eye in 
mammals(78). The biological roles of HA are widespread and widely appreciated(79-81). 
They range from development, angiogenesis, cellular migration and receptor mediated 
signaling through receptor CD44 and receptor for HA-mediated motility (RHAMM) in ECM 
remodeling and mediation of inflammatory responses(82, 83). HA chain length plays an 
essential role in the biological functions elicited in native and hence the engineered tissues. 
Therefore the molecular weight of HA is an important consideration for the response elicited. 
For instance, while the low molecular HA (less than 3.5X104 Da) is known to be involved in 
cytokine activity implicated in inflammatory responses(84), the higher molecular weight HA 
(above 2X105 Da) is known to inhibit cell proliferation(85). Similarly, (1-4KDa) smaller 
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fragments of HA have a positive effect in promoting vascularization during injury, whereas 
the (1-9KDa) large fragment showed no significant effects(85, 86). Not only is the usage of 
HA at the correct molecular weight and chain length, but also the hyaluronidas (HAS) 
isozyme (Figure 1.7) that is responsible for degradation of HA in the tissue, determines the 
chain length of the degradation product. Therefore the enzymes in the tissue where the HA 
material is to be implanted is a factor for consideration while using the material in tissue 
engineering(87).  
 
 
Figure 1.6 Structure of Hyaluronic Acid (HA) 
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Figure 1.7 Chain length of HA 
The 3 HAS isozymes produce distinct chain lengths of HA. HAS1 and HAS3 can produce chains 
of 2X105-2X106 Da, while HAS2 produces HA of chain length greater than 2X105 Da (Modified 
from Allison et al., 2006(88)). 
1.6.2.1.1.2 Attempts made in Tissue Engineering and Drug delivery 
1.6.2.1.1.2.1  Hyaluronic acid alone 
HA is highly water soluble at room temperature and at acidic pH values, and exhibits high 
rates of turnover in vivo (half-life varies from only minutes in the blood to weeks in 
cartilage(80, 81, 88-90). These properties pose challenges for the material’s integrity in vivo. 
Therefore the usage of HA in its native form in tissue engineering and drug delivery 
applications is pretty limited. Several crosslinking methods are used to increase the stability 
of HA in such applications. Some of them are as follows: water-soluble carbodiimide 
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crosslinking, polyvalent hydrazide crosslinking, divinyl sulfone cross-linking, disulfide 
crosslinking, and photocrosslinking hydrogels through glycidyl methacrylate–HA 
conjugates(87). Hence these techniques of covalent crosslinking provide the opportunity to 
combine HA with more mechanically stronger polymers. 
1.6.2.1.1.2.2 HA derivatives and combinations with other polymers 
The early usage of HA was in ophthalmic drug delivery systems where it provided an ideal 
matrix for covalent attachment of drugs and showed as much as twice the retention in 
contrast to free drug (methylprednisolone esters of HA)(91, 92). Different formulations such 
as such as gels, solutions and hydrogels with several model drugs such as pilocarpine (Pi) 
and tropicamide (Tr) showed that HA ester systems were effective ophthalmic drug delivery 
systems(92). HA has also been employed in liposomal dermal drug delivery. HA was 
conjugated to the surface of liposomes by carbodiimide crosslinking of its surface carboxyl 
residues to the amine residues on the liposome. The epidermal growth factor showed an 
encapsulation efficiency of >87% in these HA conjugated liposomes(93). Avid binding of 
these HA conjugated liposomes to a cellular monolayer in culture were seen that did not 
occur with the unmodified liposomes(93). Sodium butyrate used as an anti proliferative drug 
in treatment of cancer has an extremely short half-life of five minutes in vivo. In order to 
bypass this constrain butyratic ester derivatives of HA were synthesized by stepwise 
chemical treatment of HA. The degree of substitution (DS) varied from 0.1 to 2.24 (1.8- 
28.4%). MCF breast cancer cell lines showed maximum anti- proliferative response with DS 
of 0.2. It was seen that complete internalization of the HA vehicle occurred in two hours 
through CD44 receptors that are frequently over expressed on cancer cells(94). From these 
and several other systems where HA and its derivatives have been used to deliver drugs, its 
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innate role that facilitates binding of HA to receptors/ specific cell types helps achieve 
efficient targeted delivery of intended drug to a tissue while its activity is preserved.  
Another major application of modified HA is in formulation of tissue engineering scaffolds. 
Radiation mediated crosslinked HA networks have been used as scaffolds for cell growth 
with positive outcomes(95). HA modified with methacrylic anhydride (MA) was 
photopolymerized to produce HA–MA hydrogels containing porcine chondrocytes(96). The 
chondrocytes within the HA scaffolds were viable and were able to produce neo-cartilage 
within the porous networks. Photopolymerizable HA–MA hydrogels have also been used in 
heart valve applications, in which the HA hydrogels were designed to mimic the cardiac 
ECM from which the heart valves develop(97). HA has been combined with other natural/ 
synthetic polymers to produce scaffolds. For example, HA has been combined with 
polypyrrole to create a multifunctional copolymer(98, 99). When implanted into rats, there 
was a marked early increase in local vascularization(99). On the other hand it was observed 
that polypyrrole–HA polymers were subsequently sulfonated, which was shown to 
significantly reduce platelet and cell adhesion(98).  
Benzyl derivatives of HA (Hyalograft C and HYAFF-11) are used as polymeric scaffolds for 
tissue engineering of cartilage(100). Though the laboratory tests have given mixed results, 
the human clinical results show normal cartilage formation when implanted into previously 
damaged tissue(101). Hence benzyl esters of HA have a great potential as scaffolds and drug 
delivery vehicles for chondrocytes in tissue engineering. Another HA-based scaffold 
examined for tissue engineering–based cartilage regeneration is auto-crosslinked 
polysaccharide polymer (ACP). While comparing ACP with HYAFF-11, poly (L- lactic acid) 
(PLLA) and poly (DL- lactic- glycolic acid) (PLGA) in an osteochondral defect, faster 
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degrading scaffolds of ACP, PLGA had greatest regeneration, while it was slower in 
HYAFF-11, PLLA that had slower degradation rates. These in vivo data revealed that the 
scaffolds degraded within 4 months and were able to repair the osteochondral lesions, again 
emphasizing the selection of type of HA and the consideration of hyaluronidase system in the 
tissue that would degrade it(102, 103). HYAFF-11 scaffolds have shown very positive effects 
as scaffolds for engineering of vascular and hepatic tissue and showed great ability for 
maintenance of cell phenotype indicating that it could be used as scaffolds for many tissue 
engineering applications(104, 105). 
Combining chitosan and high molecular weight HA (2.4X106 Da) in a three-dimensional 
(3D) copolymer system promoted chondrocyte adhesion. The production of aggrecan and the 
native rounded morphology of seeded chondrocytes increased with the concentration of 
added HA and the scaffolds with HA performed better than scaffolds of chitosan alone(106). 
Incorporation of chondrocytes and HA into orthopedic implants by crosslinking HA to amine 
terminated PLGA–poly (ethylene glycol) (PEG) scaffolds allowed the attachment and 
proliferation of donor chondrocytes. It was also observed that collagen II expression, a 
marker of healthy cartilage phenotype, and DNA synthesis were significantly increased in 
polymers that incorporated HA(107). Combining HA with divinyl sulfone (DVS), and 
crosslinking with ultraviolet light, created suitable surfaces for cell adhesion. When a DVS-
crosslinked HA scaffold was dehydrated before seeding with smooth muscle cells, gels were 
more porous and conducive to cell migration and infiltration, but did not lose their non-
immunogenic properties(108-110).  Follow up studies conducted on the same material 
showed that smooth muscle cells increased the synthesis of ECM components elastin and 
collagen of aortic valve tissues, over cells cultured on tissue culture plastic; this synthesis 
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was controlled by HA fragment size and dose(108, 111). Such studies have shown that HA is 
a suitable material for vascular and cardiac tissue engineering. HA was also introduced 
directly to engineered structures exogenously. For example, collagen matricides implanted in 
rabbits have shown greater numbers of chondrocytes (1.5 times control values) after the 
addition of soluble HA. The addition of HA fragments increased the amounts of 
proteoglycans, a desirable component of remodeling(112). However, small HA 
oligosaccharides (4–16 disaccharides), on the other hand can prevent cell proliferation in 
vivo(113). These findings could have implications for improving the potency of implanted 
small diameter vascular grafts and preventing stenotic lesions after graft implantation in 
cardiovascular tissue engineering.  
With the knee osteoarthritis patients increasing to a staggering 19 million in 2010, treatment 
by visco-supplimentation has become popular. Visco-supplementation refers to the concept 
of synovial fluid replacement with intra-articular injections of hyaluronan mainly for the 
relief of pain associated with osteoarthritis(114, 115). Intra-articular injections of hyaluronan 
ameliorate pain and increase function, generally for up to 3 months with no serious adverse 
events. In the US, the first single-injection hyaluronan for visco-supplementation, Synvisc-
One®, was approved in early 2009. The global market for dermal fillers is constantly 
increasing with 100 different dermal fillers on the market for aesthetic plastic surgery and 
about half of them are based on hyaluronan(116). Thus it can be summed up that hyaluronic 
acid has already stepped into clinical treatments in tissue engineering and will gain greater 
importance in the future.  
1.6.2.1.1.3  Promises and challenges with HA  
HA has had a profound impact on the field of tissue engineering. The incorporation of HA 
into biomaterials and scaffolds has yielded a new class of biocompatible, controllable, and 
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readily degradable materials. These new scaffolds have been tested with multiple types of 
cells and have been shown to promote beneficial remodeling of engineered tissues, as well as 
the gross preservation of cell phenotypes. However harnessing the endogenous activity of the 
hyaluronan synthases to stimulate endogenous HA production may be another useful strategy 
for the future. Recent research developments regarding HA as a molecular delivery vehicle 
for pharmacological and oncological applications, as well as in the orthopedic and 
cardiovascular arenas, have the potential to transform the clinical future of tissue 
engineering. 
1.6.2.1.2 Chondroitin sulfate 
1.6.2.1.2.1 Chemical structure, properties and sources 
 
Chemically, Chondroitin sulfate (CS) is a sulphated GAG derivative. Alternating units of N-
acetylgalactosamine and glucuronic acid are the monomers that constitute the basic unit of CS 
(Figure 1.8). Hundreds of these alternating units could be present together in a CS polymer 
chains. CS is a GAG seen associated with proteins in living systems termed proteoglycan. CS is 
classified according to the position of sulfation of the monomer unit. The types of CS and their 
chemical structure are listed below  
Table 1.2 Types of Chondroitin Sulphate (CS) 
S.no. Name (Type) Synthetic name (Sulphation 
of GalNAc) 
1. Chondroitin sulfate A chondroitin-4-sulfate 
2. Chondroitin sulfate C chondroitin-6-sulfate 
3. Chondroitin sulfate D chondroitin-2,6-sulfate 
4. Chondroitin sulfate E chondroitin-4,6-sulfate 
 
Biologically, CS is a major structural component of the ECM of several tissues of the body, 
like cartilage. The biological function and efficacy of CS seems to be highly dependent on 
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the chain length of the polymer. For instance, CS extracted from the trachea is usually shorter 
Ca. 20-25 kDa, and considered to be of lower quality. On the other hand, CS polymer 
extracted from shark is considered more bioactive and of higher quality with longer chain 
length Ca. 50-80 kDa. Even CS extracted from a single source could have variable polymer 
chain length(117). Hence the type and chain length of CS is likely to determine its biological 
functions, such as interaction with growth factors, proteins in GAG complexes of the ECM 
and its ability to influence cellular function(118, 119).  CS is also an indispensible 
component of tissues for maintaining their mechanical properties. The resistance of cartilage 
to compression is attributed to the tightly packed, charged sulphate groups of CS. This leads 
to osmotic water retention and swelling of the cartilage and hence endows it with the weight-
bearing mechanical properties(120). Apart from its structural role, CS has also been an 
important player in basic biological processes including cell division and development of 
nervous system. Such biological roles are mediated by the binding of CS to growth factors, 
cytokines and regulating signaling pathways in neurons(121, 122). Age related changes in 
sulphation of the CS chains indicate their fundamental biochemical role in tissues(123) 
during age related pathological changes.  Loss of CS has been implicated in pathological 
conditions. For example, osteo arthritis (OA) in cartilage is seen to occur due to the loss of 
CS leading to cartilage degeneration. Many studies on the impact of CS administration in 
patients suffering from OA along with in vitro results suggest that CS could improve 
pathology of OA through promoting proteoglycans synthesis, usually lost during cartilage 
degeneration(124), inhibiting elastase(125-127) and cathepsin G activity(128), and reducing 
gene expression for a number of proteolytic enzymes(129).  
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The reason for a high variability in the outcomes of treating OA with CS is due to the 
variation in the chain length of the polymer used in these studies. While the high quality, 
long chain CS is more effective, the low quality, short chain CS have minimal effects on the 
pathogenesis of OA. Apart from its effects of improving OA, the anti-inflammatory effects of 
CS have led to improvement in conditions such as psoriasis and inflammatory bowel disease. 
These effects seem to be related to the inhibition of cytokines such as TNF-α(130), and IL-
1β induced translocation of NF-κB(131). However most of the effects are dependent on the 
type of CS determined by degree and position of sulphation, as well as the chain length of the 
polymer(122). 
 
Figure 1.8 Structure of Chondroitin Sulphate (CS) 
1.6.2.1.2.2 Attempts made in Tissue engineering and drug delivery 
1.6.2.1.2.2.1 Chondroitin sulfate alone 
CS is often administered orally as it is seen to improve joint-related pathologies(117). The 
intact polymer is often consumed and several studies have examined the levels of the CS in 
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blood plasma after consumption(132, 133) in humans, mice and horses. The degree of 
sulphation and chain length of the polymer were seen to determine the rate of uptake, 
retention and clearance from these biological systems. For instance, tracheal CS with lower 
molecular weight is absorbed quickly within 1-5 hours and reached a peak plasma 
concentration at around 10 hours. On the other hand shark CS of high molecular weight is 
seen to be have a slower rate of uptake at around 8.7 hours and was retained in the system for 
as long as 16 hours(133). It was also observed that desulphated chondroitin had quick uptake 
rate (15 minutes) and was also cleared within 3 hours(134). Further, in vitro experiments 
showed that there was a direct correlation between the polymer size and the rate at which it 
crossed the gut wall(135). This in turn reflected as the rate of uptake and retention of the 
polymer in the biological system. Therefore smaller CS polymer is taken up and cleared 
quickly, while the larger CS polymer takes longer time to be absorbed and cleared from a 
system.     
1.6.2.1.2.2.2  Chondroitin sulfate derivatives and combination with other polymers 
CS is a water-soluble polymer. Early attempts of using CS as a vehicle for colonic drug 
delivery, crosslinked the polymer to different degrees to achieve a biodegradable system for 
controlled release of model drugs, indomethacin. A linear correlation between degree of 
crosslinking and rate of drug release emerged, indicating that the level of crosslinking of CS 
can be used to regulate the kinetics of drug delivery(136, 137). Still, crosslinking of CS is 
used as a strategy to decrease the dissolution of CS in water. For example, treatment of 
water-soluble CS polymer with different proportions of trisodium trimetaphosphate (TMFS) 
achieved crosslinking of CS and reduced solubility for the usage of the polymer in drug 
delivery applications(138).   
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Mostly due to its highly water-soluble nature and lack of mechanical stability, CS has been 
modified with or used along with other polymers for drug delivery and tissue engineering 
applications. Porous sponge of CS-chitosan was used for the delivery of Platelet Derived 
Growth Factor (PDGF), aimed at achieving greater bone regeneration. Aqueous CS-Chitosan 
solution was subjected to freeze drying followed by crosslinking to form a porous sponge 
with 100-150µm pore size. PDGF-BB was incorporated into the CS–chitosan sponge by 
soaking CS–chitosan sponge into the PDGF-BB solution. Amount of CS could act a factor to 
control the release of PDGF-BB from the sponge(139). It was also seen that presence of CS 
increased the osteoconductive characteristics of the material. Hence, the bioactive CS could 
be used in combination with other polymers in the formulation of materials for delivery of 
growth factors. 
As CS has biological roles that are advantageous and is a water-soluble and enzymatically 
biodegradable polysaccharide, it has been used in combination with materials such as 
collagen in preparation of scaffold matrices. Addition of CS to collagen type I matrix was 
achieved by using 1-ethyl-3- (3-dimethyl aminopropyl) carbodiimide (EDC) as a crosslinking 
agent. The CS bound matrix had increased water-binding capacity, with decreased tensile 
strength and temperature of denaturation(139).  Apart from imparting advantageous 
biological properties to the scaffold, CS also presented the opportunity to control the 
scaffold’s mechanical and degradation characteristics.  
As explained in the previous section, CS is an important component of joint ECM and known 
to play crucial roles in development and amelioration of joint/cartilage pathologies. Hence, it 
is used extensively in osteochondral tissue engineering. Here again a number of CS variants 
such as modified CS or CS in combination with other natural and/or synthetic polymers have 
 33 
been utilized for the formulation of scaffolds. Scaffolds of different formats were utilized. 
Both fibrous spongy scaffolds and hydrogel scaffolds have been formulated utilizing CS.  
While employing CS in combination with Collagen type I in the form of fibrous sponge 
matrix, a clear advantage in chondrocyte proliferation and phenotype maintenance were 
seen(140). Similarly sponges with a pore diameter of 180µm were synthesized using natural 
polymers gelatin, CS and HA together. When these scaffolds were seeded with chondrocytes, 
they maintained their morphology for up to 5 weeks and showed higher levels of aggrecan 
production than scaffolds that did not contain CS and HA components. These in vitro studies 
clearly point to the potential of scaffolds incorporating CS for cartilage tissue 
engineering(141, 142). 
A number of hydrogel scaffolds have also been formulated using CS for cartilage. 
Chondrocytes have a rounded morphology and this is seen to be best preserved in hydrogels, 
and therefore hydrogel scaffolds are an ideal option for cartilage regeneration. Polymers such 
as poly ethylene glycol (PEG), poly vinyl alcohol (PVA), and poly (3-hydroxybutyrate) 
(PHB) have been used with CS to formulate hydrogels. While PVA hydrogels alone could 
not support cell adhesion, the addition of CS lowered the extreme hydrophilicity of the 
hydrogel and facilitated greater cell attachment in the scaffold(143). When CS containing 
Collagen hydrogel was conjugated to a fabric of PHB, it showed greater osteogenic potential 
than the parent fabric, on the seeded osteoblasts(144). The presence of CS in PEG hydrogels, 
promoted the chondrogenic differentiation of seeded bone marrow derived mesenchymal 
stem cells (MSCs), but did not allow them to proceed onto a hypertrophic state. This was an 
optimal outcome suitable for chondrocyte differentiation, to achieve cartilage 
regeneration(145). In a recent study, the polysaccharide backbone was modified with 
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methacrylate and aldehyde groups to form an adhesive gel. This modification led to better 
integration of the hydrogel with the implanted tissue in vivo, as seen in a rat model. This was 
due to greater scaffold-protein interaction brought about by the addition of modified 
CS(146).  Efforts have been made to deliver CS using scaffolding principles to joints affected 
by OA. For instance, a scaffold with 40% chitosan and 60% CS was designed to serve as a 
carrier of CS proved effective(147). Hence CS by itself after certain modifications and in 
combination with other synthetic and natural polymers has a great potential in scaffolding 
and drug delivery for osteochondral regeneration.  
1.6.2.1.2.3 Promises and challenges with Chondroitin sulfate  
There have been many promising outcomes with CS as a drug and as a matrix for tissue 
engineering, both in vitro and in vivo. However clinical outcomes have been inconsistent and 
have variable results. Better experimental design and ways to determine the polymer length 
and level of sulphation would be crucial to determining to the fate of exogenously 
administered CS. Better experimental design and greater understanding of the biological role 
of CS are important factors for determining the polymer’s role and most suitable type of CS 
polymer that lend the desirable biological outcomes.  
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1.6.2.1.3 Chitin and chitosan 
1.6.2.1.3.1  Chemical structure, properties and sources 
Chitin is a structural polysaccharide found in nature. Chemically, chitin is made monomer 
units of 2-acetamido-2-deoxy-b-D-glucose connected through β (1->4) linkages (Figure 1.9). 
The C-2 position in the glucose ring in the monomers has an acetamido group. The N- 
deacetylation of this chitin leads to the formation of chitosan. The degree of conversion of 
the acetamido group to amine group is never really complete. This is given by the degree of 
deacetylation (DD) of the chitosan. The DD of chitosan can vary from 30- 95%. This 
conversion of chitin to chitosan renders the material more readily soluble and processable for 
various applications (Figure 1.10). Though crystalline chitosan is insoluble in aqueous 
solution at a pH> 7.0, in dilute acid where pH <6.0, the positively charged amino group 
facilitates its solubility(148, 149).  There are three reactive functional groups in chitosan- the 
amino group at C-2, a primary and secondary –OH group at C-3 and C-6 positions 
respectively. These reactive groups allow for chemical modification of chitosan such as 
covalent and ionic modifications.  
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Figure 1.9 Structure of Chitin and Chitosan 
Chitosan is one of the highly studied and utilized polysaccharide for tissue engineering. A 
process called “internal bubbling process (IBP)” can be used to form porous structures from 
chitosan by freezing and lyophilizing a solution of chitosan. The addition of CaCO3 to 
chitosan is used in this process to create porous chitosan gels(150). This processability of 
chitosan is attributed to its cationic nature. The cationic property also leads to interaction of 
the material with negatively charged small molecules and proteins in biological systems. This 
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is structurally very similar to native GAGs and hence plays crucial role in stimulating 
favorable responses in biological systems. Chitosan’s mechanical properties are determined 
by the pore sizes, the molecular weight and crystallinity of the polymer. High porosity, lower 
molecular weight and less crystalline polymers are mechanically less competent and vice 
versa. Apart from these properties, chitosan is biodegradable. The acetylated residues of 
chitosan are targeted by lysozyme in vivo and this seems to be the major mechanism of 
chitosan degradation.  Therefore DD, and crystallinity of the polymer are inversely related to 
degradation. Thus the higher DD (>85%), the more crystalline the chitosan polymer and the 
slower its degradation in the body(151-153).  
Chitosan is known to have antibacterial properties that(154) are attributed to the attack of 
negatively charged groups on the cell wall by the positively charged chitosan polymer. This 
leads to lysis of bacterial cell wall, and hence its bactericidal activity. Inhibition of bacterial 
growth by chitosan is also attributed to its binding of bacterial DNA and interference of 
bacterial transcription(155). Chitosan is also seen to have minimal immune rejection. Chitin 
is the major source for chitosan (Figure 1.10). It is the most abundant polymer to undergo 
biosynthesis, next to cellulose. It is a constituent of the exoskeleton in animals, like 
crustaceans, molluscs and insects. It is also a polymer found in the cell wall of certain fungi. 
Most of the polymer used for commercial source comes as a byproduct of the fishery 
industry(156). 
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Figure 1.10 Nanofibers of Citin and Chitosan 
Chitin (on left) and Chitosan after deacetylation (on right) Nanofibers(157). 
1.6.2.1.3.2 Attempts made in Tissue engineering and drug delivery 
1.6.2.1.3.2.1 Chitosan alone 
The various biological properties of chitosan have been discussed above. Chitosan has also 
been used as a dietary supplement. It is seen to lower low-density cholesterol and is helpful 
in weight loss(158). Apart from its direct consumption, chitosan is used in drug formulations 
of different types such as microparticles, liposomes, granules, gels for oral and parenteral 
drug delivery. In most of these applications chitosan is physically or chemically crosslinked 
to obtain stability. The degree of crosslinking and drug loading are parameters used to 
control drug delivery(159, 160). In tissue engineering, chitosan alone was used initially. 
Since the mechanical and dissolution properties of the polymer make it tough to work with 
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and formulate scaffolds, chemical modifications and their combinations with other natural 
and synthetic polymers is at present the more popular strategy. Common strategies are 
discussed in the following section. 
1.6.2.1.3.2.2 Chitosan derivatives and combination with other polymers 
Some of the limitations chitosan suffers from are those of insolubility at neutral pH and high 
water absorption by the polymer at a rapid rate. These factors pose problems of 
processability and also lead to rapid drug release from chitosan. Hence chitosan is modified 
to overcome these limitations. Most modifications are brought about by reactions with the 
amine or hydroxyl groups of the glucoseamine unit in chitosan. Using the reactive amine 
group a number of modifying reactions are carried out. A simple example is a reaction in 
which an aldehyde functional group reacts with –NH2 group of chitosan by reductive 
amination(161). The introduction of N-cyanoethyl groups into the side chain of glucosamine 
in chitosan is a good example of this process. This reaction produced some crosslinking 
through a reaction between the nitrile group and the amine group of chitosan(162). Examples 
of covalent modifications of chitosan include acylation and quarternization. When two 
oppositely charged polymers (a polycation and a polyanion) in a solution phase, separate out 
in a solution, a dense polymer phase called coacervate and a supernatant with low polymer 
content separate out. This process is termed polyelectrolyte complex formation. 
Polyelectrolyte complex formation has been used in a number of chitosan drug delivery 
systems(163, 164) where controlled release of the loaded drug was desired. Modified 
chitosan and its blends with other polymers have been used in different formats. 
Nanoparticles and microparticles of chitosan and its derivatives have been formulated using 
techniques such as emulsification/solvent evaporation(157), spray drying(165), ionotropic 
gelation and coacervation(166), emulsion crosslinking(167) and sieving(168). Thin films 
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have been produced using solution casting, while crosslinking and gelation processes have 
been applied to produce hydrogels of chitosan for drug delivery(169). Chitosan drug delivery 
vehicles in the form of tablets and gels are applied in dental, buccal, gastrointestinal, colon-
specific, and gene delivery applications due to their favorable biological properties(169). In 
tissue engineering, chitosan had been used mostly in minimally modified forms. The focus 
presently has shifted to improving the properties by introducing chemical modifications to 
form derivatives of chitosan for specific tissue regeneration purposes. Some of them are 
listed below:  
Introduction of sugars  
Synthesis of chitosan bound to sugar has many applications in drug delivery and tissue 
engineering. This is due to the fact that cells, viruses and bacteria recognize these sugar 
moieties and hence render these polymers good agents for targeting several target 
components in tissue engineering. For example, galactosylated chitosan (GC), worked as a 
good ECM for hepatocytes(170).  Specific antigen presenting B cells were recognized by 
mannosylated chitosan (MC)(171).   
Graft polymerization 
Chemical grafting of chitosan can be used to functionalize chitosan and obtain important 
derivatives. Ceric ion, fenton’s reagent, gamma-irradiation, various radicals, and ring 
opening reactions are the various routes used to achieve graft polymerization of 
chitosan(172). Cell morphology and function were controlled by chitosan graft-polymerized 
onto poly (L-lactide) (PLA) by plasma coupling reaction(173). Further cooperative 
complementation through graft copolymerization or blend with poly (α- hydroxy acids) using 
a photosensitive crosslinking agent led to attachment of chitosan onto PLA films. These films 
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showed improved cell attachment(174). On the other hand copolymerization of chitosan with 
heparin inhibited platelet adhesion(175). Therefore graft polymerization can help modulate 
chitosan’s properties to elicit a desired cellular response.  
Immobilization of specific sequences 
Specific amino acid sequences promote cell adhesion. The most commonly used sequence is 
the arginine-glycine-aspartic acid (RGD) from adhesion proteins, such as collagen and 
fibronectin that bind cells through cellular integrin receptors. Photo crosslinking RGD 
peptides to chitosan improved the adhesion of human endothelial cells, compared to 
unmodified chitosan scaffolds(176). In another approach the –COOH group of amino acids 
such as lysine, arginine, aspartate, phenylalanine react to the –NH2 group of chitosan. These 
functionalized chitosan polymers were entrapped onto the surface of PLA to improve cellular 
responses(177). 
Production of nanofibers 
Nanofibers mimic the structure of natural ECM closely. Hence enhanced cellular responses 
are achieved on electrospun nanofiber scaffolds. Chitosan nanofibers ranging from several 
down to a few nanometers have been produced by electrospinning technique(178, 179) 
Thermal gelation 
Thermal gelling is a technique of injecting a polymeric aqueous solution, while keeping the 
temperature above the polymer’s sol-gel transition temperature and allow the polymer to 
form a gel as it reaches the body temperature.  A thermal gelling chitosan polymer was 
formed by neutralizing highly deacetylated chitosan solution with glycerol phosphate (GP). 
Chitosan remained in solution at physiological pH. Chitosan/GP solution gelled at body 
temperature and hence was an attractive, injectable hydrogel drug delivery system local 
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delivery of antineoplastic drugs like pachlitaxal(180). Derivatives of chitosan have been used 
in skin, bone, cartilage, liver tissue engineering. A detailed description of chitosan is given 
elsewhere in this book. 
1.6.2.1.3.3 Promises and challenges with Chitosan in tissue engineering 
Chitin and its derivatives have a number of applications in drug delivery and tissue 
engineering. While being an abundantly available polymer, chitosan is also biodegradable 
inside the body, mostly by the enzymatic activity of lysozyme. However chitosan/chitin by 
itself lacks good mechanical properties required in certain structural applications.  Chemical 
modifications of chitosan and blending the polymer with other natural and synthetic 
polymers are done to overcome this limitation. On the whole, chitosan has a huge potential in 
tissue engineering and drug delivery applications. 
1.6.2.1.4 Alginic acid 
 
1.6.2.1.4.1  Chemical structure, properties and sources 
Alginic acid is an anionic, strictly linear (unbranched) copolymer of mannuronic acid (M 
block) and guluronic acid (G block) units arranged in an irregular pattern of varying 
proportions of GG, MG, and MM blocks  (Matsumoto, Kawai, & Masuda, 1992)  (Figure 
1.11). C5 epimerization and flipping of sugar ring to 1C4 position (Christensena, 2011) is seen 
to occur for steric stability in the polymer. The M residues are linked at 4C1 (diequatorial 
links). The G residues are the C-5 epimers of M. These G residues are linked at 1C4 with 
diaxial links(181).  The G and M blocks are present as similar or strictly alternating (GG, 
MM, or GM). Due to the diaxial linkage, G blocks (GG) are stiffer than alternating blocks 
(GM), and hence more soluble at lower pH. The content of G in alginates varies from 40-70 
% depending on the source and determines the quality of the alginate polymer. The 
 43 
molecular weight of alginate can vary widely between 50-100,000 kDa. It is generally seen 
that alginates with high G block content are highly suitable for biomedical application due to 
the ease of processiblity, and low immunogenicity in the body. Hence the content of G and M 
blocks is a crucial factor that determines the properties and applications of the resultant 
alginate(182). Alginates are polysaccharides produced by a wide variety of brown seaweeds 
(Laminaria sp., Macrocystis sp., Lessonia sp., etc.). Additionally bacteria also synthesize 
alginates and these can be used as tools to tailor alginate production, by understanding the 
biosynthesis of the polymer in these bacteria. A family of enzymes termed mannuronan-C5-
epimerases that convert M into G at the polymer level. By genetically selecting and 
engineering Pseudomonas strains that contain only a single epimerase for the production of 
high G containing alginates has been possible. Using such strategies, alginates with up to 
90% G content and extremely long G-blocks have been produced(183-185).
 
Figure 1.11 Gellation of Alginic Acid 
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Mechanism of gellation of alginic acid in the presence of Ca2+. Possible junctions: (a) GG/GG 
junctions, (b) MG/MG junctions, and (c)mixed GG/MG, with Ca2+. 
Though such strategies are useful to engineer alginates, most of the alginates extracted for large-
scale applications originate from natural sources such as seaweeds. The quality is determined by 
the species and even the seasonal variations. The alginate could contain from 10-70% G. 
Techniques of separation such as fractionation and precipitation in calcium can help separate the 
G-block and M-block rich alginates. The molecular weight of alginate is a critical factor to 
influence its viscosity in solution, besides the concentration of the polymer. The most important 
property of alginate is its ability to gel in the presence of cations (like Ca2+, and Ba2+) (Figure 
1.12). The carboxylic acid groups of sugars in G blocks of adjacent polymer chains crosslink 
with multivalent cations to form a gel. Factors that influence the stiffness of the gel are 
molecular weight distribution of the alginate polymer (dependent on M/G ratio), and the 
stoichiometry of alginate with the chelating cation(186, 187). 
1.6.2.1.4.2 Attempts made in Tissue engineering and drug delivery 
1.6.2.1.4.2.1 Alginate alone 
The usage of polymers in biomedical applications such as drug delivery and tissue 
engineering are highly dependent on its ability to degrade in the body(188). There are 
enzymes that can degrade alginate in the human body. The mechanism of degradation of 
alginate in the body happens in multiple ways as described below: 
Disintegration of the alginate material occurs by exchange of gelling calcium ion with 
sodium. Acid hydrolysis and alkali hydrolysis are two possible processes that can lead to 
disintegration. At a physiological pH of 7.4, β-elimination by alkali hydrolysis is the 
predominant mechanism of alginate polymer length reduction. Oxidation of the gels, by 
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agents such as peroxides(189) help hasten the process, but also weaken the gel, in a ring 
opening reaction of the polymer.  
Degradation by reactive oxygen species (ROS). Most polymers including alginates undergo 
‘free radical de-polymerization’ or ‘oxidative-reductive de-polymerization’. Water molecules 
or molecular oxygen generates free radicals in living systems. Exposure of polymer to 
gamma irradiation hastens this process and can be used to enhance the rate of 
degradation(190).  
Thus the major disadvantages of alginate are the lack of enzymatic degradation and its inert 
nature that makes it non-adherent for cells. To overcome these limitations, alginate is widely 
used as its derivative in combination with other polymers in drug delivery and tissue 
engineering applications. Alginate by itself is used widely in many industries. It is used as a 
stabilizer and emulsifier in food industry, as it interacts with proteins, fats and fibers. 
Alginate-pectin mixtures are used as gelling agents independent of sugar content in foods. 
Hence, alginate is used in many low calorie substitute foods. The high hydrophilicity of 
alginates renders the material biocompatible and non-immunogenic. Therefore it is used 
widely in pharmaceutical industry as drug excipient(181), dental impression material(191), 
and as a material for wound dressing(192).   
1.6.2.1.4.2.2 Alginate Derivatives and combinations with other polymers 
In general alginates are formed into gels either by using multivalent cations or by covalent 
crosslinking. These modifications will be discussed further, here. The major purpose in 
subjecting algnates to chemical and physical modifications is to tailor their physical 
properties such as degradation, mechanical strength, and biological properties such as 
enhanced interaction with cells.  Mechanical properties like stiffness and strength of alginate 
gels can be controlled by physical factors. Concentration of polymer(193) and its molecular 
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weight(186) can be used to determine the density of polymer solution for formulation of gels. 
Increase of both these factors leads to higher viscosity of the polymer solution and hence a 
stiffer and mechanically strong gel.  Cationicpoly- (ethyleneimine) (PEI)(194) addition leads 
to improvement of alginate gel’s mechanical properties. High molecular weight PEI increases 
the resistance of the gel to de- crosslinking agents and thus improves the gel’s stiffness. 
Gelling conditions such as temperature, type and concentration of crosslinker also affect the 
mechanical properties of alginate gels. Low temperature cross-linking(195) leads to slow 
crosslinking, due to reduced rate of calcium ion diffusion. This results in the formation of 
gels with enhanced mechanical properties. Apart from these factors, the presence of cells in 
the gels is also shown to improve its mechanical strength(196).    
As discussed above in the previous section there are many methods used to control the 
degradation of alginates. Gamma irradiation(197) and partial oxidation(198) can be used to 
reduce the molecular weight of polymer and accelerate degradation rates. These techniques 
also affect the mechanical strength of alginate gels.  Gels with bimodal molecular weight 
distribution have been formulated with one molecular weight polymer being oxidized, and 
the other left untreated. This approach also accelerated gel degradation rate. In gels that are 
covalently crosslinked, the linker density(199) determines the rate of degradation as well as 
the strength of the gel.  As alginates are not conducive to cell adhesion, covalent 
modification of the polymer, coupling whole (like fibronectin and collagen)(200, 201) or 
parts of cell adhesion molecules (like RGD peptides) is a popular strategy used to increase 
cellular responses. Here the concentration(202) of these adhesion molecules and the 
composition of the gel (M/G ratio) determine the effectiveness of the gel in inducing cell 
adhesion.   
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Alginate based hydrogels have been used as drug delivery vehicles for low molecular weight 
(small) molecule drugs as well as proteins such as growth factors. Drug-alginate interactions 
play a crucial role in determining the rate of drug release from alginate gel matrices. Drug 
release rate can be completely controlled by charge polarity (hydrophilic molecules will be 
released quickly and hydrophobic ones more slowly), when there is no chemical interaction 
between the drug and the alginate matrix. Carbodiimide chemistry is used to link hydrophilic 
drugs(203) to alginate matrices to delay their release. In such a scenario the rate of drug 
release is determined by polymer degradation. Here a linker such as AAD could be used to 
attach the drug to alginate and the rate of release would be controlled by the concentration of 
the spacer.  Ionic complexes can also be used to attach drugs to alginate(204). Proteins such 
as growth factors have been successfully delivered by alginate gel systems. It was seen that 
such deliver systems preserved the bioactivity of the factors. Hence angiognic growth factors 
like β- Fibroblast Growth Factor (FGF-β)(205), and Vascular Endothelial Growth Factor 
(VEGF) loaded into alginate beads were successful in inducing angiogenesis to a greater 
extent than free administration of the growth factors. Ionic complexes were used to link 
VEGF(206, 207) to alginate matrix and the dissolution of this complex along with diffusion 
acted to control the release of active VEGF from the gels over several weeks in vivo. 
In most tissue engineering applications alginates with modified physical, chemical and 
biological properties are desirable. These characteristics can be achieved by chemically 
modifying alginate to form its derivatives and blends with other polymers. Alginate has a 
number of hydroxyl and carboxyl groups along its polymer backbone and these are ideal 
candidates for its chemical modification. Chemical modifications that can be carried out 
using the hydroxyl group are as follows: 
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Oxidation: Oxidation of alginate polymer chain produced a decrease in the stiffness of the 
polymer by breaking C2–C3 bond. Here sodium alginate is usually the substrate to be reacted 
with sodium periodate. This leads to oxidation on the –OH group at C-2 and C-3 position of 
the uronic acid on sodium alginate. Two aldehyde groups result in each oxidized monomeric 
units. The resultant oxidized alginate has reactive groups on its backbone and large rotational 
freedom of the molecule. This renders the polymer more amenable to further chemical 
modifications and greater biodegradation(208, 209).  
Reductive amination of oxidized alginate: Oxidized alginate can be used as a substrate for 
chemical reactions such as reductive amination. Reductive amination is performed with alkyl 
amine by using NaCNBH3 as reducing agent. This reaction is favorable at a pH of 6-7 and 
byproducts such as aldehyde/ ketone are negligible under the reaction conditions(210).  
Sulfation: On sulfation, alginate structurally resembles heparin and attains anti coagulant 
properties, alongside high blood compatibility(211). Reacting sodium alginate with 
formamide and chlorosulfuric acid (ClSO3H) at 60°C can sulfate it.  
Copolymerization: Microwave irradiation of sodium alginate and acrylamide led to synthesis 
of various grades of grafted polymers(212). Alginate-g-vinyl sulfonic acid prepared by 
employing potassium peroxydiphosphate/thiourea redox system has also been reported(213). 
These synthesized graft copolymer exhibit better results for swelling, metal ion uptake, and 
resistance to biodegradability in comparison to parent alginates themselves. 
Linking Cyclodextrins: α-cyclodextrin (α-CD) can be covalently linked to alginate. This 
reaction can be targeted to the hydroxyl groups of the alginate by cyanogen bromide (CNBr) 
method to prevent reaction at the carboxyl group. This specificity was necessary to form the 
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calcium–alginate beads that have great potential in encapsulating bacteria for environmental 
remediation(214).  
Chemical modifications that can be carried out using the carboxyl group are as follows: 
Esterification: Alkyl group is attached to a molecule during esterification. Addition of alkyl 
group to the backbone of alginate results in increasing the hydrophobicity of alginate. 
Alginate can be modified by direct esterification using several alcohols in the presence of 
catalyst. The alcohol is present in excess to ensure that the equilibrium is in favour of product 
formation. Propene glycol ester of alginate (PGA) was obtained by esterification of alginate 
with propyleneoxide. This is a commercially useful derivative of alginate(215). 
Ugi Reaction: Hydrophobically modified alginate can be prepared by the Ugi 
multicomponent condensation reaction. The Ugi reaction is amulti-component reaction in 
organic chemistry involving a ketone or aldehyde, an amine, an isocyanide and a carboxylic 
acid to form a bis-amide(216). 
Amidation: In amidation reaction, a coupling agent, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC-HCl) is reacted with alginate to form amide linkages 
between amine-containing molecules and the carboxylate moieties on the alginate polymer 
backbone. This results in hydrophobic modification of the alginate(217).  
A general outline of reactions used to modify alginate for biomedical applications was 
summed up above. Though mostly hydrogel of alginate is the most popular form of 
application of the polymer, other formats have also been formulated. Alginate foams(218), 
fibers(219, 220) and nanofibers(221) are other forms in which alginates are fabricated(182). 
Bioartificial pancreas, bone(222), vasculature and liver(223) are some of the tissue-
engineered organs where alginate materials have been used successfully.    
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1.6.2.1.4.3 Promises and challenges with Alginates in tissue engineering 
Alginates are a versatile class of polysaccharides that present a great tool as materials for 
tissue engineering. They have been formulated as gels, microspheres, foams and fibers in 
tissue engineering and for delivery of drugs and biological factors. Some constraints posed 
by the material are its non- enzymatic degradation in the human body and its extremely 
hydrophilic nature that discourage cell anchorage. However, these limitations have been 
overcome by subjecting its –OH and –COOH functionalities to chemical modifications. 
Understanding of the biosynthetic pathways leading to alginate biosynthesis in bacterial 
systems has been very useful in tailoring their polymer chain composition and the molecular 
weight of the polymer. Yet, more work needs to be done in improving these systems. 
Alginate hence serves as a low cost biopolymer that is a good tool in biomedical engineering. 
1.6.2.1.5 Cellulose 
1.6.2.1.5.1 Chemical structure, properties and sources 
Cellulose, the “sugar of plant cell wall” is the most abundant biopolymer in the biosphere.  
The basic monomer unit of cellulose is β-D-anhydroglucopyranose. These units are joined 
together covalently by acetal functions between the equatorial group of the C4 carbon atom and 
the C1 carbon atom (β-1,4-glycosidic bonds). These β-1,4-glycosidic linkages bestow cellulose 
with its resistance to chemical/ enzymatic attack(224) (Figure 1.13). Therefore cellulose is a 
linear-chain polymer with a large number of hydroxyl groups (three -OH groups per anhydrous 
AGU unit). This linear structure can be extended to molecules containing 1000–1500 β-D-
glucose monomer units, in a cellulose polymer chain. This chain length of cellulose is expressed 
in terms of number of constituent AGUs, termed degree of polymerization (DP). The degree of 
linearity and the presence of extensive –OH groups throughout the cellulose chain are 
responsible for formation of inter and intra molecular hydrogen bonds throughout the polymer 
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chain. This causes cellulose chains to organize in parallel arrangements into crystallities and 
crystallite strands, the basic elements of the supramolecular structure of the cellulose fibrils and 
the cellulose fibers. This arrangement of fibers in the polymer is termed its supramolecular 
structure and it in turn influences its physical and chemical properties. Cellulose is known to 
exist in at least five allomorphic forms. Cellulose I is the form found in nature. Cellulose may 
occur in other crystal structures denoted cellulose II, III and IV. Cellulose II is the most stable 
structure of technical relevance. This structure can be formed from cellulose I by treatment with 
an aqueous solution of sodium hydroxide. This leads to regeneration of native cellulose from 
solutions of semi-stable derivatives. This crystalline structure is modified from cellulose I. A 
parallel chain arrangement of cellulose in cellulose I form undergoes a change to form cellulose 
II.  This renders the cellulose II more accessible to chemical treatments and hence more reactive. 
A fringe fibrillar model is used to describe the microfibrillar structure of cellulose polymer. It 
describes the structure to be made of crystalline regions of varying dimensions called crystallites 
and noncrystalline regions. This structure explained the partial crystallinity and reactivity of 
cellulose in relation to its microfibrillar structure(225).  
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Figure 1.12 Structure of Cellulose 
 
Figure 1.13 Anhydroglucose unit of Cellulose 
Numbering of carbon atoms in anhydroglucose unit of cellulose 
 
Cellulose behaves an active chemical due to the three-hydroxyl groups in each glucose 
residue. The hydroxyl groups at the second and third positions behave as secondary alcohols, 
while the hydroxyl group at the sixth position acts as a primary alcohol (Numbering as 
shown in Figure 1.14). These –OH groups are the responsible for the reactivity of cellulose. 
Degree of substitution (DS) is the term used to indicate the average number of –OH groups 
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substituted in an anhydroglucose unit of a cellulose molecule. That is, a DS of 3 indicates 
that all the 3 –OH groups have been substituted in the anhydroglucose units of the cellulose 
derivative. In general, the relative reactivity of the hydroxyl groups can be expressed as OH–
C6 >> OH–C2 > OH–C3(226). 
Cellulose, like the polysaccharides above, has certain drawbacks. These include poor 
solubility in common solvents, poor crease resistance, poor dimensional stability, lack of 
thermoplasticity, high hydrophilicity and lack of antimicrobial properties. To overcome such 
drawbacks, the controlled physical and/or chemical modification of the cellulose structure is 
essential(226). Introduction of functional groups into cellulose can alleviate these problems, 
while maintaining the desirable intrinsic properties of cellulose. Apart from the conventional 
plant source, cellulose is also obtained from bacteria, termed bacterial cellulose. 
Understanding and engineering these biological systems has opened further doors for 
bringing in desired modifications into cellulose.   
1.6.2.1.5.2 Attempts made in Tissue engineering and drug delivery  
1.6.2.1.5.2.1 Cellulose alone 
As cellulose in its native form has extensive hydrogen bonds, it is not very processible. Most 
of the early attempts resorted to viscose process of regenerating (restoring cellulose structure 
back) cellulose from its derivatives. Regenerated cellulose has been used as a matrix for 
wound dressing. Early results indicated that implanted viscose cellulose sponges led to 
increased granulation tissue formation over a period of time and that the pore structure of the 
scaffold could influence cell infiltration within a certain limit(227). On the other hand it was 
seen that a lower content of cellulose and lower pore diameter induced greater tissue invasion 
of the implant and later on it also proved to be a matrix conducive for bone formation in a rat 
model(228). However, cellulose sponges were seen to be slow degrading matrices taking up to 
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sixty weeks for them to be degraded(229). Cellulose also was used successfully as an enzyme 
carrier by dissolving cellulose in ionic liquid and regenerating it. Usage of a hydrophobic 
ionic liquid preserved the enzymatic activity to a greater extent(230). While biodegradation 
remains a challenge for the absorption of cellulose, it was seen that treatments that markedly 
reduced crystallinity led to degradation as well as high biocompatibility of regenerated 
cellulose(231).  In recent years, microbial cellulose (MC) produced by bacterial species such 
as Acetobacter xylinum has gained much attention as a material for use in biomedical 
appliances. Though chemically similar to plant cellulose, MC has a microfibrillar and 
nanostructured arrangement that enables higher water retention by the material. This property 
is conducive in its application in wound dressing, production of vascular conduits etc(232). 
This cellulose was also seen to have a high degree of biocompatibility(233).   
1.6.2.1.5.2.2 Cellulose derivatives and combination with other polymers 
The supramolecular structure of cellulose and the extensive hydrogen bonded chemical 
structure of cellulose render it insoluble in water and organic compounds. Therefore most of 
the reactions involving cellulose are carried out in solid or swollen state as heterogeneous 
reactions. Here, the limiting factors for the hetrogenous reaction are the breakage of hydrogen 
bonds (by alkaline treatment) and degree of interaction with the reaction media (by swelling). 
Therefore, specific solvents that disrupt the hydrogen bonds in cellulose such as N, N-
dimethylacetamide and lithium chloride (DMA/LiCl), Dimethyl 
Sulfoxide/Tetrabutylammonium Fluoride (DMSO/ TBAF)(234) are used widely for the 
purpose. Hence, even though using such strategies, cellulose alone has been employed for 
different purposes as a material, its derivatives are easier to work with as they overcome the 
limitations posed by cellulose. The following section gives an overview of derivatives of 
cellulose and its combination with other polymers: 
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Cellulose Esters:  
Esters of cellulose with interesting properties such as bioactivity, thermal and dissolution 
behavior can be obtained by esterification of cellulose with nitric acid in the presence of 
sulfuric acid, phosphoric acid or acetic acid. Commercially important cellulose esters are 
cellulose acetate, cellulose acetate propionate and cellulose acetate butyrate. Cellulose esters 
of aliphatic, aromatic, bulky, and functionalized carboxylic acidscan be synthesized through 
the activation of free acids in situ with tosyl chloride, N, N’-carbonyldiimidazole, and 
iminium chloride under homogeneous acylation with DMA/LiCl or DMSO/ TBAF. A wide 
range of cellulose esters that vary in their degree of substitution, various substituent 
distributions and several desirable properties can be obtained through these reactions. 
Recently a number of enzymes that degrade cellulose esters have been reported. Some of them 
are acetyl esterases, carbohydrate esterase (CE) family 1, and Esterases of the CE 5(235-238)  
family.   
Cellulose esters have been put to use in many biomedical applications. Hemodialysis 
membranes used in purification of blood, for patients with renal failure have employed melt-
spun cellulose diacetate membrane. These membranes have been produced by Altin 
(company) and used successfully. They were advantageous and had less toxicity than 
synthetic polymer based membranes(239). Cellulose acetate is seen as a preferred material for 
the fabrication of blood filration devices that are used to separate a fraction of the blood such 
as red blood cells and leukocytes(240, 241). Cellulose acetate and regenerated cellulose 
fibrous matrices have been successful in supporting the growth of cardiac myocytes and 
present a potential scaffold platform for cardiac regeneration(242) (Entcheva et al., 2004).  
Cellulose Ethers: 
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Carboxymethyl cellulose (CMC) is the major cellulose ether. By activating the non-crystalline 
regions of cellulose, selective regions of alkylating reagents can attack the cellulose. This is 
termed the concept of reactive structure fractions and is used widely for the production of 
CMC. Another route for carrying out the same reaction is by derivatization of cellulose in 
reactive microstructures, formed by induced phase separation. This process involves the usage 
of NaOH in anhydrous state in combination with solvents like DMA/LiCl. These CMC 
products have a distribution of substituents that deviate significantly from statistical prediction 
of the product theoretically. 
CMC is used in several drug delivery and tissue engineering purposes. The release of 
apomorphine, a drug used to regulate motor responses in Parkinson’s disease was successfully 
incorporated into CMC powder formulation exhibited a sustained nasal release, and it 
performed better than starch based delivery vehicle(243). Sodium CMC has been used  
successfully in gastrointestinal drug delivery(244). Hence CMC is seen as a successful drug 
delivery system for mucosal tissue(245). Apart from drug delivery, CMC is useful as a 
scaffold in tissue engineering too. pH dependent swelling of CMC hydrogels, were capable of 
releasing drugs at the right pH present in the tissue of interest and showed potential as a 
wound dressing material(246). CMC hydrogels could be used for encapsulating cells of 
nucleus pulposis and hence are a potential replacement for intervertebral disc 
degeneration(247). CMC has been combined with chitosan(248)  and hydroxyapatite(249) for 
bone and dental regeneration purposes too.       
Silyl Cellulose: 
Silyl ethers of cellulose are characterized by a remarkable increase in thermal stability, 
lipophilic behavior and a lack of hydrogen bonds. They can be used as selective protecting 
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groups in organic synthesis, due the simple cleavage of the silyl ethers under acidic conditions 
or through nucleophilic attack. Therefore, the silyl ethers of cellulose are very attractive for 
engineering polysaccharide chemistry(250). The silylation of polar protic -OH groups of 
cellulose with chlorosilanes and silazanes leads to these silyl ethers. The degree of 
substitution (DS) and position of silyl substitution is determined by the reaction condition. All 
the three –OH groups will be substituted when trimethyl silylation with hexamethyldisilazane 
(HMDS) in liquid ammonia, is used in the reaction. Dissolution of cellulose in DMA/LiCl 
(homogeneous reaction) makes the –OH groups more accessible. Following this, if the 
synthesis takes place in the presence of imidazole, the bulky silylation reagent 
thexyldimethylchlorosilane (TDSCl) leads to complete silylation at O6 and O2 (DS value=2.0). 
Here, the primary and the most reactive secondary -OH groups are converted. If silyl ether 
formation starts with the same reagent in cellulose suspension in aprotic dipolar media like N-
methylpyrrolidone (NMP), which contain gaseous ammonia, silylation of all primary C6-OH 
groups takes place. This state does not permit any further reaction of the secondary hydroxy 
groups(251). 
Cellulose Sulfonates: 
The most frequently synthesized and used cellulose sulfonates are the p-toluenesulfonates 
(tosylates), methanesulfonates (mesylates), p-bromobenzenesulfonates (brosylates), and 
trifluoromethanesulfonates (triflates). The synthesis of sulfonates is through simple 
esterification of the -OH groups of cellulose with the corresponding sulfonic acid chlorides or 
anhydride is a way to attach nucleofuge groups to cellulose(252). By varying the solvent and 
reaction conditions, the DS of the polymer can be controlled. For instance, at temperatures of 
7°C, cellulose tosylate with a maximum DS of 2.3 can be formed with tosyl chloride in the 
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presence of triethylamine. The DS of sulfonated cellulose can also be controlled by the molar 
ratio of tosyl chloride to glucose units of the cellulose.  
Aminocellulose: 
Aminocellulose are aminodeoxy derivatives bearing the nitrogen function directly on the 
cellulose skeleton. These are useful in immobilization of enzymes and other proteins. By 
having a specific structural design based on cellulose tosylates. Aminodeoxycellulose are 
synthesized with corresponding halogen derivatives and sulfonates as starting materials. PDA 
cellulose is a material used successfully for immobilization of enzymes like oxidoreductases, 
glucose oxidases, peroxidases using gluteraldehyde. Diazo coupling and redox coupling have 
also been utilized to link ascorbates, and dyes. Here too, the solvent composition and reaction 
conditions can determine the reaction chemistry (SN2) and hence the DS of the product 
formed(253). 
Resinification of cellulose:  
Resinification of cellulose can impart crease-resistance termed ‘‘durable press’’ properties to 
cellulose. The reaction of cellulose with bi- or poly-functional compounds leads to formation 
of crosslinked cellulose matrix, called resinified cellulose(224).  
Graft polymerization of cellulose: 
A new approach to modification of cellulose is by graft polymerization. A graft copolymer 
generally consists of a long sequence of one monomer, referred to as the backbone polymer 
(main chain) (cellulose in this case) with one or more branches (grafts) of long sequences of a 
different monomer(254). Graft copolymerization permits the combination of the best 
properties of two or more polymers in one physical unit(226). The aim with cellulose graft 
polymerization is to retain the inherent properties of cellulose and incorporate qualities from 
 59 
the polymer grafted onto it. Depending on the nature of the grafted polymer, properties such 
as dimensional-stability, resistance to abrasion and wear, wrinkle recovery, oil and water 
repellence, elasticity, sorbancy, ion exchange capabilities, temperature responsiveness, 
thermal resistance and resistance to microbiological attack can be incorporated into 
cellulose(255-259). 
The methods for graft polymerization of cellulose can be generally classified into three major 
groups such as (i) free radical polymerization, (ii) ionic and ring opening polymerization and  
(iii) living radical polymerization. 
Strategies used in cellulose graft polymerization can be divided into three categories: 
The ‘grafting to’ approach- here the functional pre-formed polymer with its reactive end-
group is coupled with the functional groups located on the backbone of cellulose, the major 
polymer. The inherent weakness of this approach is a hindrance to diffusion caused by 
crowding of polymer chains on the surface (Odian, 2004). 
The ‘grafting-from’ approach- here the growth of polymer chains occurs from initiating sites 
on the cellulose backbone. This is the most commonly used approach. Easy access of the 
reactive groups to the chain end of the growing polymer is achieved in ‘grafting-from’ 
approach. This makes it possible to attain high graft density(260). 
The ‘grafting through’ approach- in this approach, a vinyl macromonomer of cellulose, is 
copolymerised with a low molecular weight co-monomer. Though this approach is more 
convenient, a cellulose-derived macromonomer has to be synthesized. This poses a limitation 
to this technique (Odian, 2004). 
1.6.2.1.5.3 Promises and challenges with cellulose  
Cellulose and other polysaccharides discussed above have been gaining importance as 
polymeric materials. Increasing the knowledge of organic, polymer chemistry and the 
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chemistry of low-molecular weight polysaccharides can greatly help us understand more 
about the chemistry of cellulose and control the different processing techniques for cellulose 
to a greater extent. Having a multidisciplinary approach will further help us utilize the 
polymer more in biomedical applications. The development of derivatives and grafted 
polymers of cellulose have been important steps towards the utilization of cellulose, which is 
considered as a renewable resource. Processes such as lyocell processing of cellulose are 
environment friendly techniques and promise a safer polymer processing technology. New 
insights are still being obtained on the process of wood pulping and biosynthetic pathways in 
cellulose synthesis. By using this knowledge, engineering cellulose and utilizing bacteria for 
production of the polymer are the advances we could expect in the future.  
1.6.2.2 Proteins in tissue engineering 
Proteins are the building blocks of life and their sophisticated chemistry makes them excellent 
scaffolding materials for BTE. Some common proteins used in BTE are: 
1. Collagen 
2. Fibronectin 
3. Fibrin 
4. Vitronectin 
5. Keratin 
6. Silk 
1.6.2.2.1 Collagen 
About 20- 30% of mammalian protein is collagen and therefore it is the most abundant animal 
protein biopolymer(261). There are around 28 types of collagen found in various tissues(262).  
All of the collagen shares a structural similarity. Their basic unit is termed tropocollagen and 
consists of 3 parallel polypeptide chains- GXY, where G is glycine, X is usually proline, and 
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Y is usually 4-hydroxyproline, arranged to form a triple helical structure. This tropocollagen 
further forms the fibrous collagen structure seen in different tissues(263). The natural source 
of collagen is animal tissue like skin, tail and tendon. Collagen can be formulated into 
hydrogels, fibers and microspheres. These matrices have been used for drug delivery(264) and 
in BTE applications(265). In the case of bone 60% of its weight is attributed to the mineral 
content. The remaining 40% of bone weight comes from the proteins and water. Of the 
proteins found in bone, collagen constitutes 90%. Hence many BTE scaffolds use collagen as 
a biomaterial by itself or in combination with other materials. Collagen acts as a ligand to the 
cellular integrin that act as their receptors like α2β1 and α1β1 integrin. This binding of 
collagen to integrin elicits a signaling cascade that is conducive to cell survival, adhesion, 
proliferation and osteoblastic differentiation(266). Though collagen has excellent tissue 
compatibility and osteoconductive properties, collagen matrices lack mechanical strength to 
be used for BTE. Therefore, oftentimes collagen is combined with other natural/ synthetic 
polymers for BTE applications(267). 
1.6.2.2.2 Fibronectin 
Fibronectin too is an ECM protein. It provides structural support, and also acts as ligand to 
certain integrin receptors, apart from recruiting other biological factors(268). These 
functionalities of fibronectin offer it the ability to induce cell adhesion, proliferation and 
differentiation. There are two forms of Fibronectin- the secreted, soluble form produced by 
hepatocytes in the liver and the insoluble form secreted by cells such as fibroblasts.  The 
soluble form of fibronectin is a major component of blood plasma. The secreted fibronectin 
from cells is composed of two non- identical polypeptide chais linked by a disulfide bond at 
the carboxy terminal end of the peptides.  There are three modules in each subunit of 
fibronectin. Each subunit is about 230- 270 KDa in molecular weight. The three modules 
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forming each of these subunits are: type I, type II and type III(269). Owing to its 
biocompatibility and cell adhesion properties, fibronectin and the adhesion subunits of 
fibronectin have been coated onto many BTE implants(268, 270).  
1.6.2.2.3 Fibrin 
Fibrin is an ECM protein formed during blood clot. The polymerization of soluble fibrinogen 
turns to insoluble fibrin by the action of thrombin(271). Fibrinogen is made of three pairs of 
polypeptides Aα, Bβ and γ, bridged by disulfide bonds(272). When thrombin cleaves Aα and 
Bβ chains at their N- termini, the polymerization of fibrinogen to fibrin ensues(273). The 
fibrin fibrils aggregate to form a clot. The FDA has approved fibrin sealants for use as 
medical adhesives. Fibrin biomaterials are used as drug delivery and wound healing 
scaffolds(274). 
1.6.2.2.4 Vitronectin 
Glycoprotein vitronectin is also a ligand for integrin receptors on cells(275). Vitronectin is 
found both in circulation and in different tissues. It is also seen that vitronectin plays a role in 
linking cell adhesion, humoral immunity and cell invasion into tissues. Vitronectin mediates 
cell adhesion and spread and hence coating scaffolds with fibronectin induced cell adhesion 
and spreading(276). 
1.6.2.2.5 Keratin 
Keratin is a protein found in animal tissues such as nail, hair, and horns. It presents a 
filamentous structure made of hierarchically arranged structures. Cell adhesion domains 
termed LDV domains were found in keratin(277). It was seen that keratin biomaterials led to 
growth and differentiation of MC3T3-E1 preosteoblasts. Hence keratin is seen as a potential 
scaffolding platform for BTE(278). 
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1.6.2.2.6 Silk 
Silk is a protein produced by insects like worms and spiders. It is also a hierarchically 
structured filamentous protein(279). A glycoprotein matrix called sericin embeds the two 
microfilaments of silk and this constitutes the basic structure of silk. The sericin protein in silk 
fibroi is shown to have immunogenic effects. Therefor, this protein is removed from silk 
while using the material for biomedical applications. Silk is a 370 kDa fibroin protein, with a 
lighter chain fibroin of 25 kDa and a P25 protein of 325 kDa form the microfilament 
structure(280). The presence of α-helix and β-turns in the protein structure of silk renders the 
material mechanically strong. The silk produced by silk worm B. mori is the most polular 
source of the protein. Silk based materials are being developed as various tissue engineered 
scaffolds including materials for bone(281). 
1.7 Design of Scaffolds for BTE 
There are several processing techniques used in BTE for the formulation of 3D porous 
scaffold structures. These processing techniques facilitate the inclusion of more than one 
material into a desired shape and form with pore sizes that are needed for the particular tissue 
engineered application. Some of the most common techniques are as follows(282). 
1.7.1 Processes used for fabrication of macro and microporous BTE scaffolds 
1.7.1.1 Thermally induced phase separation (TIPS) 
In this technique, a homogenous solution of the polymer used for scaffolding is dissolved in 
dimethylcarbonate overnight. Ceramics are added to the polymer solution and dispersed into 
the polymer phase by sonication. This mixture is then maintained at -196°C for two hours 
after quenching in liquid nitrogen. This mixture is transferred into a cooling bath at -10°C 
with the application of vacuum. The solvent evaporates after the mixture is subjected to 48 
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hours of -10°C, followed by 48 hours of exposure to 0°C. Finally it is transferred to an oven at 
room temperature for the material to reach its equilibrium mass(283).  
The TIPS technique can produce scaffolds with macro and microstructures, with a high degree 
of porosity for various tissue engineering applications(284, 285). It is possible to gain control 
over the porosity of the scaffold formulated by modulating the parameters like concentration 
of the polymer and ceramic used, the solvent used for the system and the temperature of 
quenching(284). PDLLA/ Bioglass scaffolds prepared by TIPS have shown to support MG-63 
osteosarcoma cell line viability and proliferation and hence can be seen as potential scaffolds 
for BTE(286). Scaffolds of PDLLA or PLGA/ 45S5 Bioglass with high porosity hold promise 
as a scaffold for BTE(286, 287). Scaffolds formulated using TIPS have shown to have 
nanotopographical features and hence greater bioactivity(288, 289). 
1.7.1.2 Solvent casting and particle leaching 
The solvent casting technique involves casting of a well-dissolved polymer or a polymer/ 
seramic composit solution to allow the solvent to evaporate. The casting mould can be used to 
design the 3D shape of the resulting scaffold material. While the technique is very simple to 
carry out, there are some disadvantages to it as well. Only a few shapes can be formulated and 
the process could lead to entrapment of solvent in the matrix. The entrapped solvents could 
attribute to the scaffold’s toxicity as well as denaturation of bioactive molecules in a 
composite scaffold system(290).  
Polymer microsphere constructs made by water oil/water emulsions can further be sovent 
sintered with the inclusion of salt or sugar during the sintering step. These porogens can be 
leached once the sintering is achieved. This technique gives tissue engineers the scope of 
engineering matrices with controlled porosity(288). However particle leaching has 
disadvantages such as limitations of dimensionality achieved in the scaffold, solvent retention, 
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and loss of bioactivity of encapsulated biomolecules. BTE scaffolds that incorporate calcium 
phosphate with graded porosity have been formulated using this technique(291). Optimally 
porous salt leached PLGA microsphere 3D sintered matrices have been used to improve the 
oxygen transfer in an otherwise less porous 3D porous sintered microsphere matrix(36). 
1.7.1.3 Solid freeform fabrication techniques (SFFT) 
Scaffolds with controlled macro and micro porous architecture are created by conventional 
foam fabrication procedures such as phase separation, porogen leaching and emulsion-solvent 
diffusion(292, 293). Computer aided imaging by micro CT and magnetic resonance (MR) has 
aided with production of scaffolds with programmed porosities, using SFFT(293). A PLLA/ 
TCP composite scaffold with about 90% porosity was successfully developed using 
SFFT(285). Its porosity was programed to be 400 µm in between the multiple layers of the 
scaffold along with micropores of 10 µm diameter. Similarly PLA scaffolds developed by 
SFFT combined computer aided programed macropore size of 500–800 µm, with solvent 
derived 50–100 µm void size(292). Though SFFT gives better control over the scaffold 
architecture, it may be a time consuming technique.  
1.7.1.4 Microsphere sintering 
Applying thermal(294) or solvent sintering(295) can sinter polymeric microspheres formed by 
emulsion solvent evaporation technique. This leads to the formation of 3D porous matrices 
with a porosity of 30- 40%, with pore diameter around 90 µm(294), as reported in literature. 
The polymer solutions could be made to incorporate bioactive molecules like ceramics and 
growth factors(296). The mechanical properties of these matrices can be constructed so that it 
is close to cancellous bone. The microsphere platform also offers scope for other 
modifications such as incorporation of nanofibers to be used in BTE(297).  
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1.7.1.5 Coated scaffolds 
Porous scaffolds prepared by any of the above techniques can be coated by dipping in a slurry 
of polymer or by electrophoretic deposition (EPD). The slurry could contain ceramics or 
growth factors. The slurry dipping technique performs better than EPD technique of 
coating(298). Deposition of biomineral by SBF solution using the slurry dipping technique 
has been used successfully in many BTE scaffolds to make them more osteoconductive(299).  
1.7.1.6 3D Printing 
3D Printing is an extension of SFF technology, where complex free structures can be created 
using a computer-aided design (CAD). Unlike many other machining processes that are 
subtractive in nature to create a desired scaffold structure, the 3D Printing technique uses an 
additive manufacturing approach (AM). The rapid prototyping (RP) system used in 3D 
printing combines liquids, powders and sheets to form the parts of the scaffold(300). 
Depending on the polymer used, the process can be tailored and performed at high or room 
temperature. This flexibility allows for incorporation of factors, hydroxyapatite and cells into 
the scaffold structure(301). In fused deposition molding (FDM) a CAD design is created using 
the information from CT and MR imaging data(302). The CAD data is input into the printer’s 
software that slices the data to form instructive printable layers. This information is sent to the 
polymer extrusion head and it prints the entire design one layer after another. Many polymers 
such as PCL(303), PDLLA and PLLA(304) have been used and in a combination with TCP 
and AH for producing BTE scaffolds using 3D printing(305). Some constraints of polymer 
processing parameters still exist with 3D printing, but progress is being made at a rapid pace 
with 3D printing technology.  
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1.7.2 Processes used for fabrication of nanoscale BTE scaffolds 
TIPS (described above), self-assembly of polymers, and electrospinning can be used to 
fabricate BTE scaffolds with nanoscale features. 
1.7.2.1 Self assembly 
Using the principles of protein folding can be applied towards the formation of an orderly 
nanofibrillar network. As few as two to three peptides can self assemble through their 
hydrophobic end groups to form nanofibers(306-308). Hydrogels(309) formulated by peptide 
molecule self assembly and nanofibers incorporated into scaffolds are examples of BTE 
scaffolds where the self assembly of proteins and peptides has been employed(310).  
1.7.2.2 Electrospinning 
Electrospinning is a popular technique for formulating polymeric nanofibrillar scaffolds for 
BTE. When an electric field is applied to a polymer solution, to over come the forces of 
surface tension, a continuous jet of polymer solution is obtained. This jet of polymer is 
allowed to collect at a grounded collector plate and the solvent evaporates leaving back the 
polymeric nanofibers at the collector plate(311). Electrospinning is a versatile technique that 
is simple and can be used to produce nanofibers of different fiber diameter(312), 
alignment(312) and could be fabricated to incorporate minerals(313). However nanofibers 
suffer from a few constraints. The electrospun nanofiber matrices have a surface to volume 
ratio that leads to burst release of encapsulated factors. Another issue is that the fibers form a 
2D mat rather than a 3D scaffold. Hence electrospinning alone cannot be used to formulate 
scaffolds for BTE as these matrices are not 3 dimensional and have no mechanical 
compatibility with bone(289).  
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1.8 Cells used in BTE  
Though scaffolds can act as the support structures, including cells and factors into tissue 
engineered constructs is essential for complete bone regeneration. While the incorporation of 
growth factors has proved to be beneficial, there are challenges of non-targeted bone 
formation and problems of maintaining the bioactivity of the factors while delivering them. 
Hence using cells is a clinically relevant and a simpler option in BTE. There are two cell types 
that could be used in tissue engineering. These two types of cells are somatic cells and stem 
cells. 
1.8.1 Somatic cells in BTE 
1.8.1.1 Cells used in analysis of BTE scaffolds 
Transfected cells that are immortalized are used to test a number of BTE scaffolds in culture. 
They can replicate osteoblastic proliferation and differentiation in the body. Studies with these 
cell types have indicated the potential of the BTE scaffold to perform in the body. Examples 
of such cell types are the murine MC3T3-E1 cells that are preostoblats derived from mouse 
calvaria(314) and the MG-63, Saos-2 and U-2 OS human osteosarcoma cell lines(315). They 
however have limited use with scaffolds implanted into the body, as these cells are capable of 
causing cancers due to the presence of transfected genes in them. 
1.8.1.2 Cells used in vivo 
Primary calvarial osteoblasts from rats(316), mice and humans(317) are used to determine the 
osteoconductive potential of BTE scaffolds. These are more reflective of the environment in 
the body and the responses may be more clinically relevant when examining the response of 
bone to a biomaterial being tested(316). They can also be transplanted into the body of 
animals of the same species. However their availability may be a limiting factor for their 
usage in vivo.  
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1.8.2 Stem cells in BTE 
While somatic cells like osteoblasts and periosteal cells can be used in BTE constructs, they 
have limited potential for expansion and avoiding de-differentiation. Hence stem cells hold 
great potential in BTE. The scaffolds can include features like nanoscaled dimensions and 
chemical functionalities that can direct the differentiation of stem cells. Stem cells could be of 
two types based on their source:  
1. Embryo derived  and  
2. Adult derived 
1.8.2.1 Embryo derived stem cells 
1.8.2.1.1 Embryonic stem cells 
Embryonic stem cells (ESCs) are totipotent stem cells with the ability to differentiate into 
multiple lineages. They also have the ability to maintain this potential while proliferating 
greatly. They have shown great potential towards osteoblastic differentiation. ESCs offer a 
great differentiation potential, but also have the ability to form tumors when implanted in 
vivo. This is termed teratogenicity. Apart from this, obtaining ESCs would involve their 
harvest from unborn embryos. Therefore using them in humans is challenging due to ethical, 
clinical and regulatory concerns associated with ESCs.  
1.8.2.1.2 Amniotic fluid derived stem cells (AFSCs) 
Amniotic fluid derived stem cells (AFSCs), are partly embryonic in origin and have are a little 
less multipotent than ESCs. They can maintain their potential while dividing upto 250 times. 
They can differentiate well in the osteoblastic lineage. Studies have used AFSCs to 
characterize the performance of BTE scaffolds in vitro.  
 70 
1.8.2.2 Adult stem cells 
1.8.2.2.1 Induced pluripotent stem cells (iPSCs) 
Induced pluripotent stem cells (iPSCs) were formulated to overcome the limitations of ESCs. 
By the transfection of the reprogramming factor genes (Oct4, Sox2, cMyc and Klf4) into 
somatic cells, the cells are reprogrammed to stem cells (iPSCs). These cells are being 
investigated for use in BTE(318). 
1.8.2.2.2 Bone marrow derived mesenchymal stem cells (BM-MSCs) 
The bone marrow has multipotent stem cells that can differentiate into cells of the 
mesodermal lineage including bone, cartilage, adipose, and skeletal muscle(319). These BM-
MSCs, are used widely both in research and in clinical procedures(320). The ease of 
accessibility, their large potential for self renewal, and minimal ethical and regulatory issues 
concerning BM-MSCs, makes these cells an attractive option for application in BTE(321). 
MSCs are found in the bone marrow and thought to play an essential role in bone 
healing(322). Their participation could be direct (they can differentiate into cells of the 
osteochondral lineage) and indirectly too by secretion of cytokines that allow for progenitor 
cells to home into the site of injury and help with processes like angiogenesis(323). BM-
MSCs are also known to have immunomodulatory effect when implanted into an osseous 
defect(324, 325).  
1.8.2.2.3 Adipose derived stem cells (ADSCs) 
The fat tissue in the body contains a population of multipotent stem cells called Adipose 
derived stem cells (ADSCs)(326, 327). These cells have a great proliferative and multilineage 
differentiation potential. Several experiments have shown the potential of ADSCs to 
differentiate in the osteogenic lineage when given the right media in vitro(328).  
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ADSCs have shown to be osteogenic when implanted into animals along with biodegradable 
BTE scaffold. Ectopic ossification by ADSCs that turned into osteoblasts under subcutaneous 
implantation(329) in mice and the capability of ADSCs to heal cranial defects by 
intramembranous ossification demonstrated their potential to be used in BTE(330). Hence the 
first phases of clinical trials combining ADSCs with autologous materials to induce bone 
formation were successful(331). Hence BM-MSCs and ADSCs are the most clinically 
relevant stem cell sources, presently. 
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2 Chapter 2 Preliminary Studies 
Cellulose and Collagen Derived Micro-Nano Structured Scaffolds for Bone Tissue 
Engineering2 
2.1 Introduction 
 
Scaffold based tissue engineering strategy has emerged as an alternative to autografts and 
allografts to regenerate damaged or lost tissue(332, 333). Bone graft substitutes or scaffolds 
are routinely used as viable alternatives to biological grafts due to ease of fabrication, 
handling and storage. Scaffolds often utilize a biodegradable three-dimensional (3D) 
architecture to serve as a temporary ECM to support tissue ingrowth. In particular, scaffolds 
for BTE are desired to have osteoconductive (promote osteoblast proliferation), 
osteoinductive (promote osteoblastic differentiation of progenitor cells) and osteointegrative 
(form an intimate contact and anchor into the surrounding bone) properties to promote bone 
regeneration(334). In the repair of a bone defect, the scaffold is designed to maintain the 
structure of the defect and restore the functions of the lost bone. Ideally the scaffold should 
satisfy a number of design criteria to achieve comparable properties present in autologous 
grafts: The scaffold should be (1) biocompatible so that it is integrated with the host tissue 
without any adverse immune response, (2) mechanically competent in order to tolerate the 
local forces. This is most critical for protecting the tissues and transmitting the compressive, 
tensile forces and mechanical cues across the defect to the regenerating cells, (3) 
biodegradable with non-toxic degradation products that can be metabolized and excreted by 
                                                
2 This study was published as a research article: Aravamudhan A, Ramos DM, Nip J, Harmon 
M, James R, Deng M, Laurencin CT, Yu X, Kumbar SG. Cellulose and Collagen Derived Micro-
Nano Structured Scaffolds for Bone Tissue Engineering. J. Biomed. Nanotechnology, 9 (4), 719-
731, 2013 
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the body, and with controllable degradation kinetics to match the rate of bone formation so 
that the newly produced tissue compensates the mechanical and mass loss of the degraded 
matrix, (4) osteoconductive with porous structures to allow cell infiltration, proliferation, 
neovascularization, and nutrient transport. It is desirable for BTE scaffolds to have highly 
interconnected pores with a minimum pore size of >100 µm to promote ingrowth of tissue and 
vasculature(335). The interconnected pore spaces enable the transport of oxygen and 
nutrients. Surface roughness of the scaffold promotes cellular adhesion, proliferation, and 
differentiation of anchorage-dependent cells(336, 337). (5) Lastly, scaffolds should be able to 
integrate with the surrounding osseous tissue through the formation of bonds with the bone. 
Scaffold chemical composition and topographical properties play an important role in guiding 
cell behavior and tissue regeneration in vivo. For instance, scaffolds presenting acrylate 
groups have been reported to maintain multipotency of progenitors(338) while functional 
groups such as amine, hydroxyl and carboxyl, lead to greater differentiation in the 
osteochondral lineage(38, 339), both in the absence and presence of inductive media. Recent 
studies have demonstrated the importance of topographical features in regulating cell 
behavior, including preferential adhesion, migration, proliferation and expression of cell-
specific phenotype(340). Several studies have reported the role of nano, micro and 
combination of micro-nano dimensional patterns in regulating stem cell differentiation into 
osteogenic lineage even in the absence of inductive media(64, 341, 342). In our previous 
studies we have reported enhanced cell migration and mature osteoblast phenotype 
development on the hierarchical structures comprised of micro-nano dimensions for BTE 
applications(297). 
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Biomaterials of both synthetic and natural biodegradable polymers have shown great promise 
in tissue engineering. Though synthetic polymers such as polyesters can be synthesized with 
desired molecular weight and elasticity, their degradation pattern often is reported to have a 
negative impact on tissue healing due to acidic degradation products(343). Different buffering 
systems made of polymer–polymer or polymer-calcium phosphates have been developed to 
neutralize acidic degradation products(344). On the other hand, polymers of natural origin due 
to their compositional similarity with native ECM components offer greater biocompatibility 
in tissue healing(335, 345). It is often a challenge to produce load-bearing scaffolds using 
natural polymers due their limited solubility and processability. For example, collagen(346, 
347), chitosan(345), polysaccharide(348) and protein based scaffolds are often presented in 
the form of porous sponges, fiber matrix or hydrogels. These scaffolds lack the mechanical 
stability and require chemical crosslinking to produce stable scaffolds. During scaffold 
fabrication, extensive processing and crosslinking compromises the biological functionality of 
these scaffolds(349-351). In this work we report the fabrication and characterization of 
mechanically stable micro-nano structured scaffolds based on a derivative of cellulose and 
type I collagen for bone tissue engineering. Sintered microspheres of cellulose acetate 
microstructure contribute towards ideal mechanical and pore property of the scaffolds for 
BTE. Scaffold surface functionalization with collagen nanofibers combines the nano fiber 
structures with the microsphere based scaffold framework to enhance the surface area as well 
as bioactivity. In this work we report the fabrication, optimization and characterization of 
cellulose acetate, and collagen functionalized scaffolds for BTE application.   
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2.2 Materials and Methods 
2.2.1 Materials 
 
Cellulose acetate (Mn 30 K) (CA), ethyl cellulose (Mn 30 K) (EC), and poly(vinyl alcohol) 
(30,000–70,000) (PVA) were procured from Sigma-Aldrich (St. Louis, MO, USA). 
Poly(lactic-co-glycolic acid) 85:15 (PLGA) was purchased from Alkermes (Wilmington, OH). 
Acetone, dichloromethane, cyclohexane, 10% formalin in PBS and gluteraldehyde were 
purchased from Fisher Scientific (Fair Lawn, NJ, USA). Promega MTS reagent kit 
(Madison, WI, USA), Bio-Rad Alkaline phosphatase (ALP) substrate kit (Hercules, CA, 
USA) and Invitrogen quantity PicoGreen dsDNA assay kit (Eugene, Oregon, USA) were used 
in this study. Alizarin Red and cetylpyridinium chloride were procured from Acros Organics 
(New Jersey, USA). Cell culture media was prepared by mixing 1:1 ratio of F-12 Nutrient 
Mixture (Invitrogen, Greens Island, NJ) and DMEM (Invitrogen, Greens Island, NJ, USA). 
Basal media was prepared by adding 10% FBS (Invitrogen, Greens Island, NJ, USA) and 1% 
Penicillin-Streptomycin (Invitrogen, Greens Island, NJ, USA) to 1:1 mixture of F-12 and 
DMEM. Osteogenic media was prepared by adding 0.05 mM L-ascorbic acid (Sigma, St. 
Louis, MO, USA) and 3.15 mM glycerol 2-phosphate disodium salt (Sigma, St. Louis, MO, 
USA) to basal media. RNAse and DNAse free water and 7.4 pH PBS buffer used were 
purchased from Invitrogen (Greens Island, NJ, USA). Human osteoblasts used in this study 
were purchased from PromoCell (Heidelberg, Germany). 
2.2.2 Polysaccharide Microsphere Fabrication 
 
Microspheres of CA and EC were fabricated via an oil-inwater solvent-evaporation technique. 
In brief, 20% EC or 13% (w/v) CA solutions in methylene chloride and acetone at a ratio 9:1 
were emulsified into an aqueous phase containing 1% (w/v) PVA. Emulsion was stirred at a 
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constant stirring rate of 250 rpm overnight and hardened microspheres were collected 
following solvent evaporation. Microspheres were washed repeatedly with deionized (DI) 
water and segregated into different sizes namely: 300–425, 600–710 and 710–800 m using 
sieves. Control PLGA microspheres were also prepared using a similar protocol. 
2.2.3 3D Porous Scaffold Fabrication 
 
Polysaccharide microspheres were sintered together into 3D porous scaffolds at the room 
temperature using a mixture of solvent and non-solvent(352, 353). In brief, a Teflon mould 
was filled with CA or EC microspheres to which 200 µL of an optimized solvent/non-solvent 
composition was added to cover the microspheres to achieve sintering. The solvent/non-
solvent composition of acetone: cyclohexane ratio was varied from 1:0, 2:1, 3:1, 4:1 and 5:1 
to achive microsphere sitering. The solvent and non-solvent mixture was allowed to evaporate 
in a fume hood for 30 minutes followed by vacuum drying for an additional 24 hours. 
Cylindrical scaffolds measuring 10 mm by 5 mm were fabricated to characterize compressive 
mechanical properties and porosity while 8 mm by 2 mm tablet type cylindrical scaffolds 
were made for evaluating in vitro osteocompatibility studies. Control PLGA microsphere 
scaffolds were fabricated by heating the stainless steel mold at 95°C for 2 h to achieve 
sintering. 
2.2.4 Functionalization of 3D Scaffolds: Micro-Nano Structured Scaffolds 
 
Sintered microsphere scaffolds were surface functionalized with collagen type I nanofibers 
using principles of molecular self-assembly(354). Optimization studies used different aqueous 
collagen concentrations, solution pH and incubation time. These studies were aimed to 
achieve uniform collagen functionalization without compromising the pores in the sintered 
microsphere scaffolds. In a typical study scaffolds were incubated in a 0.1% (w/v) solution of 
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collagen type I with a pH adjusted to 5.2 at 37°C for 24 h(355). These nanofiber-functionalize 
scaffolds were washed with DI water and stored in a desiccator until further use. 
2.2.5 Collagen Content in Micro-Nano Structured Scaffolds 
 
The amount of collagen present on each scaffold was quantified with a calorimetric 
bicinchoninic acid (BCA) Protein Assay Reagent kit (Pierce). Proteins form a purple colored 
chelation complex with BCA via reduction of cupric ions to cuprous ions. The purple color of 
this complex is directly proportional to the protein concentration and the absorbance was read 
at 562 nm using a BioTek plate reader. In brief, collagen coated micro-nano structured 
scaffolds were transferred to a new 48 well plate and incubated with 1 mL of aqueous 1% 
acetic acid for 1 hour followed by mixing with the aid of a pipette to extract all collagen from 
the scaffold. Similarly collagen remaining on the TCPS surface during coating experiment 
was also extracted for the estimation of collagen content. A 25 µL of the collagen extract was 
mixed with 200 µL of BCA reagent followed by 30 min incubation at 37°C and analyzed at 
562 nm using a plate reader. A sample size of n = 6 was used for all these estimations. The 
absorbance of six known collagen concentrations: 62.5, 125, 250, 500, 1000 and 2000 µg/mL 
were used to construct a standard curve to convert absorbance readings to collagen 
concentrations. 
2.2.6 Scanning Electron Microscopy (SEM) 
 
Surface morphology of the scaffolds was characterized by using SEM and field emission 
SEM (FESEM). Scaffold surfaces were sputter coated with Au/Pd using a Hummer V 
sputtering system (Technics Inc., Baltimore, MD) prior to imaging. The samples were viewed 
using JSM 6400 scanning electron microscope (JEOL, Boston, MA, USA) operated at an 
accelerating voltage of 20 kV at various magnifications. Uncoated micro-nano structured 
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scaffolds were imaged using a tabletop TM-1000 (Hitachi, Closter, New Jersey) at various 
magnifications. Nanofiber diameter was measured using Image J, NIH software. For each 
fiber diameter measurement 3 different samples at 3 different locations were considered 
(average of 100 fibers).  
2.2.7 Micro-Nano Structured Scaffolds: Collagen Nanofiber Stability in Solution 
 
Collagen nanofiber stability on the micro-nano structured scaffolds, in culture media up to 28 
days, was qualitatively determined by using SEM. In brief, micro-nano structured scaffolds 
were incubated in 1.8 mL of basal media up to 28 days and media was changed every other 
day. At predetermined time points of 1, 3, 7, 14, 21 and 28 days scaffolds (n = 3) were taken 
out and gently washed with DI water and dried. Scaffolds were imaged at various 
magnifications to qualitatively estimate nanofiber stability. 
2.2.8 Compressive Mechanical Properties 
 
Cylindrical scaffolds (10×5 mm) of CA, both in dry and wet (n = 12) conditions were tested 
under compression until failure using an Instron® tester (model 5544; Instron, Canton, MA). 
Dry scaffolds were incubated in PBS overnight and held at a temeprature of 37°C in the water 
bath to produce scaffolds for testing under wet conditions. Prior to testing, excess of PBS 
from the sacffolds was wiped using a Kimwipes TM. Both dry and wet samples were subjected 
to compression testing at a rate of 1 mm/min at ambient conditions until failure. 
From the load and displacement values a stress–strain curve was constructed. For each 
scaffold the following parameters were calculated: 
(1) Compressive modulus = slope of the linear region of the stress versus strain curve, 
(2) Compressive strength = maximum force/the original cross-sectional area,  
(3) Maximum compressive load = maximum force applied, and 
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(4) Energy absorbed at failure = area under the stress–strain curve at the point of failure. 
2.2.9 Porosimetry 
 
Both simple polysaccharide microsphere scaffolds and micro-nano structured scaffolds were 
characterized for median pore diameter and porosity. Micromeritics Autopore III porosimeter 
(Norcross, GA) was employed to measure the volume of mercury intrusion at specific 
pressures for the scaffolds (n = 6). The scaffold pore volume and the pore size were calculated 
by substituting this information into the Washburn equation. A set of 6 scaffolds (10×5 mm) 
in a 5 mL penetrometer was used for each measurement. 
2.2.10 Cell Culture 
 
HOB were plated in tissue culture flasks (125 cm2) and cultured in basal media as specified in 
the materials section. The media was replaced every other day, and culture was maintained in 
a tissue culture incubator at 37°C and 5% carbon dioxide. Cells were trypsinized at 90% 
confluency and cells at passage 6 were used for scaffold seeding. Both CA and EC scaffolds 
were autoclave sterilized at 121°C for 30 min. Control PLGA scaffolds were sterilized by 
incubation in 70% ethanol for 15 min and 30 min UV light exposure on both sides. Optimized 
collagen concentration and pH conditions were used for collagen nanofiber functionalization 
of scaffold. Functionalization experiments were carried out using sterile microsphere scaffolds 
and collagen solution in the cell culture hood and maintained in a tissue culture incubator at 
37 °C for 24 hours. Scaffolds were placed in 24-well plates and incubated with 2 mL of basal 
medium for 30 min prior to cell seeding. Each scaffold was seeded with 50,000 cells and 
allowed to stand for 2 h in the incubator prior to adding 1.8 mL of basal media to allow HOB 
adhesion onto scaffolds. Following 24 hours of incubation, the medium was changed from 
basal to osteogenic. Cultures were maintained for 28 days and media was changed every other 
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day. One set of scaffolds was cultured in basal media up to 28 days to establish HOB viability 
using MTS assay. For all these experiments a sample size of n=5 was used. 
2.2.11 Cell Viability Assay 
 
The cell viability on these scaffolds was measured using MTS assay at culture times of 1, 3, 7, 
14, 21 and 28 days. The metabolically active cells react with the tetrazolium salt in the MTS 
reagent to produce a formazan dye that can be observed at 490 nm. At each time point the 
cellular constructs were washed twice with PBS to removenon-adherent cells and then 
transferred to a new 24-well plate. These constructs were incubated with 200 µL of MTS 
reagent with 1 mL of basal medium for 2 hours. Aliquots were taken and their absorbance was 
read on a plate reader (BioTek Synergy HT, USA). The absorbance of six known cell numbers 
10,000, 30,000, 50,000, 75,000,100,000, and 150,000, were used to construct a standard curve 
to convert absorbance readings to cell numbers. The absorbance values of the samples were 
fitted with the standard curve to determine the cell number on the scaffolds. 
2.2.12 Cell Proliferation (Picogreends DNA Assay) 
 
HOB proliferation after changing to osteogenic media was quantified by measuring the 
amount of cellular DNA content at various culture points using a PicoGreen® 
dsDNAassay(297, 356). In brief, at different culture times of 1, 3, 7, 14, 21 and 28 days the 
cellular constructs were washed twice with PBS, transferred to new well plates and 1mL of 
1% Triton X-100 solution was added to lyse the cells. The well plates underwent three freeze-
thaw cycles, between −70°C and room temperature. The contents were mixed individually 
with the aid of a pipette to extract cell lysate from the 3D scaffolds prior to analysis. 125 µL 
of sample DNA was transferred into a new well plate to which 375 µL (component B) and 
500 µL (Component A) kit reagents were added. Well plates were covered with aluminum foil 
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to prevent light exposure and incubated for 5 min. A BioTek plate reader was used to measure 
fluorescence (485 nm/535 nm). Optical readings were converted in DNA concentration using 
a standard curve(352). 
2.2.13 Alkaline Phosphatase Activity 
 
ALP expression by HOB cultured scaffolds at various time points was evaluated as an early 
marker of the retention of osteoblast phenotype using an ALP substrate kit(357). A 100 µL of 
cell lysate was transferred into a well plate to which a 400 µL of P-NPP (para-nitro phenol 
phosphate) substrate and buffer solution were added and incubated at 37 °C for 30 min. After 
30 minutes, adding a 500 µL of 0.4 N of sodium hydroxide stopped the reaction. The intensity 
of the color produced though the reaction is proportional to ALP activity. The optical density 
of the solution was measured at 405 nm using a BioTek plate reader. The results for ALP 
activity optical density were normalized to DNA content determined in a companion DNA 
assay(352).  
2.2.14 Mineralized Matrix Deposition Assay 
 
Mineralized matrix deposition on the scaffolds by HOB was evaluated using an Alizarin Red 
staining method for calcium deposition(358). This colorimetric analysis is based on 
solubilizing the red matrix precipitate with cetylpyridinium chloride (CPC) to yield a purple 
solution. In brief, at 7, 14, 21 and 28 days of cell culture, cellular constructs were fixed in 
10% formalin at 4 °C for 1 h and then stained with 40 mM alizarin red solution for 10 min at 
room temperature. After washing 5–10 times with distilled water to remove the 
adsorbed/absorbed dye, chemically bound red matrix precipitate was solubilized in 1 mL of 
10% CPC until color was stable. The optical density of the solution was read at 562 nm using 
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BioTek plate reader. The results for calcium deposition were also normalized with DNA 
content determined in a companion DNA assay(297). 
2.2.15 Live/Dead Cell Viability 
 
Cell viability on scaffolds was performed using a live/dead cell viability kit and then imaged. 
In brief, calcein AM enters live cells and reacts with intracellular esterase to produce a bright 
green fluorescence, while ethidium homodimer-1 enters only dead cells with damaged 
membranes and produces a bright red fluorescence upon binding to nucleic acids. Scaffolds 
were imaged at 3 days using a BioRad Radiance 2100 Multiphoton/Laser Scanning Confocal 
Microscope (LSCM) at magnifications of 10× and 20× with and without transmitted light to 
view cells independently and alongside the scaffold. 
2.2.16 Statistical Analysis 
 
All results were first evaluated using one-way analysis of variation (ANOVA) followed by 
Tukey’s (HSD) analysis of the differences between groups with a confidence range of 
95.00%. 
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2.3 Results  
2.3.1 Fabrication of Sintered Microsphere Scaffold and Effect of Solvent Composition on 
Sintering Morphology 
 
In general cellulose microspheres had a rough morphology as opposed to control PLGA 
microspheres as evidenced by SEM images. These microspheres were segregated into 
different sizes using sieves(295). Figure 1 illustrates the morphology of the microsphere 
scaffolds at different sintering conditions. For instance, scaffolds sintered with higher solvent 
content in the solvent/non-solvent composition lead to greater bonding between adjacent 
microspheres (Figures 2.1(A)–(H)). Increasing the solvent content resulted in distorted 
microsphere structure with compromised pore properties. Based on the morphology and pore 
property measurement studies, scaffolds sintered at a ratio of 3:1 acetone: cyclohexane was 
found to be optimal for further characterization (Figures 2.1(C) and (D)).  
2.3.2 Morphology of Functionalized Microsphere Scaffolds with Collagen to Form Micro-
Nano Structures 
 
Figure 2.2 and 2.3 indicate the morphology of the CA and EC cellulose collagen micro-nano 
structured scaffolds respectively, at various magnifications and scaffold depths. Collagen 
nanofiber assembly was found to be uniform throughout the scaffold architecture. These fibers 
were in the diameter range of 140±40 nm for CA scaffolds and 120±34 nm for EC 
scaffolds(355). We also characterized the quantity of collagen present in each scaffold using a 
calorimetric BCA protein assay. The average collagen content on each polysaccharide 
scaffold and the encapsulation efficiency are presented in Table 2.1. 
The porous microsphere scaffold could retain only 42% of the collagen on the scaffold and 
rest was deposited on the TCPS. Functionalizing scaffolds of different materials with collagen 
nanofibers may present different morphologies and material properties. Uniform collagen 
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nanofiber functionalization around the cellulose microsphere surfaces without compromising 
in the pore properties was evident in the images (Figures 2.2 and 2.3). 
2.3.3 Temporal Stability of Nanofibers on the Scaffold Surface Under Culture Condition 
 
Collagen nanofiber functionalized scaffolds were incubated in culture media for three weeks, and 
imaged at different time points (Figure 2.4) using SEM at 50 and 500× magnifications in order 
to determine the stability of collagen nanofibers. These scaffolds were imaged on Day 1 
(Figures 2.4(A), (B)), Day 3 (Figsures 2.4(C), (D)), Day 7 (Figures 4(E), (F)), Day 14 and 
(Figures 4(G), (H)), Day 21 (Figures 2.4(I), (J)). It is apparent from the images that collagen 
nanofibers not only remained stable but supported passive mineralization with time. 
2.3.4 Mechanical Property and Porosity of Scaffolds Under Dry and Wet Conditions 
 
Dry CA scaffolds under compression testing showed an average maximum compressive 
modulus of 266.75 ± 33.22 MPa, strength 12.15 ± 2.23, load 225.14 ± 42.09 and energy at 
failure 0.34±0.13 J. The same scaffolds under wet conditions showed an average maximum 
compressive modulus of 130.53±13.97 MPa, strength 7.15 ± 1.24 MPa, load 144.76 ± 24.43 N 
and energy at failure 0.36±0.12 J (Table 2.2). Under wet conditions, the compressive 
mechanical properties of the scaffolds reduced to almost half that of the scaffold under dry 
condition. Nanofiber functionalized scaffold porosity was found to be 33.9±5.2% with an 
average pore diameter 185.4± 8.6 µm.  
2.3.5 Cell Survival and Proliferation 
 
Figure 2.5 showed osteoblast survival measured up to 28 days on micro-nano structured 
scaffolds, control PLAGA scaffolds and TCPS. At all time points TCPS showed significantly 
higher cell number based on metabolic activity compared to test scaffolds and control PLGA 
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(Figure 2.5) in basal media. However, cell numbers on test and PLAGA control scaffolds 
were comparable. The observed differences in cell metabolic activity may be due to the 
difference in number of cells that initially adhered to the scaffold and the change in scaffold 
environment (2D and 3D). For instance, a fraction of the seeded cells may attach to the 3D 
porous scaffold while the rest will attach to the TCPS container. Higher metabolic activity on 
2D TCPS compared to 3D scaffold environment may reflect the inverse relationship between 
cellular proliferation and phenotypic differentiation. HOB proliferation in osteogenic media 
showed significantly higher DNA content on the micro-nano structured scaffolds than TCPS 
(Figure 2.6). 
2.3.6 Differentiation Measured by Alkaline Phosphatase Content and Mineral Deposition 
 
Osteoblasts cultured on micro-nano structured scaffolds resulted in the higher levels of ALP 
expression as compared to TCPS controls (Figure 2.7). Expression of ALP on polysaccharide 
micro-nano structures was either higher or comparable to PLAGA micro-nano structures. 
Scaffold mineralization also followed a similar ALP expression trends where significantly 
higher amounts of calcium were deposited on the micronano structured scaffolds as compared 
to TCPS control (Figure 2.8). In general, calcium deposition on polysaccharide structures was 
either higher or comparable to PLAGA micro-nano structures. osteoblasts seeded on EC 
scaffolds start showing very early expression of phenotypic markers (ALP and Calcium 
deposition) while CA scaffolds make up towards the later time points (Figures  2.7 and 2.8).  
2.3.7 Cell viability and morphology 
 
In Figure 2.9, the cell viability at different planes and locations of the scaffold can be seen. For 
instance, for similar cell seeding densities micro-nano structured scaffolds showed significantly 
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higher number of viable cells distributed uniformly throughout scaffold architecture (Figures 
2.9(C), (D)) while the viable cells were only at the microsphere junctions on the microsphere 
scaffolds (Figures 2.9(A), (B)). 
 
Table 2.1 Quantification of Collagen on Scaffold and Coating Efficiency 
Total Collagen 
Concentration used for 
coating 
Collagen per 
scaffold 
 
Collagen on  
TCPS 
 
Scaffold 
coating 
Efficiency 
 AVG STD AVG STD  
2000 µg/mL 847.5 171.7 1146.7 166.8 42.3% 
 
 
Table 2.2 Sacffold Compressive mechanical properties in dry and hydrated state 
  
 
 
 
 
 
 
 
 
Dry Scaffold Wet Scaffold 
Compressive Modulus (Mpa) 
266.75±33.22 130.53±13.97 
Maximum Compressive Load (N) 
225.14±42.09 144.76±24.43 
Compressive Strength (MPa) 
12.15±2.23 7.15±1.24 
Energy at Failure (J) 
0.34±0.13 0.36±0.12 
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Figure 2.1 Optimization of Sintering solution 
Effect of solvent/non-solvent composition on the morphology of the resulting sintered 
microsphere scaffolds. Anetone is a solvent for CA while cyclohexane is a non-solovent. 
Acetone:cyclohexane ratio was varied from 1:0, 2:1, 3:1, 4:1 and 5:1. The 30× and 100× SEM 
images of CA scaffolds with varying acetone/cyclohexane sintering solution concentrations: A. 
2:1 30×, B. 2:1 100× C. 3:1 30×, D. 3:1 100×, E. 4:1 30×, F. 4:1 100×, G. 5:1 30×, H. 5:1 
100×. Higher solvent compositions led to greater bonding between adjcent microspheres.  
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Figure 2.2 Morphology of CA-collagen scaffolds 
SEM micrographs (B and C) illustrate the top view of CA-composite scaffold surface 
morphology where A is a control CA scaffold without collagen. Micrographs A-D were recorded 
on an environmental SEM without applying Au-Pd coating. Representative micrographs D-F 
illustrates the deep interior surface morphology of the composite scaffolds taken on several 
randomly broken pieces of the different scaffolds. Micrographs E and F at higher magnifications 
were imaged after coating with Au-Pd using a FESEM. Preferred Collagen nanofiber (140 ± 
40nm) assembly on the microsphere surface may be attributed to polysaccharide hydrophilic 
nature as well as slower water evaporation during scaffold drying process. Collagen coating was 
uniform throughout the scaffold 3D architecture with enhanced surface area as compared to neat 
CA scaffolds.  
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Figure 2.3 Morphology of EC-collagen scaffolds 
SEM micrographs (B and C) illustrate the top view of EC-composite scaffold surface 
morphology where A is a control EC scaffold without collagen. Micrographs A-C, E and F were 
recorded on an environmental SEM without applying Au-Pd coating. Representative 
micrographs D-F illustrates the deep interior surface morphology of the composite scaffolds 
taken on several randomly broken pieces of the different scaffolds. Micrograph D was imaged 
after coating with Au-Pd using a FESEM. Collagen nanofibers (120 ± 34 nm) coating was 
uniform throughout the scaffold 3-D architecture. Composite scaffolds in general present 
enhanced surface area as compared to EC scaffolds.      
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Figure 2.4 Collagen Nanofiber stability in vitro 
Stability of collagen nanofibers in composite scaffolds following incubation in culture media.  
Representative SEM micrographs (A B) Day 1, (C,D) Day 3, (E,F) Day 7, (G,H) Day 14 and (I, 
J) Day 21 illustrates the deep interior surface morphology of the composite scaffolds taken on 
several randomly broken pieces of the different scaffolds at two different magnifications of 50 
and 500 X. Culture media was replaced every other day just to mimic cell culture conditions. 
Scaffolds were imaged after coating with Au-Pd using a FESEM. Collagen nanofibers act like a 
nucleating agent and favored salt deposition from the culture media which seemed to increase 
A B 
C D 
E F 
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with culture time. It was difficult to image samples with increasing culture time due to increased 
amount of salt deposition that lead to charging and destroyed the image quality. 
 
 
 
Figure 2.5 Metabolic activity of seeded HOBs 
Proliferation of HOB seeded on polysaccharide composite scaffolds in basal media measured 
using MTS assay. At each time point quintuplicate samples were measured and comparisons 
were made within the group. (*) indicates the statistical significance within the group at p<0.05. 
These studies were designed to establish composite cellulose material compatibility with HOB. 
In general HOB proliferation on cellulose composite scaffolds was comparable to PLAGA 
composite scaffolds and attained confluency by day14.  TCPS control showed significantly 
higher cell number beyond 7days as compared to composite scaffolds.  
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Figure 2.6 Prolifeartion of seeded HOBs 
Proliferation of HOB seeded on polysaccharide composite scaffolds in osteogenic media 
following day 1 culture in basal media. At each time point quintuplicate samples were 
measured and comparisons were made within the group. (*) indicates the statistical 
significance within the group at p<0.05. Cell proliferation was significantly higher on 
composite scaffolds up to day 14 as compared to TCPS 2D control. CA composite scaffolds 
showed significantly higher amount of DNA at day 7 and the composite scaffolds achieved 
confluency by day 14. Higher amount of DNA content on composite scaffolds can be 
attributed to material bioactivity, 3D environment and higher surface area offered by 
nanofiber structures.    
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Figure 2.7 ALP activity of Seeded HOBs 
Normalized alkaline phosphatase activity expressed by HOB cultured on polysaccharide 
composite scaffolds in osteogenic media following day 1 culture in basal media. At each time 
point quintuplicate samples were measured and comparisons were made within the group. (*) 
indicates the statistical significance within the group at p<0.05. In general significantly higher 
levels of ALP activity were observed on composite scaffolds as compared to TCPS controls. 
ALP activity was polysaccharide composites was either higher are comparable to PLAGA 
composites.    
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Figure 2.8 Mineralization by seeded HOBs 
Relative mineralized matrix deposited on scaffolds at various culture points normalized with 
DNA content. Significantly higher amount of Calcium was deposited on the composite scaffolds 
as compared to TCPS control. Calcium deposition on polysaccharide composites was either 
higher are comparable to PLAGA composites. At each time point quintuplicate samples were 
measured and comparisons were made within the group. (*) indicates the statistical significance 
within the group at p<0.05.  
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Figure 2.9 Viability of seeded HOBs 
Representative confocal micrographs showing survival and morphology of HOB cultured on 
polysaccharide CA (A), (B) and micro-nano structured scaffolds (C), (D) without (A), (C) and 
with (B), (D) transmitted light at 3 days after cell seeding. Confocal images clearly indicated the 
higher cell number on composite scaffolds as compared to neat scaffolds. Majority of the cells 
were viable had a well-spread morphology and distributed uniformly throughout the microsphere 
surface and microsphere junctions. Cell survival was determined by viability assay where live 
cells appear as fluorescent green color and dead cells as fluorescent red.  
B A 
C D 
 96 
 
2.4 Discussion 
 
Scaffolds are designed to serve as a temporary ECM and hence are required to provide structural 
support and a physical environment for cells to attach, grow, migrate and respond to signals(332, 
333). Additionally scaffolds for BTE should provide mechanical properties similar to bone(359). 
A variety of scaffolds in various forms and pore properties have been fabricated and 
characterized for bone tissue engineering applications using polymers of both natural and 
synthetic origin(346, 360). In particular, biodegradable polyesters including PLA, PGA, and their 
copolymer (PLAGA) based scaffolds and orthopedic fixation devices in the form of screws and 
plates have been widely researched(361). Reproducible mechanical and degradation properties 
obtained by the precise control over molecular weight and crystallinity during polyester synthesis 
makes them attractive for scaffolding applications(353, 362, 363). However, acidic degradation 
products may cause inflammation depending on the anatomical compartment and their clearance 
from those locations(364). A comprehensive 9-year clinical study reported several inflammatory 
foreign body reactions and severe osteoarthritis in the joints near α-hydroxyester implants(365). 
To achieve mechanical and degradation properties ideal for implant performance, high molecular 
weight and crystalline polymers were used(362) with degradation varying from 2–6 years based 
on the molecular weight and crystallinity(362). However, a six-year evaluation of ankle fractures 
stabilized with PLA screws showed the absence of osseous replacement(366). Faster degrading 
implants show delayed tissue replacement with evidence of an osteolytic lesion during 
the final stages of degradation. Polyester blends with other class of polymers and ceramics have 
been reported to neutralize acidic degradation products and support tissue healing(344, 367, 
368). Scaffolds derived from polymers of natural origin, namely polysaccharides and proteins, 
are known to be bioactive and highly biocompatible(369). Further these scaffolds support cell 
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attachment, proliferation and differentiation in vitro and during in vivo implantation(370). 
In our earlier publications we have demonstrated the benefits of sintered microsphere scaffold 
platform in terms of controlling mechanical and pore properties as well as cell and tissue 
infiltration using both in vitro and in vivo experiments(64, 363). Sintered microsphere scaffolds 
are designed as a negative template of trabecular bone. For instance, trabecular bone is 70% 
porous with 30% material content while sintered microsphere scaffolds present about 30% 
porosity with 70% material content(371). We have also demonstrated that scaffolds fabricated 
using microspheres in the size range of 600–710 µm present optimal pore volume and 
mechanical strength to support bone repair and promote tissue ingrowth(353). In our previous 
study we have reported the feasibility of fabricating mechanically strong sintered microsphere 
scaffolds using cellulose derivatives and evaluated their ability to support HOB growth and 
mineralized matrix production(352). Collagen is the most abundant protein within the ECM. 
The most abundant type-I collagen readily forms fibrils in a self-assembly process. Hence 
collagen has been popularly used to coat non-biological surfaces to simulate native ECM fibrous 
structures. Numerous pre-clinical and human clinical studies have utilized ECM scaffolds of 
both allogeneic and xenogeneic origin for the repair and regeneration of different tissue types 
with a huge success. These scaffolds promote angiogenesis, recruitment of circulating progenitor 
cells and complete scaffold degradation coupled with damaged tissue remodeling. This study 
evaluates micro-nano structured biomimetic scaffolds with correct combination of mechanical 
properties and ECM mimicry obtained by surface functionalization of cellulose based sintered 
microsphere scaffolds with collagen nanofiber for BTE applications. 
Sintered microsphere scaffold platforms have been shown to offer several advantages over 
conventional salt leaching andelectrospun nanofiber scaffolds  scaffolds for load bearing bone 
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healing applications(295, 371). This technique creates 100% interconnected porous structures 
with a great control over mechanical and pore properties(363). Scaffold mechanical properties 
greatly depend on the number of bonds and extent of bonding between adjacent 
microspheres(295). For instance, use of larger microspheres creates larger pores with lesser 
number of bonds with adjacent microspheres in the scaffold and hence results in reduced 
mechanical properties. Two cellulose derivatives, namely cellulose acetate and ethyl cellulose, 
were used to fabricate microspheres using an oil-in-water-emulsion-solvent evaporation 
method(352).  
In general cellulose microspheres had a rough morphology as opposed to control PLAGA 
microspheres as evidenced by SEM images. Scaffold mechanical and pore properties are 
inversely proportional and therefore a balance between these two important parameters needs to 
be optimized for BTE application(371). Hence, we chose microspheres in the diameter range of 
300–425, 600–710 and 710–800 µm for fabricating 3D porous structures via a solvent/non 
solvent sintering technique and characterized their mechanical properties(295). This study 
concluded that scaffolds fabricated from 600–710 µm sized microspheres resulted in optimal 
mechanical and pore properties as well as osteoblast response(352). In this study we wanted to 
optimize the combination of solvent/non-solvent composition and sintering conditions to 
fabricate scaffolds using 600– 710 µm sized microspheres of both CA and EC. For these 
polymeric systems acetone was used as a solvent and cyclohexane as a non-solvent. Solvent/non 
solvent assisted polymeric microsphere sintering based on Flory-Huggins solution theory is 
published elsewhere(295). According to this theory a greater affinity between the solvent and 
polymer allows the solvent to dissolve progressively longer chains causing the surface of the 
microspheres to swell and intertwine with each other(295). Hence at an optimal solvent/non-
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solvent composition microsphere surfaces turn sticky, bond with adjacent microspheres and 
harden as the solvent evaporates(295). Very few attempts have been made to create natural 
polymer based sintered microsphere scaffolds for BTE applications. One of these studies 
combined chitosan with PLAGA and produced the heat sintered microsphere scaffolds and 
evaluated its cellar response in vitro(372) and the response when implaned into the body(373).  
These scaffolds showed superior osteoblast phenotype expression as compared to PLAGA 
control scaffolds but clearly failed to have significant effect in vivo bone healing(373). Such an 
oberved effect may be due to crosslinking of chitosan to produce Schiff base at elevated 
temperature during sintering(161, 349). Often crossliked natural polymers tend to loose their 
bioactivity due to utilization of available functional groups to produce crosslinked bonds(161). In 
general hydrogels, sponges or fiber matrices created using natural polymers were reported to be 
bioactive, but clearly lacked mechanical competence(346). As such cellulose and chosen 
cellulose derivatives are practically isoluble in water in spite of being hydrophillic, which makes 
them attractive for creating microspheres and their scaffolds without crosslinking(253). 
Type I collagen is the major organic ECM component of bone offering bioactivity and 
strength(369). On the other hand, the role of topographic features including pores, fibers, ridges, 
grooves and their combinations in the nanometer scale have been shown to influence cell 
function and consequent regenerative capacity(374). Therefore, presentation of this bioactive 
collagen in nanofibrillar form is intended to endow the greatest biomimetic properties possible to 
the scaffold(375).  Collagen nanofiber functionalization was carried out to improve the 
bioactivity(297, 355) of the 3D porous scaffolds fabricated as above.. The collagen nanofibers 
presented a uniform coating of the cellulose (CA and EC) microspheres (Figures 2.2, and 2.3). 
Functionalizing scaffolds of different materials with collagen nanofibers may present different 
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morphologies and material properties. For instance, water contact angles for CA, EC and 
PLAGA are roughly 55, 35 and 80°, which makes cellulose scaffolds relatively hydrophilic than 
the control PLAGA(375-377). This lead to uniform collagen nanofiber functionalization around 
the microsphere surfaces without compromising the pores (Figures 2.2, 2.3). Such a difference 
in hydrophilicity of the scaffold material may reflect in different levels of cell adhesion, 
proliferation and differentiation in spite of both the test and control scaffolds being coated with 
collagen nanofibers compromising the pores(378, 379). In our earlier communication we have 
reported micronano structured scaffolds using two synthetic polymers on the sintered 
microsphere scaffold platform(297). The PLLA nanofibers were created in the open pores of the 
poly phosphazene microsphere scaffold using thermally induced phase separation 
technique(297).  These scaffolds were successful in promoting the osteoblast phenotype 
development but compromised scaffold pore properties to some extent. The hydrophilic nature of 
polysaccharide microspheres promote uniform deposition of collagen nanofiber adhesion on the 
microsphere surface without affecting the pore properties of the scaffold, a factor that is critical 
for tissue ingrowth while increasing the surface area for cell adhesion and biomimetics at the 
same time(297).  In a similar approach polysaccharide microfibers functionalized with 
collagennanofibers acted as an ECM equivalent and promoted osteogenesis and angiogenesis in 
vitro(380) .  Several studies reported the use of collagen in the form of hydrogel to deliver cells 
and tissue void filler where they clearly lacked the mechanical properties(355). Micro-nano 
structured scaffolds effectively combine the benefits two natural polymers without 
compromising pore and mechanical properties. Sustainment of the functionalized collagen 
nanofibers in culture as well as in vivo implantation can predict the scaffold bioactivity and 
performance. It is apparent from the images that collagen nanofibers not only remained stable 
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but increased passive mineralization with time(335). This form of biomineralization is a 
prerequisite for proper osteoinduction in vivo by a biomaterial(381), and points to the possible 
bioactivity of the material towards directing osteogenesis in vivo(335). 
Mechanical properties of degradable polymers significantly vary under physiological conditions 
as opposed to dry samples(382). Hence we observed that the mechanical properties of the 
cellulose based scaffolds halved. These values were superior to several polysaccharidebased 
tissue-engineering scaffolds and PLAGA-based heat sintered microsphere scaffolds of similar 
pore properties earlier reported in literature(353, 363). These polysaccharide scaffolds showed 
compressive mechanical properties are comparable to those in the mid range of human trabecular 
bone and ideally suited for bone tissue engineering applications(359). This mechanical property 
is 
highly desirable to serve the functional role of replacing lost bone tissue and the biological role 
of directing progenitor cell differentiation into osteoblastic lineage(383). Nanofiber 
functionalized scaffold porosity was found to be with an average pore diameter 185.4°+/_8.6 µm. 
Nanofiber functionalization neither compromised the mechanical property nor the porosity of the 
microsphere scaffolds. These micro-nano structures made of natural polymers may significantly 
improve the scaffold performance both as a supporting material as well as a bioactive platform 
for bone regeneration(371). 
Osteoconductivity, the ability of a material to support the survival of osteoblasts, is an important 
basic characteristic of a scaffold in bone tissue engineering. Figure 2.5 shows osteoblast survival 
measured up to 28 days on micro-nano structured scaffolds, control PLAGA scaffolds and 
TCPS. At all time points TCPS showed significantly higher cell number based on metabolic 
activity compared to test scaffolds and control PLAGA in basal media. However, cell numbers 
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on test and PLAGA control scaffolds were comparable. Such observed differences in cell 
metabolic activity may be due to the differences in number of cells that initially adhered to the 
scaffold and the difference in scaffold environment (2.2D and 2.3D). For instance, a fraction of 
the seeded cells may attach to the 3D porous scaffold while the rest will attach to the TCPS 
container. Higher metabolic activity on 2D TCPS as compared to 3D scaffold environment may 
reflect the inverse relationship between cellular proliferation and phenotypic differentiation. 
HOB proliferation in osteogenic media showed significantly higher DNA content on the micro-
nano structured scaffolds than TCPS (Figure 2.6). Higher DNA content observed on the micro 
nano structured scaffolds presumably due to increased surface area and bioactivity provided by 
collagen nanofiber. Type-I collagen is known to enhance osteoblast viability and proliferation. 
Hence collagen coated implants supported the osteoblast spreading through rapid formation of 
focal adhesions and their associated stress fibers(347). Often 2D surfaces such as TCPS could 
induce greater number of focal adhesions but clearly fails to mimic the desired 3D environment. 
Collagen functionalized scaffolds present a 3D environment and brings about a desirable cellular 
response(384). In general higher DNA content is an indication of higher levels of mitotic 
(proliferative) cellular activity. Higher DNA content was observed on the TCPS as compared to 
test scaffolds (CA, and EC). This may represent a scenario where cells are at different stages of 
maturity on scaffolds than on TCPS. For instance, as osteoblasts progress towards mature 
osteocyte lineage, they are seen to be in the interphase state of cell cycle(385-387). Hence DNA 
content may not be a true indicator of cell division during an interphase stage wherein DNA 
content is likely to be more than cell number. Such an observation was made on the scaffolds 
using MTS assay (metabolic activity) and pico green DNA assay in the current study. In this 
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situation, it may translate into a greater level of cellular activity towards the differentiation 
program than cell division on test scaffolds.  
Osteogenic differentiation is characterized by the robust ALP expression at early stages while 
mineralization occurs at later stages(388, 389). It is clear from the literature that a robust ALP 
expression inevitably leads to mineralization of the regenerated tissue(388). Osteoblasts cultured 
on 
micro-nano structured scaffolds resulted in the higher levels of ALP expression as compared to 
TCPS controls (Figure 2.7). Expression of ALP on polysaccharide micro-nano structures was 
either higher or comparable to PLAGA micro-nano structures. Scaffold mineralization also 
followed a similar ALP expression trend where significantly higher amounts of calcium were 
deposited on the micronano structured scaffolds as compared to TCPS control (Figure 2.8). In 
general calcium deposition on polysaccharide structures was either higher or comparable to 
PLAGA micro-nano structures. Similar observations were also made on the polymeric scaffolds 
coated with cell matrix derived proteins where these scaffolds lead to higher levels of ALP 
expression as well as calcium deposition in vitro. The two cellulose derivatives EC and CA by 
virtue of their structure present different physical, mechanical and chemical properties. For 
instance, osteoblasts seeded on EC scaffolds start showing very early expression of phenotypic 
markers (ALP and Calcium deposition) while CA scaffolds make up towards the later time 
points (Figures. 2.7 and 2.8). Such an observed phenomenon may be due to the differences in 
relative hydrophilicity of the two materials. It has been reported that hydrophilic functionalities 
such as hydroxyl and methyl groups (as seen in EC) favor osteoinduction(37) compared to the 
more neutral acetate groups, which translates into early osteoblast maturation on EC scaffolds in 
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contrast to CA scaffolds. Often in addition to material chemistry and surface topography, 
mechanical properties of the scaffolds contribute towards cell differentiation(390). 
 
2.5 Conclusions 
In this work we report fabrication and characterization of cellulose and collagen based micro-
nano structured scaffolds for BTE applications. This natural polymer based scaffolds show 
compressive mechanical properties in the mid range of human trabecular bone and may be 
ideally suited for bone tissue engineering applications. Collagen nanofiber functionalization did 
not compromise mechanical and pore properties of the microsphere scaffolds. Better human 
osteoblast adhesion, proliferation, alkaline phosphatase expression and mineralized matrix 
synthesis on these scaffolds as compared to that on control tissue culture plastic and PLAGA 
scaffolds confirm the potential for use in bone tissue engineering.  
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2.6 SPECIFIC AIMS 
 
Tissue engineering seeks to design functional substitutes to achieve regeneration of lost tissue. 
Biodegradable three-dimensional (3D) porous structures called scaffolds are an important 
component of engineered tissue. Scaffolds derived from polymers of natural origin, like 
polysaccharides and proteins have improved biocompatibility over synthetic scaffolds due to 
their biochemical similarity to the native ECM. However, due to limitations of solubility and 
processing, polysaccharide and protein scaffolds have been fabricated as porous sponges or fiber 
matrices that do not have mechanical properties essential for bone tissue-engineering (BTE) 
applications. Polysaccharide, cellulose that forms the primary structural component of plant cell 
walls is analogous to the structural protein, collagen in the ECM of bone. Extensive hydrogen 
bonding between hydroxyl functionalities gives cellulose strength that makes it suitable for load 
bearing applications. This bonding also makes the polymer difficult to process due to its limited 
solubility in common solvents and instability at higher temperature. This limitation can be 
overcome by the use of derivatives of cellulose for scaffold fabrication. Previously we have 
reported fabrication of mechanically strong cellulose acetate (CA) and their collagen nanofiber 
functionalized scaffolds for BTE applications. These scaffolds have shown to have 
osteocoductive (support growth of osteoblast) abilities. The present project aims to characterize 
the response of seeded mesenchymal stem cells (MSCs) on these scaffolds and to examine the 
regenerative potential of polysaccharide and collagen based micro- nano structured scaffolds. 
We hypothesize that polysaccharide chemistry and collagen nanofibers offer bioactivity to 
induce the osteogenic differentiation of (MSCs in vitro, would be biocompatible and 
mediate effective bone regeneration in vivo. This project will be conducted by performing the 
following three specific aims: 
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2.6.1 Specific Aim 1: To characterize and contrast the unmodified and collagen 
functionalized CA scaffolds for their material properties 
 
The CA and CA-collagen scaffolds will be contrasted with PLGA and PLGA-collagen scaffolds 
for the efficiency of collagen nanofiber functionalization. Further, the change in material 
crystallinity and surface morphology will be determined, in order to understand the difference in 
physical properties of the test and control scaffolds after being functionalized with collagen 
nanofibers. The hydration property of all the materials subjected to different treatments will be 
studied. 
2.6.2 Specific Aim2: To test the performance of CA-collagen, micro-nano structured 
scaffolds in vitro using bone marrow derived MSCs. 
 
The CA and CA-collagen scaffolds will be tested for their ability to support adhesion, 
proliferation and differentiation of MSCs in the presence of basal and osteogenic media in vitro 
and contrasted with PLGA and PLGA-collagen scaffolds. We will assess cell viability, 
proliferation, expression of osteogenic genes, proteins, ALP activity (early osteogenic 
differentiation marker) and mineralization (later stage marker).  
2.6.3 Specific Aim3: To test the performance of CA-collagen, micro-nano structured 
scaffolds in vivo 
2.6.3.1 Specific Aim3a: To test the biocompatibility of CA-collagen, micro-nano structured 
scaffolds in vivo in a subcutaneous implantation. 
 
The scaffolds would be tested for their biocompatibility in vivo. The scaffolds would be 
implanted subcutaneously in rats. Results will be compared with control scaffolds. At 4, 8, and 
12-week time points, animals will be sacrificed and implant will be evaluated for 
cytocompatibility, and cellularization by histological examination.  
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2.6.3.2 Specific Aim3b: To test the performance of CA-collagen, micro-nano structured 
scaffolds in vivo in a bone defect in mouse calvarium.  
 
The CA, CA-collagen and PLGA scaffolds will be tested for their functional performance in 
vivo. At 8-week time point, the animals will be sacrificed and new bone formation will be 
evaluated by X-ray radiography and histological analyses. 
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3 Chapter 3 
Characterize of the Material Properties of Unmodified and Collagen Functionalized CA 
Scaffolds 
3.1 Introduction 
 
Several scaffold fabrication techniques and materials are used in constructing the scaffolds for 
BTE.  It is crucial to achieve a mechanically strong, porous, three dimensional scaffold that 
allows cells of the organ to infiltrate into the materials as well as induce the stem cells to 
differentiate and heal a defect, once the material is implanted. A sintered microsphere 
microsphere scaffold serves the needs of mechanical strength and material transfer (33(391)- 
40%(392) porosity is usually observed), in a 3D environment. However, most bodily ECM 
components are presented as nanofibers(393). A number of studies have shown the biological 
efficacy of nanofiber matrices in inducing favorable tissue healing response(289, 310). Hence 
taking this factor into consideration, we formulated a two-component system made of a base 3D 
porous sintered CA scaffold further functionalized with collagen nanofibers(391). The principle 
of protein self-assembly was employed to achieve the formation of collagen nanofibers on these 
3D porous structures of CA(355). Synthetic polymer PLGA was used as the control material due 
to its widespread application in BTE(394-396). PLGA has also been approved for several 
applications like drug delivery and suture formulations(397). The PLGA materials were 
formulated into 3D porous sintered microspheres with similar dimensions as CA and 
functionalized with collagen nanofibers similarly. It has been shown in literature that protein 
assembly on hydrophilic and polar surfaces may be more biomimetic than on hydrophobic, 
nonpolar surfaces(398). We hypothesized that the CA material due to its hydrophilic and polar 
nature may lead to more effective collagen nanofiber presentation, with nanofibers decorating 
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the microspheres(391) rather than significantly occupying the pores in contrast to PLGA which 
is known to be a much more hydrophobic material. In this study CA and PLGA microspheres 
were subjected to incubation in the functionalizing buffer (without collagen) and the 
functionalizing solution (with collagen). The changes in the scaffold’s wettability, chemical 
nature, and crystallinity with treatment were examined. Additionally quantification of total 
amount of collagen functionalizing the materials and the presentation of these fibers were 
examined. As the material characteristics of a scaffold dictate its biological performance, it is 
important to examine the change in the phiso- chemical nature of a matrix when subjecting it to a 
modification such as collagen nanofiber functionalization of scaffolds by self-assembly. 
 
3.2 Materials and Methods 
3.2.1 Materials  
 
Cellulose acetate (Mw: 30K) (CA), and Polyvinyl Alcohol (30,000-70,000) (PVA) were 
procured from Sigma -Aldrich (St. Louis, MO, USA). Poly (lactic-co-glycolic acid) 85:15  
(PLGA) was purchased from lakeshore biomaterials (Birmingham, USA).  Acetone, 
Dichloromethane, Cyclohaxane, Paraformaldehyde and Gluteraldehyde were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA).  
3.2.2 Preparation of microspheres  
 
Oil in water solvent- evaporation, followed by sintering of formed microspheres using a 
solvent/non-solvent mixture was used for producing microsphere of i) Cellulose acetate (CA), ii) 
poly (lactic-co-glycolic acid) 85:15 (PLGA). In brief, 13 (w/v) % of CA polymer was dissolved 
in a solvent mixture containing methylene chloride and acetone at a ratio of 9:1 to produce 
microspheres.  A 20 (w/v) % solution in methylene chloride was used in the case of PLGA 
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polymer to produce the microspheres. The polymer solutions were then poured in a thin stream 
into an aqueous media containing 1.25(w/v) %  PVA as a surfactant, with constant stirring at 
250rpm to form an oil-in-water emulsion. These suspensions were stirred overnight to evaporate 
the solvent to obtain hardened microspheres. Isolated microspheres were washed repeatedly with 
deionized (DI) water, dried, and sieved into different microsphere sizes. Microspheres in the size 
range of 600-710 and 710-800µm were mixed at a weight ratio of 1:1 and sintered into micro 
porous scaffolds using either solvent-non-solvent or heat sintering based on the polymer(352, 
391).   
3.2.3 Preparation of micro-porous sintered microsphere scaffolds 
 
Teflon molds of different dimensions were filled with CA microspheres to which a 200µL 
volume of an optimized solvent/non-solvent composition, acetone: cyclohexane in the ratio of 
3:1 (v/v), was added to cover the microspheres. Solvent was allowed to evaporate at room 
temperature to obtain sintered microsphere scaffolds. Cylindrical scaffolds measuring 5mm 
diameter X 10mm height were used for the characterization of hydration properties. The control 
PLGA micro porous scaffolds with identical micro-particle sizes were produced by heat sintering 
at 95oC for 45 minutes using Teflon molds(352). 
3.2.4 Preparation of micro-nano structured scaffolds  
 
 A modified biomimetic approach was used to functionalize micro porous scaffolds with type I 
collagen. In brief, both control and test scaffolds were incubated in a 0.1  (w/v) % collagen type I 
solution with a pH adjusted to 4.2 at 37°C for 7 days to promote molecular collagen self-
assembly.  The dried scaffolds were treated with UV light for 30 min each side to achieve 
collagen nanofiber stability and washed repeatedly with DI water to remove buffer salts.  
Microspheres in the size range of 300-425µm diameters were functionalized with collagen and 
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used for material characterizations presented in this study. The effect of coating buffer pH was 
studied by incubating scaffolds in the buffer alone without collagen (391).  
3.2.5 Quantification of Scaffold collagen Content 
 
Amount of collagen present on each scaffold was estimated with a calorimetry using a 
bicinchoninic acid (BCA) Protein Assay Reagent kit (Pierce). Proteins form a purple colored 
chelation complex with BCA via reducing the cupric ions to cuprous ions. The purple color of 
this complex is directly proportional to the protein concentration and the absorbance was read at 
562 nm using a BioTek plate reader. In brief, collagen coated composite scaffolds were 
transferred to a new 48 well plate and incubated with 500µL of aqueous 1% acetic acid overnight 
with agitation followed by mixing with the aid of a pipette to extract all collagen from the 
scaffold. Similarly collagen remaining on the TCPS surface during the coating experiment was 
also extracted and quantified. A volume of 25µL of the collagen extract was mixed with 200µL 
of BCA reagent followed by 30 min incubation at 37oC and analyzed at 562 nm using a plate 
reader. A sample size of n=4 was used for all estimations. The absorbance of six known collagen 
concentrations 0, 62.5, 125, 250, 500, and 1000 µg/mL were used to construct a standard curve 
to convert absorbance readings to collagen concentrations. The content of collagen on the 
scaffolds and the plates used for incubation were measured and the percentage of collagen on the 
scaffold against that on the plate was calculated to obtain the collagen coating efficiency on each 
scaffold.  
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3.2.6  Morphology of collagen by two- photon microscopy  
 
 Micro-nano structured scaffolds namely PLGAc and CAc were imaged at an excitation 
wavelength of 890nm and the collagen second harmonic generation (SHG) signal along with 
autofluorescent signal from the scaffold material were acquired with bandpass filters of 435–
485nm (SHG), 500–550nm (scaffold autofluorescence), and 570–620nm (scaffold 
autofluorescence). The SHG signal is generated from the triple helical structure of collagen.  
3.2.7 Characterization internal structure of scaffolds by SEM 
 
Scanning electron microscopy (SEM) was used to characterize scaffold morphology and evaluate 
collagen fiber diameter and distribution. Scaffolds were sputter coated with Au/Pd using a 
Polaron E5100 sputtering system (Quorum Technologies, East Sussex, UK) to achieve an 
eighteen nanometer thick coating before viewing under SEM. The samples were viewed using 
FEI Nova NanoSEM 450 scanning electron microscope (FEI, Hillsboro, OR, USA) operated at 
an accelerating voltage of 2kV at various magnifications. Collagen fibers at different locations 
were selected randomly on the functionalized samples and these images were used for measuring 
the fiber diameter using FIJI, NIH software and averaged (an average of 100 fibers). 
3.2.8 Scaffold water uptake by gravimetric analysis 
 
Scaffolds of 10mm X 5mm size were used for analysis of weight and volume changes on 
hydration over 72hours. Scaffolds dry weight and dimensions were noted prior to testing for 
hydration studies (0h). All groups namely CA and PLGA (treated with DI water), CA- buffer/ 
PLGA-buffer (treated with buffer without collagen) and CAc/PLGAc (treated with collagen 
solution) were individually placed in microcentrifuge tubes with 1mL of PBS (pH 7.4) 
(n=6/group) and incubated at 37°C. At the end of 24h, 48h and 72h, the scaffolds were isolated 
and the changes in weight were noted with a Mettler Toledo® (XP56C-Mass Comparator) 
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balance with an accuracy of 0.01mg and dimensional changes were measured with a digital 
calipers (at six different points on the scaffold).  The volume changes in the individual 
cylindrical scaffolds were calculated using the relation=π X (diameter/2)2 X height.  
3.2.9 Microsphere surface chemistry by ATR-FTIR analysis 
 
 Fourier Transform Infrared Spectroscope (FTIR), Nicolet Magna 560, using ZnSe and Ge 
crystal (Nicolet Instrument Corporation, Madison, WI, USA) was used to measure the 
Attenuated Total Reflection (ATR)-infrared red (IR) spectra of the CA, CA-buffer, CAc and 
PLGA, PLGA-buffer, PLGAc treated microsphere surfaces.  The Nicolet OMNICR software was 
used to blank the runs every time before samples were placed on the pedestal for measurement of 
their spectra. Sample scans were run at 320 scans per specimen to extract the spectra in the range 
400-4000cm-1. 
3.2.10 Microsphere surface crystallinity by XRD analysis 
 
 A Bruker D2 Phaser powder diffractometer (Bruker axs, Inc., Madison, WI, USA), was used to 
measure the wide angle x-ray diffraction of CA, CA-buffer, CAc and PLGA, PLGA-buffer, 
PLGAc microspheres. A 2θ between 10-60° with an increment of 0.02° was captured, for all the 
polymers.  
3.2.11 Polymer molecular weight by GPC analysis  
 
A Waters GPC system with Jordi Gel fluorinated DVB columns (1-100K, 2-10K & 1-500Å) was 
used for running the PLGA, PLGA-buffer and PLGAc microparticles. Tetrahydrofuran (THF) 
was used as a mobile phase along with Varian 380-LC Evaporative Light Scattering Detector 
(ELSD) detector. In brief, 0.1 (w/w) % polymer solutions in THF were filtered through 0.2µm 
nylon filter prior to testing. A flow rate of 1.25mL/min with an injection volume of 100µl was 
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used for the analysis. The molecular weight distributions were compared with polystyrene 
standards with molecular weight ranges 450- 200,000 Da.  For CA based samples, a Waters GPC 
system with two mixed bed Jordi Gel DVB columns were used with dimethylacetamide 
(DMAC) as the mobile phase.  For this analysis 0.2 (w/w) % CA in DMAC was used with at an 
injection volume 200µL and a flow rate of 1.25mL/min. Samples were analyzed using a Waters 
2414 refractive index detector (RI) detector. The molecular weight distributions were compared 
with poly (methyl methacrylate) (PMMA) standards with molecular weight ranges 2000-
1100,000Da.  
3.2.12 Statistical analysis  
 
All data are reported as the mean ± standard deviation (SD) of results from at least three 
independent runs. In case of experiments with two groups a student t- test was performed. In the 
case of experiments with multiple groups and multiple time points a 2- way- ANOVA with 
Bonferroni posttest was performed. In the case of experiments that focused on one time point and 
several groups, a one- way- ANOVA with Tukey posttest was performed.  95% Confidence 
interval was employed to arrive at the p values. The denotation of significances given by p 
values are- *p<0.001 (extremely significant), #p<0.01 (very significant), @p<0.05 (significant). 
Analyses were performed using GraphPad Prism Software (GraphPad Software, San Diego, CA).  
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3.3 Results 
3.3.1 Characterization of collagen nanofibers  
 
Scanning electron microscopic (SEM) images showed a smoother microsphere surface for PLGA 
while CA scaffolds presented a rougher surface with many features (Figure 3.1a). Similar 
quantity of collagen content was observed on both PLGA and CA scaffolds as determined by 
protein assay (Figure 3.1b). However, major differences were observed in terms of collagen 
assembly, fibril diameter and collagen distribution on PLGA and CA micro-nano structures. 
Collagen fibers on PLGA showed a wider range of fiber diameter distribution with a mean fiber 
diameter of 150nm, while the collagen fibers on CA showed a narrow range of distribution with 
a mean fiber diameter of 80nm (Figure 3.1c). ). At 50,000X magnification, the collagen fibers of 
CAc presented a D-band like pattern of triple helical collagen. Such banding patterns were very 
sparse in the case of the collagen fibers on PLGA (Figure 1d). On subjecting the PLGAc and the 
CAc scaffolds to two-photon excitation, the second harmonic signal derived from the collagen 
fibers on CAc was stronger than that of PLGAc (Figure 1e). In addition, the CAc group typically 
had collagen fibers arranged in co-operative sheets while the collagen fibers in the PLGAc group 
were more dispersed. 
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3.3.2 Analysis of hydration property  
 
The volumetric changes on hydration between PLGA and CA groups also showed a significant 
volume gain by all the CA groups in contrast to PLGA (Figure 2d). The volume changes on the 
PLGA groups occurred in the first 24h of hydration (Figure 2e), are also in agreement with 
weight gain profiles (Figure 2b). Volumetric changes for both PLGA and CA based scaffolds 
were stabilized by 24 hours. However at 72 hours, only PLGAc and PLGA-buffer groups 
showed volumetric changes (Figure 2e), which remained unaltered for all CA groups (Figure 
2f). 
3.3.3 Characterization of Materials properties  
 
To investigate the changes in material properties due to treatment with the collagen solution, the 
ATR-FTIR spectra of both PLGA and CA were probed after incubation in water (PLGA, CA), 
aqueous buffer without collagen (PLGA-buffer, CA-buffer) and with collagen (PLGAc, CAc). 
The characteristic alkyl groups (2800-2900cm-1), C-O ester group (1050- 1450cm-1) and C=O 
stretch (1750cm-1) of PLGA remained unaffected. However, major differences in absorbance 
frequencies were noted around 1600cm-1 and 3300cm-1 following treatment with acidic collagen 
solution (Figure 3.3a).  The XRD spectra of the PLGA groups treated with buffer and collagen 
showed a steeper peak at around a 2θ angle of 20°, in contrast to the non- treated PLGA (Figure 
3.3b). In the case of CA groups, all treatments showed characteristic bands of ether (1040cm-1), 
acetyl ester (1220cm-1) and carbonyl (1740cm-1) groups that were unaffected following acidic 
collagen solution treatment(399). However, the treatments lead to an additional band around 
1600cm-1 (Figure 3.4a). Following treatment CA showed a steeper peak at around a 2θ angle of 
20° in its XRD pattern (Figure 3.4b).   
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Scaffolds derived from PLGA showed significant decline in weight average molecular weight 
(Mw) and Z-average molecular weight (Mz) with no change in polydispersity index (PI) (Figure 
3.5 a, b, c, d). On the other hand in the case of CA the buffer and the collagen treatments 
resulted in a decrease in number average molecular weight (Mn) that affected the PI ((Figure 3.5 
e, f, g, h).  
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Figure 3.1 Characterization of collagen nanofibers 
SEM images of a) PLGA, PLGA- buffer treated and PLGAc, CA, CA-buffer treated and CAc 
scaffold interiors. Scale bar on top = 1mm, middle =50µm, and bottom = 5µm b) Percentage of 
total collagen on scaffolds after coating (coating efficiency), n=4, Unpaired t-test done and no 
statistical significance was seen. c) Diameter of collagen fibers on PLGAc and CAc at 
magnifications of 50,000X, n=10, Unpaired t-test done and a *P<0.001 was obtained. d) SEM 
images of collagen nanofibers on PLGAc and CAc at 50,000X (D- band-like patterns indicated 
by arrows on CAc), scalebar = 2 µm and e) Second harmonic signals from collagen fibers on 
PLGAc and CAc at 10X (blue color indicated by arrows), scalebar = 100 µm.  
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Figure 3.2 Hydration properies 
Effect of hydration on the scaffold weight and volume changes over 72 hours of incubation in 
PBS at 37°C. Changes in scaffold weight a) PLGA and CA groups, b) PLGA, PLGA- Buffer 
treated and PLGAc, c) CA, CA- Buffer treated and CAc. Changes in scaffold volume  d) PLGA 
and CA groups e) PLGA, PLGA- Buffer treated and PLGAc, f) CA, CA- Buffer treated and 
CAc. Two- way ANOVA with Bonferroni post- test, with 95% confidence intervals, *P<0.001, 
#P<0.01, @P<0.05. 
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Figure 3.3 Changes in PLGA chemistry on collagen treatment 
a) ATR- FTIR (from 400- 4000 cm-1) and b) XRD spectra (2θ= 10-60Ο) of PLGA, PLGA- 
buffer treated and PLGAc (Red- PLGA, blue- PLGA buffer treated, pink- PLGAc, green- 
lyophilized collagen). 
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Figure 3.4 Changes in CA chemistry on collagen treatment 
a) ATR- FTIR (from 400- 4000 cm-1) and b) XRD spectra (2θ= 10-60Ο) of CA,CA- buffer 
treated and CAc. (Red- CA, blue- CA buffer treated, pink- CAc, green- lyophilized collagen)  
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Figure 3.5 Molecular weight changes on collagen treatment 
Molecular weights determined by Gel permeation chromatographic analysis of a), b), c), d) PLGA 
and e), f), g), h) CA  polymers after treatments: a), e) Mn- Number average molecular weight, b), 
f) Mw- weight average molecular weight, c), g) Mz- z average molecular weight, d), h) PI- 
Polydispersity index= Mw/Mn). One – way ANOVA with Tukey post test, with 95% confidence 
intervals, *P<0.001, #P<0.01, @P<0.05. 
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3.4 Discussion 
 
In our scaffold system, the 3D porous sintered CA and PLGA matrices are exposed to a mildly 
acidic buffer solution (pH 4.2) dissolving the collagen, for a prolonged period of time to allow 
the solution to evaporate and to allow the nanofibers to self assemble. The effect of this 
treatment on the material may be important as there could be certain physical and chemical 
changes happening to the parent polymer during the treatment.  
A smoother microsphere surface was observed for PLGA while CA scaffolds presented a 
rougher surface with many features (Figure 3.1a). The surface topography of materials could 
play an important instructive role in directing cellular responses. For instance osteoblasts were 
seen to maintain their phenotype(400) and respond more towards signaling factors like BMP-
2(401), and vitamin D3(402, 403) when cultured on microscale and nanoscale(404) rough 
surfaces. Hence the CA materials may be more osteoconductive in nature than the PLGA 
materials due to the rougher topography presented by them. 
The total collagen content was not very different when the CA and the PLGA 3D porous sintered 
microsphere scaffolds were functionalized with collagen nanofibers (Figure 3.1b). However the 
morphology of the fibers was very different between the PLGAc and CAc groups (Figure 3.1c, 
d, e). The D- banding patterns (Figure 3.1d) and the greater levels of second harmonic signal 
generated by the collagen on CAc than PLGAc (Figure 3.1e) may indicate a more native 
presentation of the functionalizing collagen nanofibers on the CA surface than on the PLGA 
surface. It has also been shown that collagen nanofiber in its native form is far more inductive 
towards bone formation than collagen that is denatured(405, 406). Hence we hypothesize that 
CAc matrices may be more osteoinductive than the PLGAc scaffolds.  
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The water uptake by all the CA groups was significantly higher than PLGA groups (Figure 
3.2.a, d). All CA structures gained significant weight in the first 24 hours and achieved 
equilibrium weight by 72 hours. The CA-buffer and CAc groups showed progressive weight gain 
at all time points between 24-72h. The addition of collagen in CAc (Figure 3.2c) and the 
presence of additional carboxylic acid groups in CA-buffer samples (Figure 3.4a) increased 
exposure to acidic pH resulting in greater hydrophilicity and weight gain than CA structures.  
Exposure of CA to highly acidic or alkaline environment may lead to deacetylation(399), by 
showing changes at ether (1040cm-1), acetyl ester (1220cm-1) and carbonyl (1740cm-1) groups. In 
the case of CA groups, all treatments showed characteristic bands of ether (1040cm-1), acetyl 
ester (1220cm-1) and carbonyl (1740cm-1) groups that were identical and thus these chemical 
groups were unaffected following acidic collagen solution treatment(399). However, treatment 
lead to an additional band around 1600cm-1 on CA microsphere surface due to the presence of 
carboxylic acid salts.  Hence the mild acidic environment did not have a degradative effect on 
CA due to its more robust chemistry (Figure 3.4a, b).  
 However, PLGA-buffer groups appear to be more hydrophobic as the acidic pH treatment may 
lead to degradation on the surface (Figure 3.3a). The intensity of absorbance around 1600cm-1 
increased due to the cleavage of ester bond resulting in carboxylic acid salts (O=C-ONa) of 
PLGA following treatment. Likewise the increase in absorbance around 3300cm-1 in PLGA was 
attributed to an increase in hydroxyl content from alcohol groups (Figure 3.3a, b), probably due 
to a mild degradative change on the surface of the polymer(407, 408). Lee et al also observed 
such changes with the degradation of PLGA when it was exposed to irradiation(407). 
The wettability of surfaces also plays an important role in determining cellular responses like cell 
adhesion(409). Cells adhere to materials through adhesion mediating proteins that adsorb onto 
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biomaterial surface. While highly hydrophobic surfaces favor high level of protein adsorption, 
they also mediate more material- protein and protein-protein interactions, but minimal protein- 
cell interaction due to masking of the active protein domains responsible for cell adhesion(410). 
This is explained by the rigid conformation of proteins achieved on hydrophobic non- polar 
surfaces against a more flexible protein conformation achieved on hydrophilic non- polar 
surfaces(398), which may quantitatively adsorb less protein(410). On the other hand highly 
hydrophilic surfaces may not allow for protein adhesion on their surface at all and hence such 
surfaces too are not good for cell adhesion on materials(411, 412). Hence the hydration behavior 
of material would dictate protein adsorption and self- assembly on it. 
The chemical functional groups on a material can influence cellular responses immensely. For 
instance Curran et al. cultured bone marrow derived mesenchymal stem cells (MSCs) on glass 
substrates modified to contain the functional groups: like -CH3, -SH, –COOH, –OH, and –NH2, 
under basal and octeogenic and chondrogenic conditions. They found that the -CH3 functional 
groups helped maintain the multipotency of MSCs, while the –OH and –NH2 groups were 
conducive for osteogenic differentiation, and the –COOH and –SH groups on the substrate 
supported chondrogenic differentiation. These differences were observed both under basal and 
stimulated conditions(413). Many other studies have used materials that varied only by the 
chemical functional groups on the biomaterial’s surface and all of them have shown that the 
chemical functionalities on the material surface can have a profound influence on stem cell 
behavior(37, 340). These changes can be attributed to the resulting material surface energy and 
hydration characteristic that determine the conformation of adsorbed proteins and in turn cellular 
adhesion(414). 
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From these observations in literature that state the importance of chemical functionalities, 
hydrophilic characteristics and their relationship to the conformation of adsorbed proteins, we 
conclude that the hydrophilic characteristics of CA scaffolds presumably induced the adsorbed 
collagen nanofibers to be presented in a more native conformation than on PLGA. We 
hypothesize that these may translate into better cell adhesion and differentiation responses in 
vitro and in vivo. 
 
3.5 Conclusions 
 
We conclude that the process of collagen nanofiber functionalization on CA and PLGA scaffolds 
had very different outcomes. While the quantity of collagen present in both the scaffolds was 
similar the native structure of collagen nanofibers was apparent on CA scaffolds than on PLGA. 
On examining the water uptake behavior of these matrices, it was seen that the PLGA matrices 
did not have significant improvement in their hydrophilic nature, while the CA matrices showed 
greater water uptake on treatment with the collagen solution. The stable nature of CA against the 
more readily degradative nature of PLGA led to preserving the chemistry of CA, while inducing 
a mild degradation on the surface of PLGA microspheres that nullified the effect of collagen that 
usually renders the material more hydrophilic upon its incorporation. 
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4 Chapter	4	
Characterization of Human Bone Marrow Derived Mesenchymal Stem Cell (hMSC) 
Response to CA-Collagen, Micro-Nano Structured Scaffolds in vitro 
4.1 Introduction 
 
In BTE the scaffold plays an important role. But in order to achieve complete bone healing, the 
delivery of cells and/ or growth factors(397) and/ or small molecules is necessary(415). While 
growth factors like BMP-2(416), VEGF(417), FGF-2(418) have been very effective in inducing 
tissue responses like bone formation, angiogenesis and homing and proliferation of stem/ 
progenitor cells, a number of constrains still exist in the delivery of these factors(415). For 
instance BMP-2 is very effective in inducing bone formation, but ectopic bone formation has 
also shown to occur at non-target sites that can lead to pathological outcomes(419). Yet another 
constraint in delivering proteins such as growth factors is the challenge of retaining their 
biological activity during the process of their targeted delivery. On the other hand small 
molecules that are easier to handle and pose less threat of denaturation or loss of function during 
processing, but induce many different cellular signaling pathways and targeting a specific 
therapeutic outcome without side effects is a challenge(420). However delivering the patient’s 
autologous bone marrow derived stem cells is a simple and clinically relevant strategy to 
improve the outcomes of bone healing. It has been demonstrated that bone marrow derives 
mesenchymal stem cells (MSCs) are capable of differentiating in the osteochondral lineage. 
Additionally, the phisio- chemical nature of the biomaterial has dictated the differentiation of 
stem cells in the specific lineage. A detailed description of the mechanisms by which materials 
dictate protein adsorption and in turn cell adhesion is given in the Discussion section of chapter 
3. Briefly, the various factors influencing the differentiation of MSCs(421) are the mechanical 
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property of the matrix(422), chemical functionalities(37) on the surface of the scaffold, the 
hydration properties(410) and the surface topography of the biomaterial(379, 400). Many studies 
have used these mechanical and phisio- chemical properties alone and in combination with 
inductive media to differentiate stem cells in the osteochondral lineage. In Chapter 3, the higher 
hydrophilicity of all the CA materials over PLGA was established. The collagen nanofibers on 
the CAc 3D- porous scaffolds presented a more native triple helical presentation than on PLGAc. 
We hypothesized that these differences in material charecteristics between the PLGA and CA 
(uncoated and collagen coated) scaffolds may positively influence MSC differentiation in the 
osteo-chondral lineage in vitro. Hence, here in this chapter high density cultures of MSCs were 
seeded onto PLGA, CA, PLGAc and CAc 3D- porous scaffolds and their viability, 
proliferateion, osteo-chondral gene expression and the osteoblastic protein presentation were 
tested. These studies are meant to establish the osteoinductive behavior of the materials towards 
stem cells. 
 
4.2 Materials and Methods 
4.2.1 Materials  
 
Cellulose acetate (Mw: 30K) (CA), and Polyvinyl Alcohol (30,000-70,000) (PVA) were 
procured from Sigma -Aldrich (St. Louis, MO, USA). Poly (lactic-co-glycolic acid) 85:15  
(PLGA) was purchased from lakeshore biomaterials (Birmingham, USA).  Acetone, 
Dichloromethane, Cyclohaxane, Paraformaldehyde and Gluteraldehyde were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA). BioRad Alkaline Phosphatase Substrate kit (Hercules, 
CA, USA) and Invitrogen Quant-iT PicoGreen dsDNA Assay kit (Eugene, Oregon, USA) were 
used in this study. Alizarin Red and Cetylpyridinium chloride was procured from Acros Organics 
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(New Jersey, USA). Cell culture media was DMEM (HG) purchased from Lonza (Walkersville, 
USA).  
4.2.2 Preparation of microspheres  
 
Oil in water solvent- evaporation, followed by sintering of formed microspheres using a 
solvent/non-solvent mixture was used for producing microsphere of i) Cellulose acetate (CA), ii) 
poly (lactic-co-glycolic acid) 85:15 (PLGA). In brief, 13 (w/v) % of CA polymer was dissolved 
in a solvent mixture containing methylene chloride and acetone at a ratio of 9:1 to produce 
microspheres.  A 20 (w/v) % solution in methylene chloride was used in the case of PLGA 
polymer to produce the microspheres. The polymer solutions were then poured in a thin stream 
into an aqueous media containing 1.25(w/v) % PVA as a surfactant, with constant stirring at 
250rpm to form an oil-in-water emulsion. These suspensions were stirred overnight to evaporate 
the solvent to obtain hardened microspheres. Isolated microspheres were washed repeatedly with 
deionized (DI) water, dried, and sieved into different microsphere sizes. Microspheres in the size 
range of 600-710 and 710-800µm were mixed at a weight ratio of 1:1 and sintered into micro 
porous scaffolds using either solvent-non-solvent or heat sintering based on the polymer(352, 
391).   
4.2.3 Preparation of micro-porous sintered microsphere scaffolds 
 
Teflon molds of different dimensions were filled with CA microspheres to which a 200µL 
volume of an optimized solvent/non-solvent composition, acetone: cyclohexane in the ratio of 
3:1 (v/v), was added to cover the microspheres. Solvent was allowed to evaporate at room 
temperature to obtain sintered microsphere scaffolds. Cylindrical scaffolds measuring 5mm 
diameter X 10mm height were used for the characterization of hydration properties while 8mm 
diameter X 2mm thick tablets were used for cell studies and animal experiments. The control 
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PLGA micro porous scaffolds with identical micro-particle sizes were produced by heat sintering 
at 95oC for 45 minutes using Teflon molds(352). 
4.2.4 Preparation of micro-nano structured scaffolds  
 
A modified biomimetic approach was used to functionalize micro porous scaffolds with type I 
collagen. In brief, both control and test scaffolds were incubated in a 0.1  (w/v) % collagen type I 
solution with a pH adjusted to 4.2 at 37°C for 7 days to promote molecular collagen self-
assembly.  The dried scaffolds were treated with UV light for 30 min each side to achieve 
collagen nanofiber stability and washed repeatedly with DI water to remove buffer salts.  
4.2.5 In Vitro human Mesenchymal Stem Cells (hMSCs) culture on scaffolds  
 
Human bone marrow derived mesenchymal stem cells were purchased from Lonza (Lonza, 
Walkersville, USA) and expanded as per the protocol provided by the supplier. Cells used for all 
experiments were at passage 5. The basal media consisted of DMEM (HG) (Lonza, Walkersville, 
USA) supplemented with 10% FBS and 1% antibiotics (Penicillin-Streptomycin). The 
osteogenic media was composed of basal media with 0.2mM L- Ascorbic acid and 7.0mM 
Glycerol 2-phosphate disodium salt and 0.1µM Dexamethasone. 
Scaffolds were soaked in 70% ethanol for 20min and allowed to dry in the cell culture hood. 
Each side of the scaffold was exposed to UV light for 20 minutes in the tissue culture hood. 
Scaffolds were soaked in basal media overnight prior to seeding with the hMSCs. Each scaffold 
was seeded with 250,000 cells in a 50µL cell suspension and incubated for 4h before additional 
media was added. A total of 500µL basal media was added to the samples in a 48 well plate and 
then switched to osteogenic media following 24h. The media was changed every other day and 
cultures were maintained for 21 days. One set of scaffolds was also cultured in basal media up to 
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21 days to evaluate hMSC proliferation using pico-green assay.  All studies were done in 
triplicate for each time point and each group of scaffolds. 
4.2.6 Cell viability 
 
Viability of hMSCs on the scaffolds was analyzed with a live/dead cell viability kit. In brief, 
calcein AM enters live cells and reacts with intracellular esterase to produce a bright green 
fluorescence, while ethidium homodimer-1 enters only dead cells with damaged membranes and 
produces a bright red fluorescence upon binding to nucleic acids. Scaffolds were imaged on 3, 7, 
14 and 21 days of osteoinduction using a Zeiss 780 /Laser Scanning Confocal Microscope 
(LSCM) at magnifications of 10X to view cells independently and along with the scaffolds. 3D 
reconstruction of the confocal stacks was done using Imaris software (Bitplane). 
4.2.7 Cell proliferation  
 
Rate of hMSCs proliferation after transferring to osteogenic media was quantified by measuring 
the amount of cellular DNA content at various culture points using a Picogreen dsDNA assay. In 
brief, at different culture time of 3, 7, 14 and 21 days, the cellular constructs were washed twice 
with PBS, transferred to new well plates and 1ml of 1% Triton X-100 solution was added to lyse 
the cells. The well plates underwent three freeze-thaw cycles, between -70oC and room 
temperature, and mixed with the aid of a pipette to extract cell lysate from the 3D scaffolds prior 
to analysis. 125µL of sample DNA was transferred into a new well plate to which 375µL 
(component B) and 500µL (Component A) kit reagents were added. Well plates were covered 
with aluminum foil to prevent light exposure and incubated for 5min. A BioTek plate reader was 
used to read fluorescence (485nm/535nm). Optical readings were converted in DNA 
concentration using a standard curve.  
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4.2.8 Alkaline phosphatase activity 
 
Alkaline phosphatase activity of hMSCs on the scaffolds was evaluated as a marker of osteoblast 
phenotype progression using an ALP substrate kit. A 100µL of cell lysate was transferred into a 
well plate to which a 400µL of P-NPP (para- nitro phenol phosphate) substrate and buffer 
solution were added and incubated at 37ºC for 30min. After 30 minutes, 500µL of 0.4N of 
sodium hydroxide was added to stop the reaction. The intensity of the color produced though the 
reaction is proportional to ALP activity. The optical density of the solution was measured at 
405nm using a BioTek plate reader. The results for ALP activity were optical density and these 
were normalized to scaffold volume. 
4.2.9 Mineralized matrix deposition by cells 
 
Mineralized matrix deposition by osteoinduced hMSCs on the scaffolds were evaluated as 
marker of mature osteoblast phenotype using an Alizarin Red staining method for calcium 
deposition at 21 days of osteoinduction. This colorimetric analysis is based on solubilizing the 
red matrix precipitate with cetylpyridinium chloride (CPC) to yield a purple solution. In brief, at 
21 days of osteoinductive cell culture, cellular constructs were fixed in 70% ethanol for 1h, at 
room temperature and then stained with 40mM Alizarin Red (Sigma) solution for 10 min at room 
temperature. After washing 5-10 times with distilled water to remove the adsorbed/absorbed dye, 
chemically bound red matrix precipitate was solubilized in 1mL of 10% CPC until color was 
stable. The optical density of the solution was read at 562nm using BioTek plate reader. The 
results for calcium deposition were also normalized to scaffold volume. 
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4.2.10 Gene expression  
 
The RNA from scaffolds was extracted using RNeasy Plus Universal Mini Kit (Quiagen, 
Valencia, CA, USA) as per the manufacturer’s protocol. Briefly, each scaffold was washed with 
sterile PBS (pH 7.4) and then RNA extraction was carried out using RNeasy Plus Universal R kit 
(Quiagen, Valencia, CA, USA). Briefly, Quiazol R/ chloroform extraction yielded an aqueous 
layer. This layer was loaded on to columns and washed using buffers successively to collect 
RNA in a micro centrifuge tube and suspended in 30µL of RNase-free water. The RNA was 
measured using a nanodrop spectrophotometer and 1.5µg RNA was used for DNAse treatment, 
to eliminate any remnant genomic DNA contamination. A DNA-freeTM Kit (ambion, life 
technologies, Foster City, CA, USA) was used and the manufacturer’s protocol was used to 
digest the cDNA.  
This DNAse treated RNA was used to reverse transcribe into cDNA using iSript advanced 
reverse transcription kit (Bio-rad, Hercules, California, U.S.A.), using the manufacturer’s 
protocol. To each sample, 4µL of reaction buffer and 1µL of advanced reverse transcriptase 
enzyme were added. Following incubation at 42°C for 30 minutes and enzyme inactivation at 
85°C for 5 minutes, the cDNA was ready for gene expression analysis.  
Prime- PCR (Bio- Rad, Hercules, California, U.S.A.), gene arrays where primers of 
osteochondral genes were used for the gene expression analysis. Validated SYBR green primers 
of the following genes were analyzed: GAPDH, TBP, HPRT1 (internal control genes expressions 
were normalized to), Coll1A1, Coll1A2, Coll3A1, Coll2A1, BGLAP, MMP-13, Coll10A1, 
Sox9, RUNX-2, ALPL, IBSP, BMP-2, DMP-1, SPARC (ON), MMP-9, MMP-13, IHH. To each 
of the test wells, 10µL of 2X Sos Advanced SYBR green mix, 10µl of cDNA with ultrapure 
water (equivalent to 12.5ng) was added. All controls to check for purity of starting material 
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including gDNA contamination, and RNA integrity were included and passed the quality control 
criteria. Samples used were cells seeded and osteoinduced on PLGA, PLGAc, CA and CAc. 
PLGA was kept at 1.0 and the gene expression fold changes were with reference to PLGA.  
4.2.11 Osteogenic marker Immunostaining  
 
The scaffolds seeded with hMSCs were harvested at 21 days of osteoinduction and washed with 
PBS (pH 7.4) prior to fixation with 4% paraformaldehyde (PFA) in PBS (pH 7.4) at room 
temperature for 10 minutes. The samples were then washed with PBS (pH 7.4) and 
permeabilized using 0.1% Triton X-100 in 1X PBS (pH 7.4) for 10 minutes. Samples were 
washed again with PBS (pH 7.4) and subsequently incubated in 3% bovine serum albumin 
(BSA) in 1X PBS (pH 7.4) solution for 30 min to block non- specific antibody binding. Primary 
antibodies at specific concentrations (Colleen Rabbit anti human (abcam, Cambridge, MA, 
U.S.A.) at 1:200 dilution; and bone sialoprotein Rabbit anti human (Millipore, Billerica, MA, 
U.S.A. at a dilution of 1:100)) were dissolved in 1% BSA/ PBS (pH 7.4) buffer. Scaffolds were 
incubated in primary antibody solution for one hour at room temperature. This was followed by 
rinsing of samples with PBS (pH 7.4). Dylight 594- Goat- anti- Rabbit secondary antibody 
(Jackson immune, West Grove, PA, U.S.A.) at a dilution of 1:400 was dissolved in 1% BSA/ 
PBS (pH 7.4) buffer along with Alexafluor 488- Phalloidin (Invitrogen, Eugene, Oregon, USA) 
at a 1:40 dilution were added to scaffold construct for one hour. This was followed by rinsing of 
samples 3 times with PBS (pH 7.4). NucBlue (DAPI) at a 2 drops/ ml of PBS (pH 7.4) was used 
for staining the cellular nuclei. This was followed by confocal imaging with z- stacking for each 
of the scaffolds for visualization of the marker (red)/ cytoskeleton (green) and nuclei (blue). 
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4.2.12 Statistical analysis  
 
All data are reported as the mean ± standard deviation (SD) of results from at least three 
independent runs. In case of experiments with two groups a student t- test was performed. In the 
case of experiments with multiple groups and multiple time points a 2- way- ANOVA with 
Bonferroni posttest was performed. In the case of experiments that focused on one time point and 
several groups, a one- way- ANOVA with Tukey posttest was performed.  95% Confidence 
interval was employed to arrive at the p values. The denotation of significances given by p 
values are- *p<0.001 (extremely significant), #p<0.01 (very significant), @p<0.05 (significant). 
Analyses were performed using GraphPad Prism Software (GraphPad Software, San Diego, CA). 
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4.3 Results 
4.3.1 Characterization of hMSC response  
 
Good cell viability on PLGA, PLGAc, CA and CAc from day 3 to day 21 was evident (Figure 
4.3).  In the current study all structures were seeded at a high cell density to study the osteogenic 
phenotype development and hence the cell proliferation rates were constant due to confluency 
(Figure 4.1 a, b, c and Figure 4.4). The alkaline phosphatase activity (ALP), as a precursor of 
osteoblast maturation, and mineralization determined by alizarin red staining (ALZ), as a marker 
of late stages of osteoblastic maturation, were evaluated at 21 days. The ALP activity was 
highest on CAc and it was significantly greater than CA. However, this was not the case with 
PLGAc and PLGA, as there was no difference between the two groups in ALP activity (Figure 
4.1d). Mineralization was higher on collagen-coated groups than on their uncoated counterparts. 
However mineralization on CAc was significantly greater than mineralization on PLGAc 
(Figure 4.1 e,f). These findings indicate that the osteoblastic phenotype progression may be 
greater on CAc than the other groups including PLGAc.  
To further understand if there is a difference in osteochondral progression of seeded hMSCs, the 
expression of osteochongral genes and proteins were analyzed (Figure 4.5 and Figure 4.2). 
Collage 1 (Coll1), an important ECM component of bone was significantly upregulated in all 
groups in contrast to PLGA. The CAc group had the highest collagen expression and it was 
remarkably greater than PLGAc and CA (Figure 4.2a). Osteonectin (ON), a protein associated 
with the collagen ECM, also showed a similar trend with cells on CAc showing the highest 
levels of expression (Figure 4.2b). Bone sialoprotein (BSP), a mature marker of osteoblasts, was 
upregulated considerably on CA and CAc in contrast to PLGA and PLGAc. Interestingly CAc 
performed better than CA, but cells on PLGAc and PLGA showed no significant difference in 
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BSP expression (Figure 4.2c). Additionally, an important osteoblastic transcription factor Runx2 
was seen to be significantly upregulated on CAc in contrast to all other groups (Figure 4.2d). 
Furthermore we examined genes for osteochondral progression (Figure 4.5), such as alkaline 
phosphatase (ALPL), Collagen III (Coll3A1), Matrix metalloproteinase 13 (MMP13), Sox9 and 
Collagen10A1 (Coll10A1). We saw an upregulation of these genes on the natural polymers (CA 
and CAc) in contrast to the synthetic polymers (PLGA and PLGAc). CAc showed the highest 
expression of all the genes indicating greatest osteoinduction of seeded hMSC. To visualize 
phenotype expression and cellularity within scaffolds, immunostains were performed for 
osteoblastic markers such as Coll1 and BSP along with phalloidin for cytoskeletal F-actin and 
Nucblue for cell nuclei. While the cells and markers were distributed evenly on the CA and CAc 
groups, PLGAc showed better cellular distribution than PLGA. The cells and markers were 
confined to the microspheres, with very little cellularity in the pores (Figure 4.2e,f). Thus 
osteoblastic maturation was greatest on CAc followed by CA, indicating the effectiveness of 
natural polymeric micro-nano structured scaffolds towards osteoinduction of stem cells. The 
CAc scaffolds induced greater osteogenic progression than PLGAc as the biomimetic nature of 
CAc was more conducive than PLGAc.   
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Figure 4.1 Viability, proliferation and osteoblastic markers of seeded hMSCs 
In vitro phenotype development by hMSCs seeded on to scaffolds under osteoinduction. 
Viability of seeded cells over time on PLGA (top left), PLGAc (top right), CA (bottom left) and 
CAc (bottom right) with live (green)/ dead (red) staining at a) Day 3 and b) Day 21. Scalebar = 
200µm. c) DNA content by pico- green assay over 21 days in culture d) Alkaline phosphatase 
activity at 21 days of osteoinduction on PLGA, PLGAc, CA and CAc. Mineralization at 21 days 
of osteoinduction on scaffolds measured by e) visual micrographs of alizarin red stained 
scaffolds (PLGA, PLGAc, CA and CAc- top to bottom) and f) Colorimetric quantification of 
calcium deposition on PLGA, PLGAc, CA and CAc. One – way ANOVA with Tukey post test, 
with 95% confidence intervals, *P<0.001, #P<0.01, @P<0.05. 
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Figure 4.2 Osteoblastic gene and protein expression by hMSCs 
Osteoblast markers expressed by osteoinduced hMSCs on PLGA, PLGAc, CA and CAc at 21 
days. Osteogenic gene expression of a) Collagen1A1 (Coll1A1), b) Osteonectin (ON), c) Bone 
Sialoprotein (BSP) and d) Runx2. Immunostaining for osteoblastic protein markers (Marker- red/ 
F-actin (Phalloidin)- green/ Nucleus (Nucblue DAPI)- blue) staining of PLGA (top left), PLGAc 
(top right), CA (bottom left) and CAc (bottom right)  e) Collagen1/ F- actin/ Nuclei staining f) 
Bone sialoprotein/ F- actin/ Nuclei and g) No primary control ( Background -red/ F- actin 
(Phalloidin)- green/ Nuclei (DAPI)- blue) scalebar = 200µm. One – way ANOVA with Tukey 
post test, with 95% confidence intervals, *P<0.001, #P<0.01, @P<0.05.  
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4.4 Discussion 
 
Cells adhere to materials through adsorbed ligands, by binding to these ligands via their integrin 
receptors(423). The classical view in material-protein interaction argues that a hydrophobic 
matrix, due to its favourable surface energy, adsorbs higher quantity of proteins from the 
surrounding environment. These absorbed proteins play an important function in regulating 
cellular events(424-426). However, the absolute quantity of adsorbed proteins onto a material 
could not be correlated to cell adhesion(427). Many reports identify the importance of matrix 
hydrophilicity as an essential feature for achieving cell adhesion and long term 
biocompatibility(428). Studies focused on improving the matrix hydrophilicity, without altering 
its chemistry or surface roughness, led to greater cellular adhesion demonstrating that cellular 
responses were optimal on slightly hydrophilic materials(377). Though experimental evidence is 
minimal, it is believed that hydrophilic matrices may lead to a more native-like conformation of 
the adsorbed proteins in turn producing better cellular responses(429). The differential response 
of collagen self-assembly on CA and PLGA polymers could be an attributing factor for the 
observed D-banding patterns on the CA matrix alone. 
The chemical functional groups on a material can influence cellular responses immensely. For 
instance Curran et al. cultured bone marrow derived mesenchymal stem cells (MSCs) on glass 
substrates modified to contain the functional groups: like -CH3, -SH, –COOH, –OH, and –NH2, 
under basal, osteogenic and chondrogenic conditions. They found that the -CH3 functional 
groups helped maintain the multipotency of MSCs, while the –OH and –NH2 groups were 
conducive for osteogenic differentiation, and the –COOH and –SH groups on the substrate 
supported chondrogenic differentiation. These differences were observed both under basal and 
stimulated conditions(413). Many other studies have used materials that varied only by the 
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chemical functional groups on the biomaterial’s surface and all of them have shown that the 
chemical functionalities on the material surface can have a profound influence on stem cell 
behavior(37, 340). These changes can be attributed to the resulting material surface energy and 
hydration characteristic that determine the conformation of adsorbed proteins and in turn cellular 
adhesion(414). In the present study, polysaccharide CA provides aforementioned functionalities 
and control PLGA polyester lacks these groups to study the osteochondral phenotype progression 
of seeded stem cells. Apart from this, the observed micro scale roughness of CA groups over the 
smooth morphology of PLGA, could also act as an inductive factor for osteogenic differentiation 
of stem cells(430).  
In order to understand the effect of the properties of the material towards stem cell 
differentiation, hMSCs were seeded on all the polymers and differentiated into osteoblastic 
lineage. The hMSCs showed good viability for the period in culture on both the polyesters and 
the polysaccharides. However, the cells spread on the microspheres and the interpore spaces of 
CA and CAc, and PLGAc but not in the case of PLGA. The inclusion of integrin ligand such as 
collagen or the presence of a hydrophilic polymer that allows for integrin ligands from the media 
to be presented in the right conformation may have lead to better cell spreading on the CA, CAc 
and PLGAc matrices against the microsphere focused cellularity of PLGA (Figure 4.1 a, b, c 
and Figure 4.4). PLGA is shown to have a contact angle above 90°, but CA has a much lower 
contact angle of around 55°. It has been seen that several studies that a contact angle between 35- 
65°, may be more conducive for cell adhesion than a contact angle above 90°(431, 432). Hence 
the CA materials showed greater cell adhesion and spread than PLGA, owing to their hydrophilic 
nature. 
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The presence of collagen, which is an integrin ligand could compensate in the case of PLGAc, 
leading to greater uniformity in cell distribution. However, the osteochondral progression of 
seeded MSCs was higher on CA and CAc both in terms of gene and protein levels and 
distribution (Figure 4.2, 4.5). The long bones of our body are formed by endochondral 
ossification. In this process the MSCs undergo a transition through the formation of a condensed 
chondrogenic template to facilitate the formation of bone. The material properties may have 
attributed to better cell adhesion by integrin signaling on the MSCs seeded on CA and CAc. 
These could translate into better cell- cell contact as well. This is likely to be more conducive for 
cellular condensation and hence the greater osteochondral progression seen on CA and CAc. 
Though both CAc and PLGAc possessed collage, the collagen on CAc was seen to be more 
biomimetic than the collagen on PLGAc. It has been shown in literature that denaturation of 
collagen leads to loss of mechanical stimuli needed for MSC’s osteoblastic differentiation(405, 
406). It is also known that the Hedgehog signaling pathway, seen to play an important role in 
osteochondral progression(433, 434) in the body is upregulated by type one collagen with the 
native structure(435). Hence we observed that the CAc micro-nano structured biopolymer was 
most osteoinductive, to an extent greater than its PLGAc counterpart.  
 
4.5 Conclusions 
 
We conclude that the natural polymer based micro- nano structured CAc scaffolds mediated the 
greatest degree of cell spreading and distribution along with greatest levels of osetoblastic 
differentiation of the seeded MSCs. While the PLGA platform showed similar viability and cell 
proliferation levels, the CA scaffolds showed better cell and osteoblastic marker distribution 
throughout its microspgeres and the interpore spaces. Hence these studies have shown the 
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potential of CA and CAc scaffolds to be osteoinductive when used in combination with MSCs. 
Since MSCs are a very clinically relevant cell population, the translational relevance of using CA 
and CAc scaffolds in combnation with MSCs may be great. 
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4.6 Supplemental Figures 
 
 
Figure 4.3 Viability of seeded hMSCSs 
Live (green)/ dead (red) staining of cells on scaffolds at a) Day 3, b) Day 7, c) Day 14, d) Day 
21. PLGA (top left) PLGAc (top right), CA (bottom left) and CAc (bottom right) show good 
viability of seeded hMSC throughout all culture time points. 
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Figure 4.4 Proliferation of seeded hMSCs 
a) hMSC proliferation measured by pico- green assay over 21 days of culture in basal and b) 
osteoinduced condition. Two- way ANOVA with Bonferroni post- test, with 95% confidence 
intervals, *P<0.001, #P<0.01, @P<0.05. 
 
 
 146 
 
Figure 4.5 Osteochondral gene expression by seeded hMSCs 
Osteochondral gene expression by osteoinduced hMSCs on PLGA, PLGAc, CA and CAc. a) 
ALPL- Alkaline phosphatase, b) Coll3A1- collagen 3A1, c) MMP13- Matrix metaloprotease 13, 
d) Sox9,  e) Coll10A1- collagen 10A1. One – way ANOVA with Tukey posttest, with 95% 
confidence intervals, *P<0.001, #P<0.01, @P<0.05 
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5 Chapter 5 
Charecterization of the Biocompatibility of CA-Collagen, Micro-Nano Structured Scaffolds 
in vivo 
5.1 Introduction 
 
Any foreign material that is placed into a host tends to elicit an immune reaction. When a 
material is first implanted into the body, it comes into contact with blood. A layer of protein 
from the host coats the implanted biomaterial. Various proteins like fibrin, fibrinogen, 
vitronectin and a host of other proteins are found in this mix, along with immunoglobulins like 
IgE and opsonins like compliment activated factor C3b(436) etc. The neutrophils home and try 
to resolve the new foreign body by trying to digest it with their activity. However the biomaterial 
is too large and once this acute phase resolved, the macrophages home to the implant and since 
they are also incapable of destroying the foreign body, the fusion of macrophages occurs, leading 
to the formation f multinucleated giant cells (MNCs), that are characteristic of a foreign body 
reaction (FBR). Eventually a layer of collagen produced by fibroblasts encapsulates the implant. 
This is known as fibroencapsulation of the biomaterial(437). 
Biocompatibility is a complex factor that involves the immune response by the body to the 
implanted foreign material. Though every material tends to elicit an immune response, it is 
important to make sure that the FBR to a material is acceptable as per the norms laid out by 
regulatory agencies before implantation into the body. Though cell viability in vitro can and is 
used as a measure of biocompatibility, implantation into the body is necessary to understand the 
tissue response to the material and establish its safety for usage an implant biomaterial for tissue 
engineering. The (IOS) 10993 criteria for biomaterial biocompatibility mandates implantation 
into animals and require that the implants be non- toxic on implantation(437).  
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Taking these factors into consideration, implantation of CA, CAc and PLGA polymers under 
subcutaneous pouches of rats were conducted. The rats were sacrificed and the immune response 
in the tissue infiltrating into the scaffold matrix were determined by histological staining and 
histomorphometric measurements. These studies were designed to test the safety of the new CA 
and CAc polymeric scaffolds against an FDA approved (PLGA) polymer. 
 
5.2 Materials and Methods 
5.2.1 Subcutaneous implantation 
 
 Sprague Dawley rats of 250-300 grams of body weight were purchased from Charles River 
(Wilmington, MA, USA). All procedures for animal use were approved by the Institutional 
Animal Care and Use Committee (IACUC), at the UConn Health. Isoflurane (3%) in a gaseous 
mix with oxygen was used as the anesthetic. Each rat was implanted with six scaffolds, two of 
each kind (PLGA, CA and CAc). Briefly, the dorsal side of the rats were shaved and prepped 
with betadine and alcohol. A 2.5 cm long incision was created to make a subcutaneous pouch 
and individual scaffolds (8X2mm) were implanted into pouches. The pouches were sutured and 
animals were monitored regularly. At each of the 2, 4, 8 and 12 weeks of implantation time 
points, two rats were sacrificed using carbon dioxide overdose and four scaffolds (n=4) of each 
type (PLGA, CA and CAc) were removed and collected for evaluation.  
5.2.2 Histological staining 
 
The scaffold samples were harvested along with the surrounding subcutaneous tissue, washed in 
PBS (pH 7.4) and fixed in 4% PFA/ PBS (pH 7.4) overnight at 4°C. The scaffolds were rinsed in 
PBS (pH 7.4) after fixation and transferred to a 1:1 mix of OCT and 30% Sucrose solution in 
PBS (pH 7.4). The samples were incubated for 24h at 4°C. The samples were then transferred to 
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OCT alone at room temperature for an hour. The samples were flash frozen and sectioned into 
10µm thick sections and captured on cryo-films. The cryo films were fixed onto slides using UV-
curing adhesive. The samples were hydrated in water and Hematoxylin and eosin staining and 
Gomori Trichrom staining was performed. 
5.2.3 Histomorphometric analysis  
 
The hematoxylin and eosin stained samples were used for characterization of cell types 
infiltrating the implants. Two independent evaluators scored the samples for multinucleated giant 
cells (MNC) characteristic of foreign body response, macrophages, fibroblasts and blood vessels 
based on cell morphology, in consultation with a clinical pathologist. The gomori trichrome 
samples were used as guidelines for confirmation of cellular phenotype. FIJI (NIH) software was 
used to count the total number of cells in each type and to measure the tissue area in the pore of 
each group of scaffold. All the scores were normalized to the tissue area fraction. Tissue area 
fraction was equal to Tissue area in section (i.e. tissue area in the pores of the scaffold)/ Total 
area of the section. An n=3 was used for this analysis.    
5.2.4 Statistical analysis  
 
All data are reported as the mean ± standard deviation (SD) of results from at least three 
independent runs. In case of experiments with two groups a student t- test was performed. In the 
case of experiments with multiple groups and multiple time points a 2- way- ANOVA with 
Bonferroni posttest was performed. In the case of experiments that focused on one time point and 
several groups, a one- way- ANOVA with Tukey posttest was performed.  95% Confidence 
interval was employed to arrive at the p values. The denotation of significances given by p 
values are- *p<0.001 (extremely significant), #p<0.01 (very significant), @p<0.05 (significant). 
Analyses were performed using GraphPad Prism Software (GraphPad Software, San Diego, CA). 
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5.3 Results 
5.3.1 Cellularity in the scaffolds  
 
Subcutaneously implanted PLGA, CA and CAc scaffolds in Sprague Dawley® rats retrieved at 
week 2, 4, 8 and 12 were processed for histology. At the earliest time point CA scaffolds had 
very little cellularity compared to PLGA controls. However, the CAc scaffolds presented good 
cellularization at the early time point (2 weeks) (Figure 5.1a). The collagen content of the tissue 
was also higher in CAc than CA (Figure 5.1c). As time progressed the cellularization of CA 
groups increased at 4 weeks (Figure 5.1 b,d) with the CAc scaffolds showing more 
cellularization than CA. However by 8 weeks all the materials looked similar in terms of their 
cellular and collagen content (Figure 5.2 a, c). At 12 weeks there was a marginal decrease in the 
cellularity of PLGA, but the tissue infiltration of the CA and CAc scaffolds were greater (Figure 
5.2 b, d). Quantitatively the tissue infiltration in the CA material was lower than PLGA in the 
earlier time points after implantation of the material (at 2 and 4 weeks). However at 8 weeks all 
the scaffolds had a comparable amount of tissue infiltration and by 12 weeks the CA material 
showed greater cellular content than the other groups (Figure 5.3b).  
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5.3.2 Immune response to scaffolds  
 
The macrophages population on CA was considerably higher than CAc at the earliest (week 2) 
time point (40X magnified images of Figure 5.1 a,c). However these differences were 
insignificant with progress in time (40X magnified images of Figure 5.1 b,d; Figure 5.2 a, c; 
b,d; Figure 5.3 c). The multinucleated giant cells (MNCs) representing the FBR of the tissue to 
the biomaterial indicated a significantly higher FBR to CA than on PLGA, but not on CAc soon 
after implantation at around 2 weeks (40X magnified images of Figure 5.1 a,c and Figure 5.3 
a). These significances did not persist at later time points (40X magnified images of Figure 5.1 
b,d;Figure 5.2 a, c) until 12 weeks (Figure 5.2 b, d) when PLGA showed considerably greater 
number of MNCs than CA and CAc (Figure 5.3 a). 
5.3.3 Vascularity in scaffolds 
 
Vascularity of all the materials were pretty low to begin with at 2 weeks but increased at a 
similar rate on all the materials (Figure 5.3 d). 
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Figure 5.1 Staained histological sections at early time points 
Histological staining of subcutaneously implanted PLGA, CA abnd CAc at early time points. (a, 
c- at 2 weeks , b, d- at 4 weeks ). a), b)- Hematoxylin and eosin staining, c), d)- Gomori 
trichrome staining. Scalebars on 1X magnification = 3mm, scalebar on 20X and 40X 
magnifications= 300 µm. 
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Figure 5.2 Stained histological sections at late time points 
Histological staining of subcutaneously implanted PLGA, CA abnd CAc at late time points (a,c- 
at 8 weeks, b,d- at 12 weeks). a), b) Hematoxylin and eosin staining, c), d) Gomori trichrome 
staining. Scalebars on 1X magnification = 3mm, scalebar on 20X and 40X magnifications= 300 
µm. 
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Figure 5.3 Histomorphometric analysis of subcutaneous implants 
Histomorphometric analysis of implanted scaffolds over time- Immune response represented by 
a) multinucleated giant cells (MNCs), and, b) percentage tissue area, c) macrophages and d) 
number of blood vessels. Two- way ANOVA with Bonferroni post- test, with 95% confidence 
intervals, *P<0.001, #P<0.01, @P<0.05. 
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5.4 Discussion 
 
Biocompatibility is a basic criterion for using any biomaterial in the body. Though 
biocompatibility was thought to be elicited by bioinert materials that did not lead to adverse 
reaction, presently it is defined as a biomaterial’s ability to elicit an appropriate tissue response 
when implanted in the body(437). As mentioned in the introduction of this chapter, the tissue 
response to the natural polymeric CA and CAc materials were contrasted with the PLGA 
scaffolds. As per the expert opinion of clinical pathologist all the materials elicited an immune 
response that indicated good immune tolerance by the body. Cellulose and its derivatives are 
well known to be biocompatible as implants(231). Its blood biocompatibility had led to the 
formulation of hemostatic devices based on cellulose. However the CA scaffolds used by us have 
tested as highly hydrophilic materials (Chapter 3). As stated in the introduction the first step in 
biomaterial recognition in the body after implantation is by adsorption of several proteins and 
opsonins onto the surface of the biomaterial. In this regards, the C3 fragment of the compliment 
system plays an important role in eliciting the FBR response. For instance Elwin et al. showed 
that C3 compliment factor adsorbed in modified surfaces that were highly hydrophobic showed 
denaturation of the adsorbed protein(438). This led to exposure of the epitopes recognized by the 
antigens in the body. With biomaterials used as contact lenses, the more hydrophilic ones lead to 
greater biocompatibility and lesser protein buildup(439). So, in general, hydrophilic materials 
have been seen to induce greater bio-acceptance in the body. It was shown by Sussman et al, that 
the same material implanted as a solid piece vs as an interconnected porous scaffold can elicit 
very different immune response. While the solid material showed a fibrotic response the porous 
sctucture showed greater biocompatibility(440). Hydrogels that show very little protein 
adsorption onto their surface have also shown great biocompatibility and tissue integration 
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responses(441). Here in these studies we observed a lack of immune tolerance for the CA 
scaffold at the early time points of 2 and 4 weeks in comparison to PLGA. However the collagen 
coated counterparts did not suffer this lag time for cellularization of the biomaterial and they had 
a lower FBR response. CA being extremely hydrophilic could have shown a lag in the adsorption 
of bodily proteins stably onto its surface at the early time points of implantation in turn leading 
to a lag in cellular infiltration/ adhesion. However the presence of exogenous collagen may have 
helped with achieving initial tissue infiltration and biocompatibility of the CAc over the CA 
scaffolds. On the other hand, at the latest time point of 12 weeks PLGA that showed good 
responses in terms of cellularization and FBR started showing a reduction in tissue content and 
an increase in MNCs representative of an increasing FBR with time in contrast to CA. PLGA 
and synthetic polymers like PLLA may elicit an adverse immune response with time due to the 
change in the environmental pH associated with the degradation of the polymer matrix(365). On 
the other hand CA which showed slow cellularization showed long term biocompatibility. The 
presence of collagen in CAc may have hastened the process of cellularization and immune 
acceptance of the material by the body. The results of material characterization (chapter 3) and 
cellular viability (chapter 4) agree well with the results of long-term biocompatibility of the 
natural polymers seen in this chapter. 
 
5.5 Conclusions 
 
We conclude that CA 3D porous microsphere scaffolds show good long-term biocompatibility. 
Inclusion of collagen nanofibers may be beneficial in achieving biocomapatibility soon after 
implantation. This implies that the CA, CAc and PLGA materials can be safely implanted into 
animals for examining functional bone regeneration by the scaffolds. 
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6 Chapter 6 
Characterization of Bone Formation by Natural Polymeric Materials in a Critical Sized 
Calvarial Defect in Combination with Bone Marrow Stromal Cells 
 
6.1 Introduction 
 
Bone represent one of the most transplanted organ(5). About 0.5 million bone grafts are carried 
out in the U.S. alone, (6-8) per annum(5). Though using bone from the patient itself 
(autografting) is considered the golden standard for achieving bone healing, it is restricted by 
availability and discomfort to the patient. Allografts on the other hand help overcome these 
limitations, but carry the threat of low remodeling due to excessive processing and possibility of 
disease transmission(9). Hence in bone tissue engineering, biomaterial scaffolds, biological 
factors and cells used alone or in a combination promises better bone regeneration(9). Here, the 
tissue engineered scaffolds act as a template for regeneration to occur and the properties of the 
biomaterial can dictate the nature of bone regeneration achieved(33).  
It is well known that the scaffold properties such as hydrophilicity(34), morphology(35), 
porosity, and mechanical properties(39) can be used to direct effective bone healing. Both 
synthetic and natural polymers have been used as scaffold materials for bone regeneration. The 
most popular polymeric materials used commercially are PLLA and PLGA(395). Though 
synthetic polymers lend themselves to be readily modified to obtain the desired molecular 
weights and hence gaining control over their mechanical and degradation properties is possible, 
concerns are raised due to their hydrophobic nature and acidic bulk degradation products that 
could impact bone formation in the body(343, 396). Strategies such as inclusion of 
hydroxyapatite have given a buffering effect under such conditions(344).  
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Natural polymers such as polysaccharides and proteins on the other hand are synthesized in 
biological systems like plants, animals and microbes and therefore their structure and chemistry 
are similar to the ECM macromolecules seen in our body(442). Hence these natural polymers 
offer greater biocompatibility in tissue healing(335, 345). Though a number of attempts have 
been made to include natural polymers with synthetic polymers for bone tissue engineering(443, 
444), very few materials made of bio-polymers alone have been successful in providing the 
functions of mechanical competence, porosity and bioactivity(445). We were successful in 
developing a natural polymeric platform that combined mechanical competence(352) with 
bioactivity(391). For example, collagen(346, 347), chitosan(345), polysaccharide(348) and 
protein based scaffolds are often presented in the form of porous sponges, fiber matrices or 
hydrogels. These scaffolds lack the mechanical stability and require chemical crosslinking to 
produce stable scaffolds. During scaffold fabrication, extensive processing and cross-linking 
compromises the biological functionality of these scaffolds(349-351). We followed a two-
pronged approach by having a mechanically competent sintered microsphere 3D- porous base 
structure made of cellulose acetate (CA), further functionalized with self-assembled nanofibrillar 
collagen (CAc)(352, 391). 
Often times, the inclusion of factors or stem cells is needed to achieve complete tissue 
regeneration and the biomaterial scaffold acts as a delivery vehicle(330). In this context, while 
the delivery of growth factors such as BMPs have had mixed outcome such as bone formation in 
non-target regions(446, 447), a clinically viable alternative is the use of patient derived bone 
marrow stromal cells (BMSCs)(448-450). The scaffold used to deliver the cells also acts as an 
instructive temporary ECM to control and direct the survival(451), proliferation(452) and 
differentiation(421) of the stem cells(453, 454) and ultimately dictated the quality of regenerated 
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bone(455). Hence the mechanical(422), pore properties(456, 457), chemical functionalities(37, 
413), topographical(39) and nanoscale(39, 379) features can all influence osteogenic 
differentiation of BMSCs. Most of these studies however do not examine the role of these 
material characteristics towards regeneration in vivo when combined with BMSCs. It is 
extremely critical to understand the behavior of materials with superior physicochemical 
properties in the body to formulate scaffolds with potential use in human bone regeneration 
applications. 
In this study, we compare the performance of a natural polymer based CA and (CAc) 
scaffolds(352, 391) along with the synthetic polymeric (PLGA) scaffold(458, 459), in terms of 
their ability to heal a critical sized bone defect in a two hole (bilateral) calvarial mouse model. In 
the first set of studies, cellulosic- CA, CAc and synthetic- PLGA 3 D-porous materials alone 
were implanted into the bilateral calvarial defects in mice. In the second set of studies, BMSCs 
from donor mice were seeded at equal numbers on to each of the matrices and implanted into the 
calvaria of mice.  
It was hypothesized that the natural polymers may act as a better matrix for cellular infiltration, 
by offering greater biocompatibility. We also hypothesized that the natural polymers (CA, CAc) 
materials may offer a more osteoinductive environment towards the seeded BMSCs and lead to 
better quality of bone formation in a critical-sized defect. The bone formation was monitored at 8 
weeks after implantation to determine the ability of scaffold alone in inducing bone formation 
and in combination with seeded BMSCs. The BMSCs from the host mice had a green fluorescent 
collagen reporter gene, as they became osteoblasts and the donor mice had BMSCs that had a 
cyan fluorescent collagen reporter gene if they became osteoblasts. Hence this tool helped us 
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identify the probable origin of bone formation in the materials seeded with BMSCs based on 
blue/ green fluorescence.  
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6.2 Materials and Methods 
6.2.1 Materials  
 
Cellulose acetate (Mw: 30K) (CA), and Polyvinyl Alcohol (30,000-70,000) (PVA) were 
procured from Sigma -Aldrich (St. Louis, MO, USA). Poly (lactic-co-glycolic acid) 85:15  
(PLGA) was purchased from lakeshore biomaterials (Birmingham, USA).  Acetone, 
Dichloromethane, Cyclohaxane, Paraformaldehyde and Gluteraldehyde were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA). 
6.2.2 Preparation of microspheres  
 
Oil in water solvent- evaporation, followed by sintering of formed microspheres using a 
solvent/non-solvent mixture was used for producing microsphere of i) Cellulose acetate (CA), ii) 
poly (lactic-co-glycolic acid) 85:15 (PLGA). In brief, 13 (w/v) % of CA polymer was dissolved 
in a solvent mixture containing methylene chloride and acetone at a ratio of 9:1 to produce 
microspheres.  A 20 (w/v) % solution in methylene chloride was used in the case of PLGA 
polymer to produce the microspheres. The polymer solutions were then poured in a thin stream 
into an aqueous media containing 1.25(w/v) % PVA as a surfactant, with constant stirring at 
250rpm to form an oil-in-water emulsion. These suspensions were stirred overnight to evaporate 
the solvent to obtain hardened microspheres. Isolated microspheres were washed repeatedly with 
deionized (DI) water, dried, and sieved into different microsphere sizes. Microspheres in the size 
range of 200- 425µm were sintered into micro porous scaffolds using either solvent-non-solvent 
or heat sintering based on the polymer(352, 391). 
6.2.3 Preparation of micro-porous sintered 3D microsphere scaffolds 
 
Metal molds were filled with CA microspheres to which a 200µL volume of an optimized 
solvent/non-solvent composition, acetone: cyclohexane in the ratio of 3:1 (v/v), was added to 
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cover the microspheres. Solvent was allowed to evaporate at room temperature to obtain sintered 
microsphere scaffolds. Cylindrical scaffolds measuring 3.5mm diameter X 1mm height were 
used for implantation into mouse calvaria. The control PLGA micro porous scaffolds with 
identical micro-particle sizes were produced by heat sintering at 95oC for 45 minutes using 
Teflon molds(352). 
6.2.4 Preparation of collagen naonfiber infused cellulose 3D microporous scaffolds   
 
A modified biomimetic approach was used to functionalize micro porous scaffolds with type I 
collagen. In brief, both control and test scaffolds were incubated in a 0.1 (w/v) % collagen type I 
solution with a pH adjusted to 4.2 at 37°C for 7 days to promote molecular collagen self-
assembly.  The dried scaffolds were treated with UV light for 30 min each side to achieve 
collagen nanofiber stability and washed repeatedly with DI water to remove buffer salts.  
Microspheres in the size range of 200-425µm diameters were sintered and infused with self- 
assembled collagen and used in this study (391).  
6.2.5 Characterization of internal structure of scaffolds by SEM  
 
Scanning electron microscopy (SEM) was used to characterize scaffold morphology and evaluate 
collagen fiber diameter and distribution. Scaffolds were sputter coated with Au/Pd using a 
Polaron E5100 sputtering system (Quorum Technologies, East Sussex, UK) to achieve an 
eighteen nanometer thick coating before viewing under SEM. The samples were viewed using 
FEI Nova NanoSEM 450 scanning electron microscope (FEI, Hillsboro, OR, USA) operated at 
an accelerating voltage of 2kV at various magnifications.  
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6.2.6 Design of calvarial implantation studies   
 
The Institutional Animal Care and Use Committee (IACUC) at The University of Connecticut 
Health Center approved all procedures for animal use and all efforts were made to minimize 
animal suffering. 10-12 week old CD-1 wild type female mice, weighing 26-32 g were used for 
implantation of the scaffolds alone. The10-12 week old male transgenic mice, weighing 25-30 g 
used as hosts for implantation had a green fluorescence in their osteoblasts as the expression of 
EGFP is driven by a 3.6 kb fragment of collagen 1 promotor (Col 3.6- TPZ mice- host)(460). 
These host mice were NOD SCID and gama irradiated (NSG) to facilitate the immune 
acceptance of donor cells. The transgenic mice used to obtain the bone marrow stromal cells 
(BMSCs) to seed the scaffolds before implantation had blue fluorescence in their osteoblasts as 
the expression of CFP is driven by a 3.6 kb fragment of collagen 1 promotor (Col 3.6 –Cyan 
mice- donor)(460, 461). Thus the BMSCs from donor mice becoming osteoblasts fluoresce blue, 
while the BMSCs becoming osteoblasts fluoresce green. Thus the fluorescent reporters acted as a 
tool to determine the quantity of active osteoblasts formed by the donor cells and the host cells. 
Critical sized calvarial defects (3.5 mm diameter) were created on both the sides of the calvarium 
of mice and a scaffold of 3.5mm diameter X 1mm height was implanted into each of the defects. 
The studies contained 3 groups with control scaffold on the left side and test scaffold on the right 
side as given by Figure 6.2 A. In the study using no cells, six samples (n=6) were used, while 
twenty-four samples (n= 24) were examined in the case of studies where the scaffolds were 
seeded with donor cells. Each scaffold was sterilized by soaking in 70% ethanol followed by UV 
treatment on both the sides for 20-minutes per side. They were then washed with sterile PBS and 
either directly implanted (study1) or implanted after seeding donor cells as described below 
(study 2). Each scaffold was seeded by immersion into 1 X106 BMSCs cultured to confluence 
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and spun down into a pellet prior to transplantation(462). The samples were retrieved at 8 weeks 
for radiological and histological examination. 
6.2.7 BMSC Culture  
 
For experiments where the scaffolds were seeded with cells, donor mice (Col3.6- Cyan) of 6-8 
weeks of age were sacrificed by carbondioxide asphyxiation and sprayed with ethanol to avoid 
contamination from mouse hair/ skin. The tibia and femur of these mice were isolated and briefly 
washed with sterile PBS.  The bone epiphyses were removed to expose the marrow and then 
flushed with media. The media was made up by adding 1% Penicillin/ Streptomycin and 10% 
FBS to α-MEM. The flushed cells were filtered using a 70µm cell strainer and the filtrate was 
spun down by centrifugation for ten minutes at 350Xg.  The pelleted cells were suspended well 
in the media and plated at a density of 3 X 106 cells/cm2. A fifty percent media removal and 
replacement was completed at day 4 of plating and a hundred percent removal and replacement 
of media was done after 7 days of culture. Once the cells reached confluency by day 10, they 
were lifted with Trypsin EDTA (2.5%) solution and suspended in media with serum to achieve a 
cellular concentration of 1X106 cells/mL of media(463). 
6.2.8 Calvarial surgery  
 
A combination of Ketamine (135 mg/kg) and Xylazine (15 mg/kg) was administered (I.P.) were 
used to anesthetize the mice (CD-1 wild type mice for implantation of scaffold alone and 3.6col-
TPZ mice in the case of experiments with BMSC seeded scaffolds), for the surgical implantation 
of the scaffolds. A clipper was used to cleanse the area and followed by topical application of 
70% ethanol to removed hairs on their heads and clean the surface for the surgery. The mice 
heads were dissected with a clean incision to reach the cranium. A 3.5mm critical sized defect 
was made on each side of the cranium using a drill bit, making sure that the underlying dura 
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matter was not damaged. A two-hole mouse calvarial model was used and the scaffolds were 
placed into theses defects as per the study design (Figure 6.2 B). In the case of the cell-seeded 
scaffolds, the BMSCs were spun down for a minute at 10,000Xg and the pellet was seeded onto 
the scaffolds by immersion of the scaffold until all the cells in the pellet got onto the material. 
Thus each scaffold received 1X106 cells (Col3.6- Cyan), in the case of the cell seeded scaffold 
implantation experiments. Hence each mouse received two implants on either side of their 
calvaria(454). 
6.2.9 Sample harvest 
 
The animals were sacrificed using carbon dioxide asphyxiation followed by cervical dislocation 
at 8 weeks post implantation of the scaffolds. An alizarin red injection (30mg/kg body weight, 
I.P.) was administered 24hours prior to sacrifice of the animals in order to label the newly 
formed bone(463). The skulls of the mice were dissected, washed in PBS at pH 7.4 and fixed 
using 10% buffered formalin for 4 days. An X-ray cabinet (Faxitron LX-60) was used for digital 
X-ray capture at a 43 magnification (6 s at 26 kVp). The samples were then cryosectioned for 
histological and immunostaining. The fixed samples were washed in PBS at pH 7.4 and 
transferred to 30% sucrose solution in PBS at pH 7.4 for a day. The tissue was embedded in 
Shandon Cryomatrix-TM placed in cryo-molds by flash freezing on dry ice. The frozen sections 
were stored in -20°C until sectioning. Leica CM3050S cryostat (Leica, Wetzlar) was used for 
obtaining 10µm thick sections of the embedded samples by employing the tape transfer 
technique (Cryofilm type IIC (10), Section-Lab Co. Ltd.)(464) The samples were imaged for 
mineral content (DIC- white) and new bone formation (red) in the case of unseeded scaffolds. In 
the case of cell seeded implants, the mineral content (white), Alizarin Complexone label (AC-
red) for new bone formation, donor cells (cyan), and host cells (green) were imaged using dark 
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field and fluorescent microscope. Serial sections were used for immunostaining for bone 
sialoprotein (BSP) and Collagen (Coll1). Another set of histological sections was serially stained 
for alkaline phosphatase and DAPI (AP/ DAPI) to determine osteogenic activity and cellularity, 
and tartrate resistant acid phosphatase (TRAP) activity to determine bone resorbing osteoclastic 
activity. A Zeiss Axio Scan.Z1 (Carl Zeiss MicroImaging Inc.) was used to details from 4-100X 
magnifications. The excitation (Ex) and emission (Em) filters used were as follows: AC: Ex-
545/25, Em-605/70; Col3.6TPZ: Ex- 500/20, Em-535/30; Col3.6ECFP: Ex-436/20, Em-480/40; 
TRAP: Ex-405/440, Em-550/560; AP: Ex-640/630, Em-690/650; Col: Ex-650/590, Em- 
738/663; BSP: Ex- 556/513, Em- 613/570. 
6.2.10 Histomorphometric analysis of calvarial implants 
 
In the case of unseeded scaffolds n=3 from each group were analyzed and in the case of cell 
seeded scaffolds n=7 was used for CA, n=7 was used for CAc and n=6 for PLGA. Some samples 
were eliminated due to sample slippage from defect. The image analysis was done using Fiji 
(NIH software). Each individual channel was used and converted into an 8-bit image. Each of 
these images was appropriately thresholded to quantify the signal and eliminate the noise.  
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6.3 Results 
6.3.1 Scaffold Morphology 
 
The 3D porous scaffolds of PLGA were golden in color (Figure 6.1A), while the CA (Figure 
6.1B) and CAc (Figure 6.1C) were opaque and white in color. Under higher magnification, with 
scanning electron microscope (SEM), the PLGA 3D porous materials (Figure 6.1 D, G, J) 
showed a smooth morphology (arrows). On the other hand the morphology presented by CAc 
(Figure 6.1 E, H, K) showed many undulations on the surface (arrows). The collagen nanofibers 
were present on the CA microspheres in CAc (Figure 6.1 F, I, L). The collagen fibers formed a 
coating on the microsphere without accumulating at the pores of the material (arrows). 
6.3.2 Radiological examination of bone formation with scaffolds alone and scaffolds along 
with BMSCs 
 
The animals were sacrificed and the whole calvaria were dissected out after 8 weeks of 
implantation (Figure 6.3- A, B, C in the case of unseeded scaffolds and Figure 6.4A- 1,2,3 in 
the case of scaffolds seeded with BMSCs) and examined by X-ray to evaluate the amount of 
bone formation in the materials. The radioopacity of the tissue formed in the case of implants 
alone was very low, and mostly represented a background signal only (Figure 6.3- D, E and F). 
This did not represent a significant amount of bone formation by the materials in the absence of 
cells. However, when the materials were seeded with 1X106 BMSCs from donor mice, the 
scaffolds showed bone formation (Figure 6.4A- 4, 5, 6). While all the materials showed bone 
formation in the presence of BMSCs, on quantifying the radioopacity in each material group, the 
amount of bone formed with CA and CAc was twice as much as what was observed with PLGA 
(Figure 6.4B). This difference was statistically very significant (P< 0.001).  
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6.3.3 Histological analysis of implantation of scaffolds alone 
 
The bone formation was not very high when the materials alone were implanted into calvarial 
defect and examined after 8 weeks of implantation (Top row -DIC in Figure 6.5, and 
supplemental Figures 6.13, 6.14). There was not much robust mineral deposition (Top row –AC 
red label in Figure 6.5, and supplemental Figures 6.13, 6.14). This was indicative of low 
degrees of bone mineral deposition. The materials showed presence of cells in their interior 
along (Middle row –DAPI Blue stain in Figure 6.5, and supplemental figures 6.13, 6.14) with 
robust alkaline phosphatase activity, indicative of osteoblastic activity (Middle row –AP Red 
stain label in Figure 6.5, and supplemental figures 6.13, 6.14). However, the PLGA scaffolds 
had most of the cellularity (DAPI- blue) and osteoblastic activity (AP- red) confined to the 
periphery of the implant (Middle rows: Figure 6.13, Inset C; Figure 6.5, Inset C). On the other 
hand the cellularity (DAPI- blue) and osteoblastic activity (AP- red) were seen well inside the 
scaffold interior and were more evenly distributed in the case of CA (Middle rows: Figure 6.13, 
Inset D; Figure 6.14, Inset C) and CAc (Middle rows: Figure 6.5, Inset D; Figure 6.14, Inset 
D). Finally, the osteoclastic activity was also seen better distributed in CA (Final rows: Figure 
6.13, Inset F; Figure 6.14, Inset F) and CAc (Final rows: Figure 6.5, Inset F; Figure 6.14, Inset 
F) than in PLGA (Final rows: Figure 6.13, Inset E; Figure 6.5, Inset E). Therefore, though the 
materials alone could not facilitate proper bone formation in the defects by themselves, the 
cellularization, osteoblastic and osteoclastic cellular activity in the case of PLGA were confined 
mostly to the periphery of the materials. In the case of CA and CAc, a well-distributed 
cellularity, along with uniformly spread osteoblast and osteoclast activity was seen. There was 
no significant difference between the test and the control materials in the quantity of cells or the 
osteoblast and osteoclast activity. Therefore the materials alone did not lead to appreciable bone 
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formation, but in the presence of BMSCs the bone formed in the test CA and CAc groups was 
twice that formed in PLGA 
6.3.4 ECM protein deposition by scaffolds and BMSCs  
 
The collagen I (Coll I) and bone sialoprotein (BSP) content of scaffolds loaded with BMSCs was 
evaluated by immunostaining (Coll I- yellow, BSP- red). Both Coll I and BSP were found in all 
the sections. The BSP content was similar between the groups (Bottom row and top row: Figure 
6.15, Figure 6.6, Figure 6.16 and Figure 6.7A). The distribution of collagen was confined to 
certain areas in the case of PLGA and a continuous collagenous ECM was absent. Therefore 
though collagen was present it did not bridge the defect well in the case of PLGA (Figure 6.15- 
A, C; Figure 6.6- A, C). However, the distribution of collagen was more  
uniform throughout the matrix in the case of CA (Figure 6.15- B, D; Figure 6.16- A, C) and 
CAc (Figure 6.6- B, D; Figure 6.16- B, D). The intensity of the signal, when contrasted to the 
host bone was weaker in the case of PLGA (Figure 6.15- A, C; Figure 6.6- A, C vs the central 
insets in the rows).  The intensity of collagen signal was comparable to host bone in the case of 
CA (Figure 6.15- B, D; Figure 6.16- A, C vs the central inset in the rows) and CAc (Figure 6.6- 
B, D; Figure 6.16- B, D vs the central insets in the rows). Quantitatively, the collagen content of 
CA and CAc was almost twice as much as the collagen presented by the regenerated tissue in 
PLGA (Figure 6.7B). The difference was very significant. All scaffolds seeded with BMSCs 
showed bone formation (DIC signal in Figure 6.17, Figure 6.8, and Figure 6.18) and new 
mineral deposition (AC- red signal in Figure 6.17, Figure 6.8, and Figure 6.18). Bone 
formation was confined to certain regions of the material in the case PLGA (Figure 6.17- A, C, 
E, G; Figure 8- A, C, E, G), with minimal closure of the defect at the interphase of calvarium 
and the dura of the mice.  
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On the other hand the bone formation was well distributed and a good bone bridge was formed at 
the interphase of the calvarium and dura in the case of CA (Figure 6.17- B, D, F, H; Figure 
6.18- A, C, E, G) and CAc (Figure 6.8- B, D, F, H). Quantitatively, the bone area on CA and 
CAc was approximately twice that seen in PLGA implants (Figure 6.9A). However the quantity 
of bone mineral deposition (Figure 6.9B), donor cells (Figure 6.9C) and host cells (Figure 
6.9C) in all the groups was no significantly different. In all the groups, the Col3.6- Cyan (donor) 
cells presented greater intensity than the Col3.6- Tpz (host cells).The donor cells also presented 
better merger with the AC (red), new mineral signal (smaller insets in each of the insets of 
Figure 6.17, Figure 6.8, and Figure 6.18).  
6.3.5 Osteoblastic and osteoclastic activity in scaffolds seeded with BMSCs 
 
The cellular content (DAPI- blue) of the scaffolds was similar between PLGA, CA and CAc 
(Lowest panel: Figure 6.19, Figure 6.10, Figure 6.20, and Figure 6.12A). The AP (red) content 
was also similar between the groups (Middle panel: Figure 6.19, Figure 6.10, Figure 6.20, and 
Figure 6.12B). However, the distribution was more uniform and a continuous layer of cells with 
active AP content was seen in the case of CA and CAc. The PLGA materials showed cell (DAPI) 
and AP distribution more in certain pockets than in the other parts of the material. There was also 
a lack of continuous tissue (Figure 6.19- E, A; Figure 6.10- E, A) and osteoblastic AP activity 
at the interphase of the cranium and dura in the PLGA implants (Figure 6.19- C, A; Figure 
6.10- C, A), while a good degree of tissue and ostoblastic activity was seen in analogous regions 
of CA (Figure 6.19- D, B; Figure 6.20- C, A) and CAc (Figure 6.10- D, B; Figure 6.20- D, B)  
Though the osteoclastic bone resorption was not different between all the groups (Figure 6.12 
C), the distribution of osteoclast activity, as given by TRAP staining was more homogenous with 
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CA (Figure 6.21- B, C) and CAc (Figure 6.11B, Figure 6.21D), than with PLGA (Figure 
6.11A, Figure 6.21A) 
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.  
Figure 6.1 Morphology of scaffold 
Examination of scaffold structure. Photographic images of 3D microporous scaffolds used (A) 
PLGA, (B) CA, (C) CAc, scale bar= 1mm; SEM images at 100X magnification (D) PLGA, (E) 
CA, (F) CAc, scale bar= 500µm; SEM images at 500X magnification (G) PLGA, (H) CA, (I) 
CAc, scale bar= 100µm; SEM images at 1000X magnification (J) PLGA, (K) CA, (L) CAc, scale 
bar= 50µm. 
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Figure 6.2 Calvarial Surgery and scaffold groups implanted 
Surgical procedure and schematic of the study groups. (A) Steps in the surgical implantation: (1) 
Creation of two circular 3.5mm defects on the two sides of mouse calvaria, (2) removal of 
calvarial bone, (3) Implantation of the scaffolds into the defects, (4) Closure of the implants by 
suturing the skin. (B) Groups 1: left side defect was filled with PLGA and the right side defect 
with CA, group 2: left side defect was filled with PLGA and the right side was filled with CAc, 
group 3: left side was filled with CA and the right side was filled with CAc. In study 1, the 
materials alone were used. In study 2, 1X106 Col3.6- Cyan BMSCs from donor mice were 
seeded on to each scaffold before implantation into host mice with Col3.6- Tpz BMSCs. 
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Figure 6.3 Calvarial impants with material only 
Whole calvaria and X- ray radiograph of defects implanted with scaffolds alone. Whole calvarial 
mount of (A) group 1- PLGA vs CA, (B) group 2- PLGA vs CAc, (C) group 3- CA vs CAc.; X-
ray radiographs of (D) group 1- PLGA vs CA, (E) group 2- PLGA vs CAc, (F) group 3- CA vs 
CAc. 
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Figure 6.4 Calvarial implants with materials and donor cells 
Whole calvaria and X- ray radiograph of defects implanted with scaffolds and cells. (A) Top 
panel: 1. Group 1- PLGA vs CA, 2. Group 2- PLGA vs CAc, 3. Group 3- CA vs CAc.; X-ray 
radiographs of 4. Group 1- PLGA vs CA, 5. Group 2- PLGA vs CAc, 6. Group 3- CA vs CAc. 
(B) Quantitative radio opacity of defect area normalized to radio opacity of host bone, both 
measured per unit area; PLGA, n=6; CA, n=6; CAc, n=7. One way ANOVA with Tukey post-
test with 95% confidence interval, *P<0.001, #P<0.01, @P<0.05. 
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Figure 6.5 Histological sections of scaffolds without cells (Group 2) 
Cell infiltration and bone forming/resorbing activity with implantation of scaffolds alone into 
calvarial defects. Flourescent histological cross sectional images of calvaria implanted with 
material alone at 8 weeks, Group 2: PLGA vs CAc, Top row: DIC- Differential interference 
channel image with AC- red labeled alizarin complexon marking new mineral deposition (PLGA 
inset A, CAc inset B); Middle row: AP- Alkaline phosphatase activity for osteoblastic activity 
with DAPI- cell nuclei (PLGA inset C, CAc inset D). Lowest row: TRAP- Tartrate-resistant acid 
phosphatase staining as a marker of osteoclastic activity (PLGA inset E, CAc inset F). 
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Figure 6.6 ECM markers immunostained on cell seeded scaffolds (Group 2) 
Immunofluorescently stained (ECM proteins: Coll1-Collagen1/ Bone sialoprotein- BSP) 
histological cross sectional images of calvaria implanted with material and BMSCs at 8 weeks, 
Group 2: PLGA vs CAc, Top row: Coll1- yellow, BSP- red (PLGA inset A, CAc inset B); 
Middle row: Coll1- yellow (PLGA inset C, CAc inset D). Lowest row: BSP- red (PLGA inset E, 
CAc inset F).  
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Figure 6.7 ECM protein content on seeded implants 
Quantification of pixel intensity of signal normalized to the defect area (A) BSP- Bone 
sialoprotein (red in Figure 6.6), (B) Coll 1- Collagen 1 (yellow in Figure 6). One way ANOVA 
with Tukey posttest with 95% confidence intervals, *P<0.001, #P<0.01, @P<0.05. 
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Figure 6.8 Stained histological sections of cell seeded scaffolds (Group 2) 
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs 
at 8 weeks, Group 2: PLGA vs CAc, Top row: DIC- Differential interference channel image to 
visualize bone and microspheres with AC- red labeled alizarin complexon marking new mineral 
deposition, Donor cells- Col3.6- Cyan (blue), Host cells- Col3.6-Tpz (green) (PLGA inset A, 
CAc inset B); Second row: DIC- Differential interference channel image to visualize bone and 
microspheres with AC- red labeled alizarin complexon marking new mineral deposition (PLGA 
inset C, CAc inset D). Third row: DIC- Differential interference channel image to visualize bone 
and microspheres with Donor cells- Col3.6- Cyan (blue) (PLGA inset E, CAc inset F). Fourth 
row: DIC- Differential interference channel image to visualize bone and microspheres with Host 
cells- Col3.6-Tpz (green) (PLGA inset G, CAc inset H). Mineral deposition, host and donor cell 
participation in bone formation by materials along with BMSCs 
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Figure 6.9 Quantification of bone formation, host and donor cells 
Quantification of pixel intensity of signal normalized to area of defect (A) Bone area fraction- 
DIC quantification, (B) New mineral formation- AC quantification, (C) Donor cells- Col3.6-
Cyan quantification, (D) Host cells- Col3.6-Tpz quantification, (E) Host (Green bars) and Donor 
(Blue bars) cells in each scaffold group. One way ANOVA with Tukey post-test with 95% 
confidence intervals, *P<0.001, #P<0.01, @P<0.05. 
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Figure 6.10 Osteoblastic activity on cell seeded scaffolds (Group 2) 
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs 
at 8 weeks, Group 2: PLGA vs CAc, Top row: AP for osteoblastic activity - red, DAPI for cell 
nuclei- blue (PLGA inset A, CAc inset B); Middle row: AP for osteoblastic activity- red (PLGA 
inset C, CAc inset D). Lowest row: DAPI for cell nuclei- blue (PLGA inset E, CAc inset F). 
 
 
Figure 6.11 Osteoclastic activity on cell seeded scaffolds (Group2) 
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs 
at 8 weeks, Group 2: PLGA vs CAc, TRAP- Tartrate-resistant acid phosphatase staining as a 
marker of osteoclastic activity (PLGA inset A, CAc inset B). 
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Figure 6.12 Quantification of osteoblastic and osteoclastic activity on seeded implants 
Quantification of pixel intensity of signal normalized to area of defect (A)DAPI- cells, (B) 
AP/DAPI- osteoblastic activity, (C) TRAP- osteoclastic activity. One way ANOVA with Tukey 
post-test with 95% confidence intervals, *P<0.001, #P<0.01, @P<0.05. 
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6.4 Discussion 
 
Scaffold based bone tissue engineering relies on the ability of this temporary ECM to direct 
tissue healing in a desirable direction(40). Though synthetic polymers are used widely for 
scaffolding applications, there is a clear need to formulate and characterize the performance of 
scaffolds made of biopolymers(442), such as polysaccharides and proteins, due to their 
inherently bioactive nature and greater cost effectiveness(445). Several attempts have been made 
to construct completely biopolymeric scaffolds(457, 465, 466) and blend of synthetic and natural 
polymers(443, 444, 459). Many of these were not very successful as the materials could not meet 
the dual goals of providing a mechanically robust support and be bioactive at the same time.  For 
example, collagen(346, 347), chitosan(345), polysaccharide(348) and protein based scaffolds are 
often presented in the form of porous sponges, fiber matrix or hydrogels. These scaffolds lack 
the mechanical stability and require chemical crosslinking to produce stable scaffolds. During 
scaffold fabrication, extensive processing and cross-linking compromises the biological 
functionality of these scaffolds(349-351). 
The system developed by us contains a cellulose derivative as the 3D sintered microsphere base, 
further functionalized by self-assembled collagen nanofibers for greater bioactivity. 
Additionally, employing BMSCs has become a clinically relevant practice and it is important 
that the materials used as scaffolds channel progenitor cell differentiation into the tissue type 
specific lineage(449, 455).  
Here in the present study, we contrast the performance of two biopolymeric systems (cellulose 
acetate (CA) and cellulose acetate- collagen (CAc)) with a synthetic polymer- PLGA, both 
formulated similarly to present a 3D-porous scaffold structure, for their ability to facilitate 
healing of a critical sized calvarial defect by (a) implantation of the material alone and by (b) 
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implantation of the materials along with clinically relevant donor derived BMSCs. The 
morphology of PLGA and CA were markedly different. While PLGA showed very smooth 
interfaces (Figure 6.1 G, J), the CA materials showed many undulations indicative of rough 
scaffold morphology (Figure 6.1 H, K). The nanofibrillar collagen coated the microspheres 
without obstructing the pores of the scaffold structure (Figure 6.1 I, L).  Deligianni et al., found 
that rough surfaces were more conducive for attachment and osteoblastic differentiation of 
BMSCs in vitro(467). Lincks et al., also found that Titanium implants with rough surfaces may 
be better for orthopaedic applications(468) and allow for greater osteointegration of the implant. 
Hence we hypothesized that the natural polymers due to the rough morphology may serve as 
better matrices to elicit osteoblast and progenitor cell response when implanted in a critical sized 
defect. 
Infiltration of cells into the scaffold interior has been a challenge with tissue engineered scaffolds 
and often times there is bone formation at the periphery of synthetic scaffolds(459) with limited 
cellularity at the core(36), due to constrains of diffusion(458) and material degradation product 
accumulation at the core of the scaffold(396). This could explain why Jiang et al., saw greater 
defect bridging in the presence of natural polymeric (chitosan and heparin) blends of PLGA, but 
only peripheral bone formation was observed with PLGA alone(459), when these polymeric 
scaffolds were implanted in the long bone defect of rabbits.  
In the present paper, our results have demonstrated that that the natural polymer based CA and 
CAc 3D- porous scaffolds show greater tissue infiltration into the interior parts of the scaffold, 
while most of the cellularity was confined to the periphery in the case of PLGA (Figures 6.5, 
6.13and 6.14). This could be attributed to higher biocompatible nature(469) of the natural 
polymeric materials in contrast to the synthetic polymers that can accumulate toxic 
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products(470) at their core due to their degradation properties(471). However, the materials were 
incapable of inducing complete healing of the defect by themselves (Figure 6.3). These results 
are in agreement with the observation of Gohil et al.(446), and Yu et al.(454), who also did not 
find considerable bone formation by collagen based materials alone, without the inclusion of 
growth factors or cells. Hence the CA and CAc materials showed greater tissue infiltration than 
PLGA, due to the higher biocompatibility of the natural polymeric systems over PLGA. 
A simple and clinically feasible method of enhancing bone healing is by the inclusion of patient 
derived BMSCs along with the biomaterial scaffold(449). Therefore, equal numbers of BMSCs 
were seeded on all the scaffolds. The CA and CAc materials lead to bridging of the defect by 
bone formation at the interface of dura and the calvarium. This bridging did not occur with 
PLGA (DIC channel in Figures 6.8, 6.17, and 6.18). Moreover, the bone formation (DIC 
channel) and new mineral deposition (AC- red channel) was confined to specific intensely 
stained regions of PLGA, while it was well distributed throughout the material in CA and CAc 
(DIC, and AC-red channels in Figures 6.8, 6.17, and 6.18). The fraction of scaffold area covered 
by bone was significantly higher in the natural polymers (CA and CAc) than PLGA (Figure 
6.9A). The bone formation as detected by the radio-opacity of the defect by X-ray revealed twice 
as much bone formation on CA and CAc in comparison to PLGA (Figure 6.4). Further, the 
collagen content and staining intensity were more and well distributed on the CA and CAc 
materials than PLGA (Figure 6.6, 6.15 and 6.16). There was also twice as much collagen 
produced on the BMSC seeded CA and CAc scaffolds than PLGA (Figure 6.7B). Thus the 
collagen deposited and the bone formed was denser with the CA groups than in PLGA, 
indicating that the quality of regenerated bone was greater when the natural polymers were used 
in conjunction with BMSCs than with the synthetic polymer.  
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PLGA scaffolds have been used in both calvarial(330) and long bone defect models(459) in 
literature. Cowan et al., employed a calvarial defect model to study the effect of PLGA by itself 
and after inclusion of appetite for bone formation. When stem cells (adipose derived and 
BMSCs) were used on these materials, only the apatite coated PLGA led to low levels of bone 
formation. The inclusion of the apatite may have led to a more conducive pH neutralized system 
to aid in bone formation by progenitors. Jiang et al., saw greater defect bridging in the presence 
of natural polymeric (chitosan and heparin) blends of PLGA, but only peripheral bone formation 
was observed with PLGA alone(459). The highly hydrophobic and degradative nature of popular 
synthetic polymeric scaffolds of materials like PLGA may not be as conducive for cell survival 
in the scaffold interior and hence these scaffolds are less likely to promote as much 
cellularization as naural polymers like CA. Our results agree well with these observations in 
literature, indicating that the use of natural polymers like CA with BMSCs may be more 
beneficial in achieving bone defect healing.  
We had coated collagen onto CA (CAc) in the hope of seeing greater regenerative outcomes due 
to presence of an ECM component of bone(472, 473). We had allowed type 1 collagen to self-
assemble into nanofibers on the CA microspheres to include a nanofibrillar bone-ECM 
component to enhance the performance of CA microsphere platform(391). We however did not 
see significant differences at 8 weeks post- implantation between CA and CAc, in terms of 
quantity or quality of the regenerated bone. This could be due to degradation of collagen from 
the matrix at an earlier time point. Though the coating may have helped with achieving 
biocompatibility at an earlier stage of implantation, on a long run there may not be much 
difference between the collagen coated and uncoated CA 3D porous scaffolds (unpublished 
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data). Hence a technique to improve the retainment of collagen for prolonged nanofiber 
bioactivity may be to chemically cross-link the collagen nanofibers(474).  
When donors BMSCs were used it was also observed that the number of donor cells far exceeded 
the number of host cells in all the three materials tested (Figure 6.9 C, D, E). Though the trends 
show an increase in both donor and host cell types on CA and CAc, they were not significantly 
different in number in contrast to PLGA (Figure 6.9E). The donor cells (Cyan- blue signal) 
showed greater degree of localization with the newly deposited mineral (AC- red signal), while a 
relatively thin layer of host cells (Tpz- Green signal) can be seen in the same regions (Boxed 
areas of the insets in-Figures 6.8, 6.17 and 6.18). Hence the donor BMSCs may have 
contributed to bone formation directly themselves and indirectly by signaling the host cells to 
home to the region of injury. The fact that no bone formation or active remodeling occurred in 
the absence of BMSCs indicated that the donor cells were indispensable for proper bone 
formation to occur. However the quality of bone formed even in the presence of BMSCs was 
twice as good on the natural polymers (CA and CAc) than the synthetic polymer (PLGA), in 
terms of ECM collagen content, area of the defect covered by bone and hence the radio-opaque 
density of the regenerated bone. Additionally there was a good bone defect closure seen when 
CA and CAc were used along with BMSCs. Finally the pattern of cellular content, bone 
formation, osteoblastic (Figure 6.10, 6.19 and 6.20) and osteoclastic (Figure 6.11, 6.21) activity 
seem to be focused to specific loci on PLGA in contrast to a more well distributed organization 
on CA and CAc. Therefore this study indicates that the usage of BMSCs in combination with an 
osteoconductive 3D- porous natural polymeric matrix such as CA/ CAc can lead to higher 
quality of bone regeneration than the convention synthetic polymers like PLGA.   
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Synthetic polymers are known to adsorb many plasma proteins non- specifically due to their 
hydrophobic nature(475). On the other hand polysaccharides such as starch, and cellulose are 
known for their hydrophilic nature and for lower degrees of non-specific protein 
adsorption(476). Hence Alves et al. noted that plasma treatments used to make synthetic 
polymeric surfaces more hydrophilic and promote cell adhesion did not lead to better cell 
adhesion on a complete polysaccharide material(477). Yunfei et al., doped 1- 7% nano-
crystalline cellulose onto PLGA. Inclusion of cellulose with PLGA led to increased 
hydrophilicity of the resulting nanofibers and helped with greater degree of cell adhesion onto 
the material than pure PLGA(478). While a degree of hydrophobicity is essential for protein 
adsorption onto materials and hence the recognition of these proteins by cells to adhere onto the 
material, a highly hydrophilic or a highly hydrophobic surface is not likely to support the proper 
conformation of adsorbed proteins and their retainment on the biomaterial surface(34) to elicit a 
healing response from the target tissue. Thus CA and CAc showed greater biocompatibility and 
progenitor cell differentiation potential than synthetic polymer PLGA. 
Several attempts have been made to employ cellulose based structures in tissue engineering. 
Barbie et al. had conducted a 34 week implantation of cellulose into the femur of rabbits and 
seen a good degree of integration and minimal inflammatory reaction with the material(479). 
Cellulose and cellulose phosphate materials were also seen to support bone healing(480). 
Additionally, CA fibrous matrices supported cardiac cell growth and activity(242). These studies 
had however not utilized the mechanical competence of cellulose, a feature extremely essential 
for a bone scaffold. In the present study we have formulated a mechanically competent, 3D 
porous structure of cellulose acetate and contrasted its performance with a model synthetic 
polymer for its ability to heal a critical sized defect of the bone. Our results indicate that 
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cellulose based materials can perform better as scaffold for bone regeneration than conventional 
synthetic polymer matrices, when designed to possess the desirable characteristics of surface 
roughness, hydrophilicity, nutrient transfer and mechanical competence. This opens the 
possibility for Cellulose based scaffolds to be used in BTE applications.  
 
6.5 Conclusions 
 
In summary, we conclude that the natural polymeric CA based 3D porous scaffolds were 
superior to well- established synthetic PLGA scaffolds of similar dimensions in inducing healing 
of critical sized bone defects. The natural polymeric materials (CA and CAc) allowed better 
cellular infiltration than synthetic materials (PLGA) when implanted into a critical sized bone 
defect, indicative of the scaffold’s osteoconductive nature when used alone. When equal 
numbers of BMSCs were seeded onto these CA, CAc and PLGA materials before implantation, 
we found twice as much bone and collagen formation with the biopolymeric scaffolds than 
PLGA. These observations indicate the higher density and quality of regenerated bone when the 
natural polymeric scaffolds were used in conjunction with stem cells. We however did not see an 
increased bone formation with the inclusion of collagen nanofibers (CAc), which contradicts our 
in vitro studies. This observation could be due to degradation of collagen at a faster rate than 
what is seen in vitro, and hence the effects of nanofibrillar collagen were negligible after 8 weeks 
of implantation. Finally, the donor BMSCs seeded were found in regions of new mineral 
deposition along with fewer host BMSCs indicating that the donor BMSCs could be involved in 
the formation of new bone both directly by depositing the matrix and indirectly by signaling the 
host BMSCs to contribute to the process. Though there were no differences in the amount of 
donor 
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BMSCs retained by the materials, the distribution of these cells were uniform throughout the 
scaffold on the biopolymers than on the synthetic polymer. This study proves that natural 
polymeric 3D- porous structures of cellulose could be used to induce effective bone formation, in 
combination with patient derived BMSCs and such matrices could be an effective alternative to 
PLA and PLGA synthetic polymers based BTE scaffolds with superior utility. 
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6.6 Supplemental Figures 
 
 
Figure 6.13 Histological sections of scaffolds without cells (Group 1) 
Histological sections of scaffolds without cells (Group 1) Flourescent histological cross sectional 
images of calvaria implanted with material alone at 8 weeks, Group 1: PLGA vs CA, Top row: 
DIC- Differential interference channel image with AC- red labeled alizarin complexon marking 
new mineral deposition (PLGA inset A, CA inset B); Middle row: AP- Alkaline phosphatase 
activity for osteoblastic activity with DAPI- cell nuclei (PLGA inset C, CA inset D). Lowest 
row: TRAP- Tartrate-resistant acid phosphatase staining as a marker of osteoclastic activity 
(PLGA inset E, CA inset F). 
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Figure 6.14 Histological sections of scaffolds without cells (Group 3) 
Flourescent histological cross sectional images of calvaria implanted with material alone at 8 
weeks, Group 3: CA vs CAc, Top row: DIC- Differential interference channel image with AC- 
red labeled alizarin complexon marking new mineral deposition (CA inset A, CAc inset B); 
Middle row: AP- Alkaline phosphatase activity for osteoblastic activity with DAPI- cell nuclei 
(CA inset C, CAc inset D). Lowest row: TRAP- Tartrate-resistant acid phosphatase staining as a 
marker of osteoclastic activity (CA inset E, CAc inset F). 
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Figure 6.15 ECM markers immunostained on cell seeded scaffolds (Group 1) 
Immunoflourescent stained (ECM proteins: Coll1-Collagen1/ Bone sialoprotein- BSP) 
histological cross sectional images of calvaria implanted with material and BMSCs at 8 weeks, 
Group 1: PLGA vs CA, Top row: Coll1- yellow, BSP- red (PLGA inset A, CA inset B); Middle 
row: Coll1- yellow (PLGA inset C, CA inset D). Lowest row: BSP- red (PLGA inset E, CA inset 
F). 
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Figure 6.16 ECM markers immunostained on cell seeded scaffolds (Group 3) 
Immunoflourescent stained (ECM proteins: Coll1-Collagen1/ Bone sialoprotein- BSP) 
histological cross sectional images of calvaria implanted with material and BMSCs at 8 weeks, 
Group 3: CA vs CAc, Top row: Coll1- yellow, BSP- red (CA inset A, CAc inset B); Middle row: 
Coll1- yellow (CA inset C, CAc inset D). Lowest row: BSP- red (CA inset E, CAc inset F). 
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Figure 6.17 Stained histological sections of cell seeded scaffolds (Group 1) 
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs 
at 8 weeks, Group 1: PLGA vs CA, Top row: DIC- Differential interference channel image to 
visualize bone and microspheres with AC- red labeled alizarin complexon marking new mineral 
deposition, Donor cells- Col3.6- Cyan (blue), Host cells- Col3.6-Tpz (green) (PLGA inset A, CA 
inset B); Second row: DIC- Differential interference channel image to visualize bone and 
microspheres with AC- red labeled alizarin complexon marking new mineral deposition (PLGA 
inset C, CA inset D). Third row: DIC- Differential interference channel image to visualize bone 
and microspheres with Donor cells- Col3.6- Cyan (blue) (PLGA inset E, CA inset F). Fourth 
row: DIC- Differential interference channel image to visualize bone and microspheres with Host 
cells- Col3.6-Tpz (green) (PLGA inset G, CA inset H). 
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Figure 6.18 Stained histological sections of cell seeded scaffolds (Group 3) 
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs 
at 8 weeks, Group 3: CA vs CAc, Top row: DIC- Differential interference channel image to 
visualize bone and microspheres with AC- red labeled alizarin complexon marking new mineral 
deposition, Donor cells- Col3.6- Cyan (blue), Host cells- Col3.6-Tpz (green) (CA inset A, CAc 
inset B); Second row: DIC- Differential interference channel image to visualize bone and 
microspheres with AC- red labeled alizarin complexon marking new mineral deposition (CA 
inset C, CAc inset D). Third row: DIC- Differential interference channel image to visualize bone 
and microspheres with Donor cells- Col3.6- Cyan (blue) (CA inset E, CAc inset F). Fourth row: 
DIC- Differential interference channel image to visualize bone and microspheres with Host cells- 
Col3.6-Tpz (green) (CA inset G, CAc inset H). 
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Figure 6.19 Osteoblastic activity on cell seeded scaffolds (Group 1) 
 Flourescent histological cross sectional images of calvaria implanted with material and BMSCs 
at 8 weeks, Group 1: PLGA vs CA, Top row: AP for osteoblastic activity - red, DAPI for cell 
nuclei- blue (PLGA inset A, CA inset B); Middle row: AP for osteoblastic activity- red (PLGA 
inset C, CA inset D). Lowest row: DAPI for cell nuclei- blue (PLGA inset E, CA inset F). 
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Figure 6.20 Osteoblastic activity on cell seeded scaffolds (Group 3) 
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs 
at 8 weeks, Group 3: PLGA vs CAc, Top row: AP for osteoblastic activity - red, DAPI for cell 
nuclei- blue (CA inset A, CAc inset B); Middle row: AP for osteoblastic activity- red (CA inset 
C, CAc inset D). Lowest row: DAPI for cell nuclei- blue (CA inset E, CAc inset F). 
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Figure 6.21 Osteoclastic activity on cell seeded scaffolds (Group 1 and 3) 
Flourescent histological cross sectional images of calvaria implanted with material and BMSCs 
at 8 weeks, TRAP- Tartrate-resistant acid phosphatase staining as a marker of osteoclastic 
activity, Top row: Group 3: PLGA vs CA, (PLGA inset A, CA inset B). Bottom row: Group 1: 
CA vs CAc (CA inset C, CAc inset D). 
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7 Chapter 7 
 Future Directions 
7.1 Stabilizing self- assembled collagen in vivo and uncovering the mechanism of 
material- protein interactions 
 
Cellulose-collagen based matrices and related characterization for bone healing applications 
clearly establish their advantages over the synthetic polymer PLGA. The observed foreign 
body reaction at early stages to cellulose following its implantation may be lower due delay 
in the adsorption of bodily proteins onto the scaffold due to its increased hydrophilicity as 
compared to PLGA. Applying collagen coating on to the cellulose scaffold via self-assembly 
process may be a viable strategy to attain greater biological activity immediately after 
implantation. Hydrophilic nature and extensive inter- and intra-molecular hydrogen bonding 
of cellulose allowed a biomimetic presentation of the ECM protein collagen. This translated 
into greater induction of stem cell osteoblastic differentiation in vitro and bone healing in 
vivo when combined with bone marrow stromal cells. Significantly higher amount of bone 
was formed with cellulose-collagen scaffolds with cells as compared to PLGA control in a 
critical sized bone defect.  
Bone healing between CA and CAc groups at 8 weeks (late) time point was at the same 
level. The erosion of collagen nanofibers from the scaffold in the body, due to the dynamic 
environment presented by MMPs could be a reason for the observed lack of difference 
between CA and CAc groups. It is worth investigating to crosslink collagen nanofibers to 
avoid their erosion to access the contributions of collagen nanofibers in long term bone 
healing.  Many chemical collagen cross-linking mythologies have been reported that retain 
the bioactivity and may serve as a means to achieve this goal(481-483). 
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An important observation during the study was the biomimetic self-assembly of collagen 
nanofibers on the cellulose surface. Few studies have looked into the absorption of protein 
and their confirmation to specific material surfaces but underlying mechanisms vastly 
remains unknown. One of the bottlenecks to understanding the mechanism of protein 
assembly on material surfaces is the lack of techniques that do not modify the proteins by 
fluorescently tagging them or subjecting it to changes that distort their native state. Using 
simulation based analysis and complimenting it with real time protein folding studies 
materials like CA would explain the differential nature of protein adsorption and nanofiber 
assembly on these surfaces. For instance, it would be good to combine optical based 
methods employing fluorescently tagged ECM protein conformational studies(484) along 
with nano-sensors to detect the variation in electrostatic potential as it interacts with a 
material over time(485). 
Collagen self-assembly on the CA scaffold was applied under static conditions in this study 
and approximately 90% of the collagen content was found on the scaffolds. Employing a 
dynamic collagen coating process with agitation and solvent evaporation may lead to 
presentation of the collagen with uniform nanofiber deposition throughout the scaffold 
architecture. Similarly MSCs were cultured on the scaffolds in a static condition prior to 
implantation. A dynamic cell culture approach in a bioreactor setup may help to increase the 
scaffold cellularity prior to implantation into an osseous defect and further improve the bone 
healing efficacy(316). 
7.2 Mechanism of bone formation in calvarial defects in the presence of BMSCs 
 
Previous studies have shown the important role of BMSCs in conjunction with scaffolds in 
healing the critical sized bone defect in rat calvaria(486). In the present study we found host 
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MSCs along with the donor BMSCs in the areas of dynamic bone formation. However, 
majority of the cell population was donor BMSCs seeded on the scaffold. In this study we 
did not able to quantify the contributions of each cell type towards the new bone formation. 
Studies could be designed to compromise donor cells ability to form bone via viral 
transfection to establish the contributions of donor BMSCs in bone healing. These studies 
may contribute to our understanding of donor BMSCs contributions in forming new bone 
against the trophic effect of BMSCs towards progenitor and bone cells from the host(486).  
7.3 Scaffold degradation properties 
Cellulose degradation is mediated by the enzyme as opposed to hydrolytic degradation that 
is seen with the PLGA. The lack of body enzymes that facilitates the cellulose degradation 
makes it stable at the implantation cites for the longer period of times. A detailed study 
should look at the effect of long term implantation of these scaffolds in a bone defect to 
study its degradation and its integration with the surrounding tissue. The lack of acidic 
degradation byproducts as seen with PLA, PGA and PLGA that compromise osseous 
formation and integration may benefit from the use of cellulose derived implants and 
scaffolds. Suitable chemical modifications to cellulose to reduce the hydrogen bonding may 
promote matrix erosion and hence control the scaffold replacement from cite of implantation 
are currently under investigation. Additionally creating hydrolytically labile ester, anhydride 
and amide linkages between cellulose backbone chains are also under investigation to 
promote cellulose erosion and degradation. In addition encapsulation of enzymes in the bulk 
of the CA scaffold or bending the material with a fast eroding natural or synthetic material 
may serve as an alternative chemical modification to promote its degradation. These efforts 
are focused on retaining the bulk mechanical strength of cellulose while giving the freedom 
to promote its degradation much like a synthetic polymer PLGA. In all these approaches 
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rigorous cell and biocompatibility studies should be conducted to establish the suitability of 
these materials for load bearing bone healing applications. Similar methodologies could be 
extended to other polysaccharide materials to promote their erosion and degradation in 
tissue healing application. 
 
. 
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Annual	Review	of	Materials	Science	26,	365-394	(1996).	425.	 A.	Krishnan,	P.	Cha,	Y.-H.	Liu,	D.	Allara,	E.	A.	Vogler,	 Interfacial	energetics	of	blood	plasma	and	serum	adsorption	to	a	hydrophobic	self-assembled	monolayer	surface.	
Biomaterials	27,	3187-3194	(2006).	426.	 E.	 A.	 Vogler,	 Protein	 adsorption	 in	 three	 dimensions.	Biomaterials	33,	 1201-1237	(2012).	427.	 J.	 Comelles,	 M.	 Estévez,	 E.	 Martínez,	 J.	 Samitier,	 The	 role	 of	 surface	 energy	 of	technical	 polymers	 in	 serum	 protein	 adsorption	 and	 MG-63	 cells	 adhesion.	
Nanomedicine:	Nanotechnology,	Biology	and	Medicine	6,	44-51	(2010).	
 231 
428.	 J.	D.	Bryers,	C.	M.	Giachelli,	B.	D.	Ratner,	Engineering	biomaterials	 to	 integrate	and	heal:	 the	 biocompatibility	 paradigm	 shifts.	Biotechnology	 and	 bioengineering	109,	1898-1911	(2012).	429.	 Z.	 Ma,	 Z.	 Mao,	 C.	 Gao,	 Surface	 modification	 and	 property	 analysis	 of	 biomedical	polymers	used	for	tissue	engineering.	Colloids	and	Surfaces	B:	Biointerfaces	60,	137-157	(2007).	430.	 M.	 O.	 Klein	 et	 al.,	 Submicron	 scale‐structured	 hydrophilic	 titanium	 surfaces	promote	 early	 osteogenic	 gene	 response	 for	 cell	 adhesion	 and	 cell	 differentiation.	
Clinical	implant	dentistry	and	related	research	15,	166-175	(2013).	431.	 K.	 Webb,	 V.	 Hlady,	 P.	 A.	 Tresco,	 Relative	 importance	 of	 surface	 wettability	 and	charged	 functional	 groups	 on	 NIH	 3T3	 fibroblast	 attachment,	 spreading,	 and	cytoskeletal	organization.	Journal	of	biomedical	materials	research	41,	422	(1998).	432.	 J.	Wei	et	al.,	Adhesion	of	mouse	 fibroblasts	on	hexamethyldisiloxane	surfaces	with	wide	 range	 of	wettability.	 Journal	of	Biomedical	Materials	Research	Part	B:	Applied	
Biomaterials	81,	66-75	(2007).	433.	 B.	 St-Jacques,	 M.	 Hammerschmidt,	 A.	 P.	 McMahon,	 Indian	 hedgehog	 signaling	regulates	proliferation	and	differentiation	of	chondrocytes	and	is	essential	for	bone	formation.	Genes	&	development	13,	2072-2086	(1999).	434.	 C.	 Scotti	 et	al.,	 Recapitulation	 of	 endochondral	 bone	 formation	 using	 human	 adult	mesenchymal	stem	cells	as	a	paradigm	for	developmental	engineering.	Proceedings	
of	the	National	Academy	of	Sciences	107,	7251-7256	(2010).	435.	 S.	 M.	 Zunich	 et	 al.,	 Osteoblast-secreted	 collagen	 upregulates	 paracrine	 Sonic	hedgehog	signaling	by	prostate	cancer	cells	and	enhances	osteoblast	differentiation.	
Molecular	cancer	11,	1	(2012).	436.	 J.	 M.	 Anderson,	 Biological	 responses	 to	 materials.	 Annual	 review	 of	 materials	
research	31,	81-110	(2001).	437.	 B.	 D.	 Ratner,	 Healing	 with	 medical	 implants:	 The	 body	 battles	 back.	 Science	
translational	medicine	7,	272fs274	(2015).	438.	 H.	Elwing	et	al.,	Conformational	changes	of	a	model	protein	(complement	factor	3)	adsorbed	 on	 hydrophilic	 and	 hydrophobic	 solid	 surfaces.	 Journal	 of	 colloid	 and	
interface	science	125,	139-145	(1988).	439.	 K.	 L.	 Menzies,	 L.	 Jones,	 The	 impact	 of	 contact	 angle	 on	 the	 biocompatibility	 of	biomaterials.	Optometry	&	Vision	Science	87,	387-399	(2010).	440.	 E.	 M.	 Sussman,	M.	 C.	 Halpin,	 J.	 Muster,	 R.	 T.	 Moon,	 B.	 D.	 Ratner,	 Porous	 implants	modulate	healing	and	induce	shifts	 in	 local	macrophage	polarization	in	the	foreign	body	reaction.	Annals	of	biomedical	engineering	42,	1508-1516	(2014).	441.	 L.	 Zhang	 et	 al.,	 Zwitterionic	 hydrogels	 implanted	 in	 mice	 resist	 the	 foreign-body	reaction.	Nature	biotechnology	31,	553-556	(2013).	442.	 J.	 Mano	 et	 al.,	 Natural	 origin	 biodegradable	 systems	 in	 tissue	 engineering	 and	regenerative	medicine:	present	status	and	some	moving	trends.	Journal	of	the	Royal	
Society	Interface	4,	999-1030	(2007).	443.	 T.	 Jiang,	 W.	 I.	 Abdel-Fattah,	 C.	 T.	 Laurencin,	 In	 vitro	 evaluation	 of	chitosan/poly(lactic	 acid-glycolic	 acid)	 sintered	 microsphere	 scaffolds	 for	 bone	tissue	engineering.	Biomaterials	27,	4894-4903	(2006).	
 232 
444.	 T.	Jiang,	S.	G.	Kumbar,	L.	S.	Nair,	C.	T.	Laurencin,	Biologically	active	chitosan	systems	for	 tissue	 engineering	 and	 regenerative	 medicine.	 Current	 topics	 in	 medicinal	
chemistry	8,	354-364	(2008).	445.	 A.	 Aravamudhan,	 D.	 M.	 Ramos,	 A.	 A.	 Nada,	 S.	 G.	 Kumbar,	 Natural	 polymers:	polysaccharides	 and	 their	 derivatives	 for	 biomedical	 applications.	 Natural	 and	
Synthetic	Biomedical	Polymers,	67-89	(2014).	446.	 S.	V.	Gohil,	D.	J.	Adams,	P.	Maye,	D.	W.	Rowe,	L.	S.	Nair,	Evaluation	of	rhBMP‐2	and	bone	 marrow	 derived	 stromal	 cell	 mediated	 bone	 regeneration	 using	 transgenic	fluorescent	 protein	 reporter	mice.	 Journal	of	Biomedical	Materials	Research	Part	A	
102,	4568-4580	(2014).	447.	 M.	 Yamamoto,	 Y.	 Takahashi,	 Y.	 Tabata,	 Controlled	 release	 by	 biodegradable	hydrogels	 enhances	 the	 ectopic	 bone	 formation	 of	 bone	 morphogenetic	 protein.	
Biomaterials	24,	4375-4383	(2003).	448.	 E.	Gómez‐Barrena	et	al.,	Bone	regeneration:	stem	cell	therapies	and	clinical	studies	in	 orthopaedics	 and	 traumatology.	 Journal	 of	 cellular	 and	molecular	medicine	 15,	1266-1286	(2011).	449.	 E.	 M.	 Horwitz	 et	 al.,	 Transplantability	 and	 therapeutic	 effects	 of	 bone	 marrow-derived	 mesenchymal	 cells	 in	 children	 with	 osteogenesis	 imperfecta.	 Nature	
medicine	5,	309-313	(1999).	450.	 P.	Bianco	et	al.,	The	meaning,	the	sense	and	the	significance:	translating	the	science	of	mesenchymal	stem	cells	into	medicine.	Nature	medicine	19,	35-42	(2013).	451.	 D.	 E.	 Discher,	 D.	 J.	 Mooney,	 P.	 W.	 Zandstra,	 Growth	 factors,	 matrices,	 and	 forces	combine	and	control	stem	cells.	Science	324,	1673-1677	(2009).	452.	 F.	G.	Giancotti,	E.	Ruoslahti,	Integrin	signaling.	Science	285,	1028-1033	(1999).	453.	 S.	Martino,	F.	D'Angelo,	I.	Armentano,	J.	M.	Kenny,	A.	Orlacchio,	Stem	cell-biomaterial	interactions	for	regenerative	medicine.	Biotechnology	advances	30,	338-351	(2012).	454.	 X.	Yu	et	al.,	Controlling	the	structural	organization	of	regenerated	bone	by	tailoring	tissue	 engineering	 scaffold	 architecture.	 Journal	 of	 Materials	 Chemistry	 22,	 9721-9730	(2012).	455.	 K.	Beitzel	et	al.,	Properties	of	biologic	scaffolds	and	their	response	to	mesenchymal	stem	cells.	Arthroscopy:	The	Journal	of	Arthroscopic	&	Related	Surgery	30,	 289-298	(2014).	456.	 P.	 Kasten	 et	 al.,	 Porosity	 and	 pore	 size	 of	 β-tricalcium	 phosphate	 scaffold	 can	influence	protein	production	and	osteogenic	differentiation	of	human	mesenchymal	stem	cells:	an	in	vitro	and	in	vivo	study.	Acta	Biomaterialia	4,	1904-1915	(2008).	457.	 C.	 M.	 Murphy,	 M.	 G.	 Haugh,	 F.	 J.	 O'Brien,	 The	 effect	 of	 mean	 pore	 size	 on	 cell	attachment,	proliferation	and	migration	in	collagen–glycosaminoglycan	scaffolds	for	bone	tissue	engineering.	Biomaterials	31,	461-466	(2010).	458.	 A.	 R.	 Amini,	 D.	 J.	 Adams,	 C.	 T.	 Laurencin,	 S.	 P.	 Nukavarapu,	 Optimally	 porous	 and	biomechanically	 compatible	 scaffolds	 for	 large-area	 bone	 regeneration.	 Tissue	
Engineering	Part	A	18,	1376-1388	(2012).	459.	 T.	 Jiang	et	al.,	 Chitosan–poly	 (lactide-co-glycolide)	microsphere-based	scaffolds	 for	bone	tissue	engineering:	In	vitro	degradation	and	in	vivo	bone	regeneration	studies.	
Acta	biomaterialia	6,	3457-3470	(2010).	
 233 
460.	 I.	Bilic‐Curcic	et	al.,	Visualizing	levels	of	osteoblast	differentiation	by	a	two‐color	promoter‐GFP	 strategy:	 Type	 I	 collagen‐GFPcyan	 and	 osteocalcin‐GFPtpz.	
Genesis	43,	87-98	(2005).	461.	 I.	 Kalajzic	 et	 al.,	 Use	 of	 type	 I	 collagen	 green	 fluorescent	 protein	 transgenes	 to	identify	subpopulations	of	cells	at	different	stages	of	the	osteoblast	lineage.	Journal	
of	Bone	and	Mineral	Research	17,	15-25	(2002).	462.	 Y.	H.	Wang,	Y.	Liu,	K.	Buhl,	D.	W.	Rowe,	Comparison	of	 the	action	of	 transient	and	continuous	 PTH	on	 primary	 osteoblast	 cultures	 expressing	 differentiation	 stage‐specific	GFP.	Journal	of	Bone	and	Mineral	Research	20,	5-14	(2005).	463.	 Y.	Liu	et	al.,	Isolation	of	murine	bone	marrow	derived	mesenchymal	stem	cells	using	Twist2	Cre	transgenic	mice.	Bone	47,	916-925	(2010).	464.	 X.	 Jiang	 et	 al.,	 Histological	 analysis	 of	 GFP	 expression	 in	 murine	 bone.	 Journal	 of	
Histochemistry	&	Cytochemistry	53,	593-602	(2005).	465.	 W.	 I.	 Abdel-Fattah,	 T.	 Jiang,	 G.	 E.-T.	 El-Bassyouni,	 C.	 T.	 Laurencin,	 Synthesis,	characterization	 of	 chitosans	 and	 fabrication	 of	 sintered	 chitosan	 microsphere	matrices	for	bone	tissue	engineering.	Acta	Biomaterialia	3,	503-514	(2007).	466.	 J.	A.	Inzana	et	al.,	3D	printing	of	composite	calcium	phosphate	and	collagen	scaffolds	for	bone	regeneration.	Biomaterials	35,	4026-4034	(2014).	467.	 D.	 D.	 Deligianni,	 N.	 D.	 Katsala,	 P.	 G.	 Koutsoukos,	 Y.	 F.	 Missirlis,	 Effect	 of	 surface	roughness	 of	 hydroxyapatite	 on	 human	 bone	marrow	 cell	 adhesion,	 proliferation,	differentiation	and	detachment	strength.	Biomaterials	22,	87-96	(2000).	468.	 J.	Lincks	et	al.,	Response	of	MG63	osteoblast-like	cells	to	titanium	and	titanium	alloy	is	 dependent	 on	 surface	 roughness	 and	 composition.	Biomaterials	19,	 2219-2232	(1998).	469.	 J.	M.	Dang,	K.	W.	Leong,	Natural	polymers	for	gene	delivery	and	tissue	engineering.	
Advanced	drug	delivery	reviews	58,	487-499	(2006).	470.	 O.	 Bostman,	 U.	 Paivarinta,	 M.	 Manninen,	 P.	 Rokkanen,	 Polymeric	 debris	 from	absorbable	 polyglycolide	 screws	 and	 pins.	 Intraosseous	 migration	 studied	 in	rabbits.	Acta	Orthopaedica	Scandinavica	63,	555-559	(1992).	471.	 F.	 von	 Burkersroda,	 L.	 Schedl,	 A.	 Göpferich,	 Why	 degradable	 polymers	 undergo	surface	erosion	or	bulk	erosion.	Biomaterials	23,	4221-4231	(2002).	472.	 L.-S.	Liu,	A.	Y.	Thompson,	M.	A.	Heidaran,	J.	W.	Poser,	R.	C.	Spiro,	An	osteoconductive	collagen/hyaluronate	 matrix	 for	 bone	 regeneration.	 Biomaterials	 20,	 1097-1108	(1999).	473.	 A.	 M.	 Ferreira,	 P.	 Gentile,	 V.	 Chiono,	 G.	 Ciardelli,	 Collagen	 for	 bone	 tissue	regeneration.	Acta	biomaterialia	8,	3191-3200	(2012).	474.	 K.	Weadock,	R.	M.	Olson,	F.	H.	Silver,	Evaluation	of	collagen	crosslinking	techniques.	
Biomaterials,	medical	devices,	and	artificial	organs	11,	293-318	(1983).	475.	 K.	 Sempf	 et	 al.,	 Adsorption	 of	 plasma	 proteins	 on	 uncoated	 PLGA	 nanoparticles.	
European	Journal	of	Pharmaceutics	and	Biopharmaceutics	85,	53-60	(2013).	476.	 C.	 Alves,	 R.	 Reis,	 J.	 Hunt,	 Preliminary	 study	 on	 human	 protein	 adsorption	 and	leukocyte	 adhesion	 to	 starch-based	 biomaterials.	 Journal	 of	 Materials	 Science:	
Materials	in	Medicine	14,	157-165	(2003).	477.	 C.	M.	Alves	et	al.,	Modulating	bone	cells	response	onto	starch-based	biomaterials	by	surface	plasma	treatment	and	protein	adsorption.	Biomaterials	28,	307-315	(2007).	
 234 
478.	 Y.	Mo	et	al.,	 Preparation	 and	properties	 of	 PLGA	nanofiber	membranes	 reinforced	with	 cellulose	 nanocrystals.	 Colloids	 and	 Surfaces	 B:	 Biointerfaces	 132,	 177-184	(2015).	479.	 C.	 Barbie,	 D.	 Chauveaux,	 X.	 Barthe,	 C.	 Baquey,	 J.	 Poustis,	 Biological	 behaviour	 of	cellulosic	materials	 after	 bone	 implantation:	 preliminary	 results.	Clinical	materials	
5,	251-258	(1990).	480.	 J.	 Fricain	 et	 al.,	 Cellulose	 phosphates	 as	 biomaterials.	 In	 vivo	 biocompatibility	studies.	Biomaterials	23,	971-980	(2002).	481.	 M.	 E.	 Nimni,	 D.	 Cheung,	 B.	 Strates,	 M.	 Kodama,	 K.	 Sheikh,	 Chemically	 modified	collagen:	 a	 natural	 biomaterial	 for	 tissue	 replacement.	 Journal	 of	 biomedical	
materials	research	21,	741-771	(1987).	482.	 M.	 Kikuchi	 et	 al.,	 Glutaraldehyde	 cross-linked	 hydroxyapatite/collagen	 self-organized	nanocomposites.	Biomaterials	25,	63-69	(2004).	483.	 L.	Ma,	C.	Gao,	Z.	Mao,	J.	Zhou,	J.	Shen,	Enhanced	biological	stability	of	collagen	porous	scaffolds	by	using	amino	acids	as	novel	cross-linking	bridges.	Biomaterials	25,	2997-3004	(2004).	484.	 B.	 S.	 Lee,	 Y.	 S.	 Chi,	 K.-B.	 Lee,	 Y.-G.	 Kim,	 I.	 S.	 Choi,	 Functionalization	 of	 poly	 (oligo	(ethylene	 glycol)	 methacrylate)	 films	 on	 gold	 and	 Si/SiO2	 for	 immobilization	 of	proteins	and	cells:	SPR	and	QCM	studies.	Biomacromolecules	8,	3922-3929	(2007).	485.	 W.	 Qiu,	 E.	 Skafidas,	 Detection	 of	 Protein	 Conformational	 Changes	 with	Multilayer	Graphene	 Nanopore	 Sensors.	 ACS	 applied	 materials	 &	 interfaces	 6,	 16777-16781	(2014).	486.	 A.	 I.	 Caplan,	 J.	 E.	 Dennis,	Mesenchymal	 stem	 cells	 as	 trophic	mediators.	 Journal	of	
cellular	biochemistry	98,	1076-1084	(2006).	
 
 
